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Thesis Abstract 
 
Cronobacter spp. are opportunistic pathogens which can be isolated from a wide 
variety of foods and environments. They are Gram negative, motile, non-spore 
forming, peritrichous rods of the Enterobacteriaceae family. This food-borne 
pathogen is associated with the ingestion of contaminated infant milk formula (IMF), 
causing necrotizing enterocolitis, sepsis and meningitis in neonatal infants.  
The work presented in this thesis involved the investigation and characterisation of a 
bank of Cronobacter strains for their ability to tolerate physiologically relevant 
stress conditions that are commonly encountered in the gastrointestinal tract. While 
all strains were able to endure the suboptimal conditions tested, noteworthy 
variations were observed between strains. A collection of these strains were Lux-
tagged to determine if their growth could be tracked in IMF by measuring 
bioluminescence. The resulting strains could be easily and reproducibly monitored in 
real time by measuring light emission. Following this a transposon mutagenesis 
library was created in one of the Lux-tagged strains of Cronobacter sakazakii. This 
library was screened for mutants with affected growth in milk. The majority of 
mutants identified were associated with amino acid metabolism. The final section of 
this thesis identified genes involved in the tolerance of C. sakazakii to the milk 
derived antimicrobial peptide, Lactoferricin B (Lfcin B). This was achieved by 
creating a transposon mutagenesis library in C. sakazakii and screening for mutants 
with increased susceptibility to Lfcin B.   
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Overall this thesis demonstrates the variation between Cronobacter strains. It also 
identifies genes required for growth of the bacteria in milk, as well as genes needed 
for antimicrobial peptide tolerance.   
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Chapter I 
 
Applications of milk derived antimicrobials in the dairy 
industry 
 
 
Literature Review 
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1. Abstract 
Milk is a polyphasic secretion of the mammalian gland containing approximately 5% 
lactose, 3.2% protein, 4% lipid and 0.7% mineral salts, but this varies between 
species. It is a complex physiological liquid that provides an array of nutrients and 
bioactive components, including antimicrobials. These antimicrobials can be derived 
from the proteins, oligosaccharides and lipids present in milk. There is enormous 
potential for the discovery of new and enhanced antimicrobials originating from 
milk. This could be of major significance to the dairy industry especially in the area 
of food safety and functional foods. This review outlines the applications of a 
number of milk derived antimicrobials that are currently in use or those that are of 
potential use for the dairy industry.  
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2. Introduction 
Milk is a valuable and highly complex biological material and is one of the most 
extensively studied foods. Its composition within any mammalian species is 
distinctive of the neonatal requirements of its offspring, providing the optimal 
composition of nutrients necessary during the newborn period of that species 
(Séverin et al., 2005). In addition to its nutritional role, milk contains hormones and 
growth factors that affect development, as well as agents that modulate immune 
function such as anti-inflammatory components (Field, 2005). Furthermore, milk 
contains an array of “bioactive factors” which provide the infant with a safeguard 
from infection with various microorganisms. Much research has been undertaken on 
the antimicrobial potential of proteins, oligosaccharides and lipids in milk. These 
antimicrobials have several mechanisms of action; they may either directly kill the 
pathogen or inhibit the pathogen binding to receptors in the gut (bacterial lectins) 
(Newburg et al., 2005). The bacteria are subsequently swept away, leaving the host 
mucosa untouched (Mills et al., 2011). They may also stimulate the immune system 
and indirectly deter the pathogen by promoting the growth of commensal bacteria; 
e.g. human milk oligosaccharides (HMO) encourage proliferation of Bifidobacterium 
and Lactobacillus species (Boehm et al., 2007). The present review will give an 
overview of the antimicrobial components of milk, and describe the current and 
potential applications of these milk-derived antimicrobials for the dairy industry.   
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3. Milk derived antimicrobials 
3.1 Milk proteins 
In regards to bovine milk proteins, caseins (insoluble) are the main (80%) 
proteinaceous component of milk and can contain different levels of phosphate (αS1, 
αS2-, β- and κ-casein). Whey proteins (soluble) comprise approximately 20% of total 
milk proteins; they consist of α-lactalbumin, β-lactoglobulin, lactoferrin, transferrin, 
bovine serum albumin, and immunoglobulin. In human milk protein, the casein to 
whey protein ratio varies throughout lactation. It can range from ~20:80 in early 
lactation to 50:50 in late lactation (Lönnerdal, 2003).  
Peptides encrypted within the sequence of the parent proteins have displayed 
antimicrobial activity and need to be released in order to become active. This can be 
achieved by hydrolysis of caseins and whey proteins by digestive proteases in the 
gastrointestinal tract (Clare et al., 2000), or by fermentation with selected proteolytic 
bacteria (e.g. lactic acid bacteria; LAB, Bacillus spp.) (Kent et al., 2012). Both of 
these methods can also be performed in vitro to create new peptides. Milk 
acidification following heat treatment has also been reported to generate active 
peptides (Zucht et al., 2005). The majority of milk derived antimicrobial peptides 
(AMPs) discovered so far are of bovine and human origin (Table 1). However, 
AMPs derived from ovine and caprine proteins have also been identified (Corrêa et 
al., 2011, López-Expósito et al., 2006a Almaas et al., 2011). The minimum 
inhibitory concentration (MIC) of milk-derived AMPs have been shown to vary 
greatly; e.g. Cp1 αs1-casein f(99-109) has an MIC of 125µg/mL while Cr5 bovine 
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αs2-casein f(164-207) has an MIC of 4.8µg/mL against Listeria monocytogenes 
(McCann et al., 2006, McCann et al., 2005). 
Milk derived AMPs are typically relatively short (12 to 100 amino acids) and do not 
have conserved sequences. However, many of them have conserved characteristics. 
For example, the majority have a positive charge and are amphiphilic (Jenssen et al., 
2006). These characteristics have been proposed to facilitate interaction between the 
positively charged peptide and the negatively charged bacterial membrane (Martin et 
al., 1995). 
Information is lacking regarding the precise mode of action of milk derived AMPs. 
Lfcin B is one of the most highly researched milk derived AMPs. It has been shown 
to have pore forming ability (Hwang et al., 1998) and has been proven to inhibit the 
DNA, RNA and protein synthesis of Escherichia coli (Ulvante et al., 2004). Tu et 
al., (2011) identified Lfcin B intracellular targets using an E. coli proteome chip. 
They found phosphoenolpyruvate was a target suggesting one of its mechanisms of 
action may be associated with pyruvate metabolism. Pyruvate assays showed an 
abnormal accumulation of pyruvate when E. coli was exposed to Lfcin B (Tu et al., 
2011) and this could inhibit growth (Webb, 1968). However, further research is 
required to elucidate the intracellular targets of other milk derived AMPs.     
3.2 Milk oligosaccharides  
Human milk contains 10-20 g/L oligosaccharides, representing the third most 
abundant solid component in milk after fat and lactose (Séverin et al., 2005). The 
composition of HMO is very intricate in comparison to bovine milk (Boehm et al., 
2007). Currently, up to 200 different structures have been defined for HMO 
(Ninonuevo et al., 2006). Infants are unable to digest HMO (Gnoth et al., 2000), 
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which indicates their presence is connected to functions outside basic nutrition. Milk 
oligosaccharides and glycans are formed with the same types of glycosyltransferases 
that synthesise human cell surface glycans. Therefore, it is conceivable they would 
have structural moieties in common (Newberg et al., 2005). The milk glycans could 
competitively inhibit the ability of pathogens to bind to receptors in the gut. 
Alternatively, HMO may act as “receptor decoys” when pathogens bind to human 
milk glycans (oligosaccharides) instead of to the host cell surface glycans. Other 
functions of HMO include immunomodulatory effects and brain development (Kunz 
et al., 2000).  
3.3 Milk lipids 
Human milk contains approximately 4% lipids, which do not initially have 
antimicrobial activity but can become antiviral, antibacterial or antiprotozoal 
following digestion in the gastrointestinal tract (Issacs et al., 1990). The lipid 
fraction of human milk consists primarily of triglycerides, which are composed of 
three fatty acids covalently bound to a glycerol molecule by ester bonds. Microbial 
killing by milk lipids is primarily due to free fatty acids (FFA) and monoglycerides, 
which are released from milk triglycerides by both milk derived bile-salt-stimulated 
lipase and lipolytic activity in the gastrointestinal tract of the breast-fed infant 
(Tormar et al., 1987). Viruses appear to be the most susceptible to antimicrobial 
lipids and unsaturated fatty acids (oleic and linoleic acids) are the most antiviral of 
the lipids in human milk (Thormar et al., 2007, Isaacs et al., 1990).  The exact mode 
of action of the lipid fraction of human milk has not been fully determined, but 
antimicrobial activity is thought to be exerted through disruption of the lipid bilayer 
(Isaacs et al., 1994). Milk gangliosides have also been shown to reduce adherence of 
pathogens and promote growth of Bifidobacteria (Bode et al., 2004). 
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4. Applications of milk derived antimicrobials 
4.1 Food safety  
Food safety is a major issue in society. Microorganisms have adapted to changes in 
food production, processing and preservation techniques, resulting in a number of 
new and re-emerging foodborne pathogens (Skovgaard, 2003). Unknown agents of 
foodborne illness (yet to be identified or not detected) account for approximately 
81% of foodborne illness and hospitalizations (Woteki et al., 2003). In addition, an 
increasing proportion of our food is imported, chronic sequelae (e.g. Guillain Barre 
Syndrome) remain a significant problem and antibiotic resistant strains are 
constantly emerging. 
Parallel to the importance of food safety, consumer demand for more natural and 
minimally processed food has become an increasingly recognised market driver. To 
restrict the level of foodborne pathogens and spoilage bacteria, several approaches to 
food preservation have been developed; these include cold storage temperatures, 
drying, pH adjustment, fermentation, thermal processing and chemical preservatives. 
Many of these methods are severe and affect the overall quality, nutritional content 
and organoleptic properties of the product (Szczepaniak et al., 2011). Therefore, 
there is substantial interest in naturally produced antimicrobial agents as food 
preservatives -especially in the dairy industry, where there is the problem of spoilage 
from spore forming bacteria.  
Bacteriocins are antibacterial peptides produced by bacteria that kill or inhibit the 
growth of other bacteria. Nisin is currently the only bacteriocin widely used as a 
food preservative (Cleveland et al., 2001); however, its practical application is 
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limited because of its low stability, reduced activity at high pH and poor efficacy in 
certain food matrices (Pol et al., 2000). Thus, there is a need for more enhanced 
preservatives which could include development of a promising milk derived 
antimicrobial.   
Examples of peptides that may improve the safety of food, particularly infant milk 
formulae (IMF), are Caseicin A and Caseicin B (Hayes et al., 2006). These peptides 
were generated following fermentation of sodium caseinate with Bacillus isolates 
(Kent et al., 2012). They are active against Cronobacter sakazakii, a bacterium 
regarded as a significant problem in powdered IMF (Healy et al., 2010). The 
CODEX Alimentarius Commission (CAC/RCP 66-2008) has a zero tolerance policy 
for C. sakazakii in IMF. In addition, IMF is not sterile and bacterial contamination 
with naturally residing bacteria can occur if rigorous hygienic good manufacturing 
practices (GMP) are not maintained. An assessment of the ability of Caseicin A and 
B to kill C. sakazakii spiked in reconstituted milk formula found that the fermentate 
reduced pathogen numbers by >4 log cfu/ml, comparing favourably with the positive 
control monocaprylin (Hayes et al., 2009). A spectrum of activity against other 
infant formula pathogens, Listeria innocua and Pantoea agglomerans was also 
shown. This research reinforces the potential application of addition of the 
fermentate to infant formula during manufacture for use as a preservative to inhibit 
C. sakazakii.  
L. monocytogenes is a food borne pathogen associated with high rates of morbidity 
and mortality (Mead et al., 1999), especially in expectant mothers and infants. It has 
been the cause of considerable commercial loss, responsible for 71% of all recalls in 
food products between 1993 and 1998 (Wong et al., 2000). In addition, there has 
been an increase in the incidence of listeriosis (Goulet et al., 2008). The authors also 
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hypothesized that the recently reduced salt content in ready-to-eat products may 
allow growth of the organism if present as a contaminant. This could increase the 
likelihood of infection when these products are consumed by susceptible individuals. 
The discovery of a milk derived antimicrobial active against L. monocytogenes 
would also be a significant boost to food safety. An example is the novel 
antibacterial peptide (Cp1) which exhibited an MIC of 125µM against both strains of 
L. monocytogenes used in the study (McCann et al., 2006). However further research 
is required regarding the feasibility of addition of this milk derived AMP to food.   
Lactoferrin (LF) is an iron-binding glycoprotein found in milk, saliva, tears, seminal 
fluids, mucins, and the secondary granules of neutrophils (Naidu, 2002). Its ability to 
bind Fe
3+
 ions facilitates its antibacterial, antiviral and antiparasitic activity 
(Adlerova et al., 2008). Activated lactoferrin (ALF) is a form of lactoferrin, and the 
‘activation’ is a patented process. ALF is sprayed on meat surfaces to aid prevention 
of bacterial contamination during processing and is considered GRAS (Generally 
Recognized As Safe) by the FDA (Food and Drug Administration) (Naidu, 2002). 
The efficacy of ALF and LF to detach collagen-bound E. coli O157:H7 was 
measured by an in vitro adhesion blocking assay. The bacterial detachment efficacy 
of ALF was 2.7 log higher than the LF treatment. Activated lactoferrin was also 
shown to display activity against a myriad of foodborne pathogens including E. coli 
O157:H7, L. monocytogenes, Salmonella spp., Campylobacter spp., Vibrio spp. 
Staphylococcus aureus, Bacillus spp. yeasts and mould as well as DNA and RNA 
viruses (Naidu, 2002). There is potential for the application of this antimicrobial 
protein as a food safety preservative.   
Lactoperoxidase (LPO) is a glycoprotein naturally present in milk, which in itself 
has no antibacterial effect, but in combination with thiocyanate (SCN
-
) and hydrogen 
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peroxide (H2O2) forms a potent antimicrobial system (lactoperoxidase-thiocyanate-
hydrogen peroxide system) against a variety of microorganisms (bacteria, fungi and 
viruses). The LPO system has been recognized as important in the preservation of 
raw and pasteurized milk (Marks et al., 2001) by inhibiting various spoilage and 
pathogenic microorganisms (Seifu et al., 2005). Numerous investigations have been 
carried out on its potential application as a natural food preservative. For example, 
the LPO system has been used to inactivate or inhibit Salmonella Enteritidis in 
tomato juice, carrot juice, milk, eggs and chicken skin extract at various pH’s and 
temperatures. It was found to be an effective preservative in fruit and vegetable 
juices, reducing cell numbers by up to 5.4 orders of magnitude. However, it was less 
effective in animal products (Touch et al., 2004). The LPO system has also been 
shown to inactivate E. coli and Shigella spp. in acidic fruit and vegetable juices by 
>5 orders of magnitude (Van Opstal et al., 2006), further highlighting its potential to 
act as an effective preservative in acidic food. 
Research on antimicrobial peptides derived from milk fat globule membrane 
(MFGM) fractions is also underway. Xanthine oxidase is a well-characterized iron-
sulphur molybdenum flavoprotein that is present in MFGMs in mammary epithelial 
cells (Spitzberg, 2005), but is not present in IMF (Stevens et al., 2000). The enzyme 
can weakly generate superoxide and hydrogen peroxide from nitrates and nitrites 
(Millar et al., 1998) and displays antibacterial activity (Stevens et al., 2000). 
Hancock et al., (2002) showed that human and bovine milk inhibited E. coli 
metabolism and this activity was dependent on xanthine oxidase activity and the 
presence of nitrite. Clare et al., (2008) screened MFGM fractions against E. coli 
O157:H7, L. monocytogenes, S. Typhimurium, P. fluorescence, B. cereus, 
Lactobacillus acidophilus and Lactobacillus gasseri. Antibacterial activity was 
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displayed against each of the pathogens, while no activity was observed against the 
Lactobacillus strains. Therefore, there is application potential for the addition of 
xanthine oxidase to infant formula or creation of a fraction from MFGM with higher 
antibacterial activity.   
“High energy” sports drinks can be quite acidic and this may lead to dental erosion 
(Mathew et al., 2002), especially in athletes with a stressed immune system. Raising 
the pH of the drinks may solve this problem, but simultaneously increases the risk of 
spoilage or occurrence of pathogenic bacteria. The bacteriocin enterocin AS-48 
(produced by Enterococcus faecalis) is an example of an antimicrobial peptide that 
may act as a natural preservative against these bacteria in less acidic sports drinks 
(Viedma et al., 2009). This study adjusted commercial energy drinks to pH 5, 
subjected the drinks to L. monocytogenes, S. aureus, Bacillus cereus and Bacillus 
licheniformis and stored them at 37°C. Addition of enterocin AS-48 (1mg/ml) 
rapidly inactivated L. monocytogenes in all the drinks tested, while the rest of the 
bacteria were killed with higher levels of enterocin AS-48 (12.5mg/ml). Discovery 
of a milk derived antimicrobial with the same function is possible. It could be added 
as a preservative to reduce the risk of dental caries. 
4.2 Functional Foods 
There are many definitions for functional foods and these are constantly evolving. A 
commonly used definition is a food which “besides nutritional effects has 
demonstrated a benefit for one or more functions of the human organism improving 
the state of health or well being or reducing the risk of disease” (Diplock et al., 
1999). There are numerous prospects for the addition of milk-derived antimicrobials 
to food products due to their wide variety of properties (evoking nutritional, 
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hormonal, immunological, neurological and nutritional responses). This may provide 
a variety of functions in that it could aid in limiting or reducing severity of the 
disease or act as a prophylaxis. Incorporation into the diet as a functional food 
therefore has the potential to decrease morbidity, mortality and healthcare costs 
related to intestinal infections (Gardiner et al., 2009). The remainder of this review 
will focus on examples of potential functional food applications in different areas of 
the dairy industry.    
4.2.1 Dental Hygiene 
 Streptococcus mutans is one of the causative agents in the development of dental 
caries (Huo et al., 2011), which is a highly prevalent disease. Once S. mutans 
adheres to the buccal surface of the tooth, acid formed by the bacteria due to 
fermentation of sugars accumulate in plaque on the teeth thereby leading to tooth 
decay (Loesche, 1986). The acid-forming and acidophilic properties of S. mutans, 
along with its ability to generate extracellular glucans, are important factors in the 
progression and maintenance of cariogenic biofilms (Loesche, 1986). 
Porphyromonas gingivalis is a black pigmenting oral anaerobe and is one of the 
primary aetiological agents of periodontal disease, a disorder of the tissues 
surrounding and supporting the teeth (periodontium).  
Malkoski et al., (2001) demonstrated that CMP (caseinomacropeptide), a C-terminal 
fragment of bovine milk κ-casein, inhibits the growth of oral pathogens P. gingivalis 
and S. mutans, as well as E. coli. This group also identified the active component as 
nonglycosylated Ser(P)
149 κ-casein-A (106-169), and designated this novel peptide 
kappacin. Huo et al., (2011) investigated the antimicrobial activity of a peptide 
fragment of human lactoferrin (hLF1-11) against S. mutans which displayed a 
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median MIC of 23.28µM. Halpin et al., (2008) investigated the ability of dairy 
powders and individual milk proteins to inhibit adhesion of S. mutans to 
hydroxylapatite (an analogue of tooth enamel). Whey protein concentrate 80 (sweet 
and acid), sodium caseinate and the casein fractions α-, β-, and κ-casein were found 
to have high levels of anti-adhesive activity. In addition to kappacin and hLF1-11, 
these proteins may have potential benefit in a functional food, such as soft cheeses 
and milk. This would be of particular importance to young children and the elderly 
who may not have sufficient dental hygiene. 
Other potential uses would be in oral care products such as toothpaste, mouth wash 
and chewing gum. One major advantage of these is there is straightforward 
accessibility to the oral cavity if supplemented as a functional food or an oral care 
product. A patent has been filed (Warner-Lambert Company) to use CPP 
(caseinophosphopeptide), a phosphorylated casein-derived peptide, in chewing gum 
compositions to promote anticariogenicity (Aimutis, 2004). In addition, there are 
examples of toothpastes (e.g. BioXtra
® 
and Oralbalance
®
) that contain the 
lactoperoxidase system, lysozyme and lactoferrin (Tenovuo, 2002) to improve dental 
health. These products could aid in lowering the vast number of people affected by 
dental caries and chronic periodontitis. In addition to these studies, there is the 
potential for the discovery of antimicrobials in milk with improved activity against 
dental pathogens.  
4.2.2 Infant Formula/Diseases 
Formula-fed infants have been shown to have higher levels of gastroenteritis than 
breast-fed infants (Quigley et al., 2007); therefore, there are opportunities for the use 
of IMF as a functional food, in order to limit the incidence of gastroenteritis in 
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bottle-fed infants. The mother’s breast milk is widely known to constitute the best 
nourishment for neonates and infants. However, various situations exist where breast 
feeding is either not possible (HIV positive mother, illness, etc) or is not chosen, and 
synthetic preparations are required. IMF has been extensively used as an alternative 
for infants instead of bovine milk. The nutritional material of milk shows significant 
disparity among species in regards to the individual components. Thus, the use of 
modified or “humanized” bovine milk in infant formula, designed to simulate human 
milk as a substitute or supplement, is an important area of research. Modifications to 
infant formulae are regularly being made as the components of human milk are 
characterized and the nutrient requirements of diverse groups of infants are identified 
e.g. soy-based, lactose free and preterm IMF (Carver, 2003; Carver, 2001).  
IMF are increasingly enriched with plant oligosaccharides and enzymatically linked 
galactooligosaccharides, which have prebiotic activity. However, they lack the 
intricacy and variety of natural HMOs, and are therefore unlikely to successfully 
imitate the structure-specific effects of HMO (Fanaro et al., 2005). HMOs have been 
shown to bind to the intestinal membrane guanylin cyclase receptor, which in turn 
blocks binding by the stable toxin (STa) of enterotoxigenic E. coli (Crane et al., 
1994). A fucosylated oligosaccharide (α-1,2-linked) from human milk inhibited 
binding of invasive strains of Campylobacter jejuni to its host cell (Ruiz-Palacios et 
al., 2002). These studies suggest HMO have potential applications in the 
development of IMF as a functional food to facilitate tackling gastrointestinal 
disease. However, the disadvantages of HMO addition to IMF include difficulty in 
reproduction of the complex composition and structure of HMO.  
Rotavirus is a major infant pathogen which is a significant cause of severe 
dehydration diarrhoea in infants, 95% of all children are infected before the age of 5 
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resulting in approximately 600,000 deaths annually (Glass et al., 2006). Milk-fat 
globule membrane (MFGM) proteins, MUC1, butyrophilin and lactoadherin have 
been demonstrated to inhibit rotavirus replication in MA104 and Caco-2 cell lines 
(Kvistgaard et al., 2004). This study illustrated that lactoadherin possesses rotavirus 
inhibitory activity, as it considerably reduced rotavirus infections in vitro. Perez-
Cano et al., (2008) showed supplementing rats with whey protein concentrate (WPC) 
modulated the immune response against the virus and reduced the severity of 
infection. WPC has also been found to reduce diarrheal induced symptoms in 
suckling mice (Wolber et al., 2005). Therefore, there is potential for addition of a 
milk derived anti-rotaviral to IMF or dairy products (cheese or yogurt) as a 
functional food. The dairy products could be given to young children of crèche going 
age and may potentially decrease the frequency and severity of the illness.        
4.2.3 Sports Drinks 
Whey protein supplements, including purified α-lactalbumin have been added to 
sport drinks due to their high protein content. While moderate exercise enhances 
immunity (Davis et al., 2004), intense athletic training has been shown to stress the 
immune system (Mackinnon, 2000). Bioactive components found in whey (e.g. IgA, 
glutamine and lactoferrin) may potentially benefit athletes by improving immune 
function, gastrointestinal health and exhibiting anti-inflammatory activity (Marshall, 
2004). 
4.2.4 Gastrointestinal Diseases 
Improving gastrointestinal health is a key issue in today’s society and the addition of 
a milk-derived antimicrobial to improve health or act as a prophylaxis against 
infection would be of interest to the dairy industry. Sprong et al., (2001) investigated 
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the efficacy of bovine milk lipids (digestion products of bovine milk triglycerides 
and membrane lipids) in potentially inhibiting gastroenteritic bacteria through 
bactericidal well diffusion assays. The pathogens tested were C. jejuni, S. enteritidis 
phage type 4, E. coli O157:H7, Clostridium perfringens and L. monocytogenes. The 
bactericidal activity of fatty acids depended on chain length; C10:0 and C12:0 fatty 
acids were toxic to all of the test pathogens. The authors hypothesised if these fatty 
acids are released during gastric digestion of milk lipids they may inhibit 
gastrointestinal infections. However, the feasibility issues of adding too much fatty 
acids or monoglycerides for antimicrobial activity include increased cost and impact 
on taste.  
Table 1 lists the antimicrobial peptides from human and bovine milk discovered to 
date. Many of these have activity against pathogens in the gastrointestinal tract; e.g. 
β-casein f(184-210) has antibacterial activity against E. coli and Salmonella species 
as well as S. aureus, Enterobacter faecium, and Yersinia enterocolitica (Minervini et 
al., 2003). Utilizing these peptides as components of a functional food in order to 
improve gastrointestinal health and reduce severity of illness is very promising.      
In regards to non-gastrointestinal infections, human lactoferrin has been found to 
interfere with the development of the HSV-1 infection at several steps of the viral 
replication cycle and with HSV-1 cell-to-cell spread in a dose and virus strain 
dependent approach (Välimaa et al., 2009). Isaacs et al., (2004) created a 
microbicide combining a milk-derived lipid-ether and a synthetic antimicrobial 
peptide and found it reduced both HSV-1 and HSV-2 by at least 1,000 fold more 
than the sum of the inactivations produced by the lipid-ether and the peptide alone. 
Therefore, there are possibilities for use of this microbicide as a functional food to 
aid limiting the occurrence and duration of cold sores (HSV-1).      
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Table 1 Milk derived antimicrobial peptides discovered to date (human and bovine)  
Name 
 
Size (amino acids) 
Actual or 
Theoretical Mw 
(Da) Charge 
Method of discovery Activity Spectrum MIC Reference 
Casein derived AMPs       
αS1-caseins       
Isracidin (bovine αS1-casein), (αS1-
CN f(1-23) 
1RPKHPIKHQGLPQEVLNENLLR
F23 
2770 
+ charge 
Chymosin digestion of 
bovine αs1- casein 
S. aureus, L. monocytogenes,  
E. coli, Candida albicans 
0.1-1 mg/ml for Gram 
positives   
0.059mM for E. coli 
Lahov et al., 1996 
Hayes  et al., 2006 
Cp1 (αS1-casein), (αS1-CN f(99-
109) 
99LRLKKYKVPQL109 1386 
+ charge 
Pepsin hydrolysate of 
bovine sodium caseinate   
B. cereus, L .innocua, L. monocytogenes, Citrobacter 
freundii, Enterobacter aerogenes, E. coli, S. 
enteritidis, S. Typhimurium 
125-1000µg/ml McCann et al., 2006 
Caseicin A Residues 21-29 of bovine αS1-
casein 21IKHQGLPQE29 
 
1049 
+ charge 
 
Degradation of sodium 
caseinate by Bacillus 
isolates 
E. coli, C. sakazakii 0.05mM Hayes et al., 2006 
Kent et al., 2012 
Caseicin B Residues 30-37 of bovine αS1-
casein 30VLNENLLR37 
 
970 
neutral 
Degradation of sodium 
caseinate by Bacillus 
isolates 
E. coli, C. sakazakii  0.22 mM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Hayes et al., 2006
Kent et al., 2012 
Caseicin C Residues 195-208 of αS1-casein 
195SDIPNPIGSENSEK208 
1486.56 
+ charge 
Degradation of sodium 
caseinate by Bacillus 
isolates 
E. coli, and minor activity against Listeria innocua 1mM Hayes et al., 2006 
Kent et al., 2012 
αs2-Caseins:        
Casocidin-I (bovine milk) Residues 165-203 of αS2-casein 
165KTKLTEEKNRLNFLKKISQRY
QKFALPQYLKTVYQHQK203 
4870 
+ charge 
Isolated from bovine milk  E. coli and Staphylococcus carnosus 3mm zone of inhibition 
with10µl of sample 
Zucht et al., 1995 
Cationic bovine αs2-CN f183-207 183VYQHQKAMKPWIQPKTKVIP
YVRYL207 
3115 
+ charge 
Pepsin hydrolysate of αs2-
casein    
E. coli, L. innocua, B. cereus, Micrococcus flavus, 
Streptococcus thermophilus 
25-99µM Reiko et al., 1999  
Cationic bovine αs2-CN f164-179 164LKKISQRYQKFALPQY179 2011 Peptic hydrolysate of αs2- E. coli, L. innocua, B. cereus, M. flavus, S. 8-16µM Reiko et al., 1999 
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+ charge casein    thermophilus 
β-Caseins       
β-CN f(184-210) human β-casein 184QELLLNPTHQYPVTQPLAPVH
NPISV210 
 
3133 
+ charge 
 
 
Hydrolysis of sodium 
caseinate with a proteinase 
of Lb. helveticus 
E. coli, S. aureus, Enterobacter faecium, Y. 
enterocolitica, Salmonella species, Lactobacillus 
species, Bacillus megaterium and L. innocua  
50-100µg/ml Minervini et al., 
2003 
Casecidin 15 bovine β-casein(193-
207) 
193YQEPVLGPVRGPFPI207 
 
1668 
No charge 
Naturally found in bovine 
colostrum 
E. coli 
  
0.4-0.5mg/ml 
  
Birkemo et al., 2008 
Casecidin 17 bovine β-casein (193-
209) 
193YQEPVLGPVRGPFPIIV209 1881 
No charge 
Naturally found in bovine 
colostrum 
E. coli  
 
0.4-0.5mg/ml 
 
Birkemo et al., 2008 
κ-Caseins       
Caseinomacropeptide (CMP) 
(bovine milk) 
Residues 106-169 of bovine 
milk κ-casein  
AIPPKKNQDKTEIPTINTIASGEP-
TSTPTTEAVEST-
VATLEDSPEVI-ES-PPEINTVQ-
VTSTAV 
7678 
+ charge 
Hydrolyses of κ-casein by 
chymosin   
Influenza, Vibrio cholerae, Streptococcus mutans, P. 
gingivalis, E. coli 
1.7mg/ml for S. mutans, 
3.8mg/ml for P. gingivalis  
4.3mg/ml for E. coli   
Malkoski et al., 2001 
Kappacin Residues 106-169 of bovine к-
casein 
106AIPPKKNQDKTEIPTINTIASG
EP-TSTPTTEAVEST-
VATLEDSPEVI-ES-PPEINTVQ-
VTSTAV109  
7678 
Anionic 
phosphopeptide 
 
RP-HPLC of 
Caseinomacropeptide 
S. mutans 59µg/ml Birkemo et al., 2008, 
Malkoski et al., 2001  
Bovine κ-casein f(18-24) 18FSDKIAK24 807 
+ charge 
Hydrolyses of κ-casein by 
pepsin   
L. innocua, E. coli, S. carnosus  MIC not determined López Expósito et 
al., 2006b 
Bovine κ-casein f(30-32) 30YVL32 393 
Neutral 
Hydrolyses of κ-casein by 
pepsin   
L. innocua, Serratia marcescens, S. carnosus MIC not determined López Expósito et 
al., 2006b 
Bovine κ-casein f(139-146) 139VESTVATL146 818 
- charge 
Hydrolyses of κ-casein by 
pepsin   
L. innocua, E. coli, S. carnosus MIC not determined López Expósito et 
al., 2006b 
Bovine κ-casein f(34-75) 34PAAVRSPAQILQ75 1250 
+ charge 
Hydrolyses of κ-casein by 
pepsin   
E. coli MIC not determined López Expósito et 
al.,  2006b 
Bovine κ-casein f(28-30) 28IQY30 422 
neutral 
Hydrolyses of κ-casein by 
pepsin   
E. coli MIC not determined López Expósito et 
al., 2006b 
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Bovine κ-casein f(42-49) 42YYQQKPVA49 955 
+ charge 
Hydrolyses of κ-casein by 
pepsin   
E. coli, S. carnosus MIC not determined López Expósito et 
al.,  2006b 
Bovine κ-casein f(25-29) 25EIPT29 657 
- charge 
Hydrolyses of κ-casein by 
pepsin   
E. coli, S. marcescens MIC not determined López Expósito et 
al., 2006b 
Bovine κ-casein f(118-121) 118RINKK121 529 
+ charge 
Hydrolyses of κ-casein by 
pepsin   
E. coli  MIC not determined López Expósito et 
al., 2006b 
Human  κcasein f(63-117) 63YQRRPAIAINNPYVRTYYANP
AVVRPHAQUIQRQYLPNSHPPT
VVRRPNLHPSF117 
6430 
+ charge 
Hydrolyses of κ-casein by 
pepsin   
S. carnosus, Gram positive and Gram negative 
bacteria and yeast  
MIC not determined Liepke et al., 2001 
Miscellaneous       
Casecidins amino acid sequence not 
published   
Data not shown 
+ charge 
Chymosin digestion of 
caseins  
S. aureus, Sarcinia, Bacillus subtilis, Diplococcus 
pneumoniae, Streptococcus pyogenes and some 
Lactobacillus 
MIC not determined  Lahov et al., 1996 
 
Bovine αs1-casein f(24-33) 24FVAPFPEVFG33 1109 
+ charge 
Isolated from water 
soluble extract of cheese 
E. coli, B. megaterium, L. innocua, S. aureus, 
Salmonella spp., Y. Enterocolitica, Lactococcus 
lactis and Lactobacillus species 
70-250 μg/ml Rizzello et al., 2005 
181-207 Cr1  Bovine αs2-casein 181KTVYQHQKAMKP-
WIQPKTKV-IPYVRYL207 
3346 
+ charge 
Chymosin digest of bovine 
sodium caseinate 
B. cereus, B. subtilis, L. innocua, L. monocytogenes, 
E. coli, S. Enteritidis, S. Typhimurium     
>84ug/ml for B. cereus 
21µg/ml for B. subtilis, L. 
mono, L. innocua and S. 
Typhimurium    
 >168µg/ml for E. coli,  
>68µg/ml for S. Enteritidis   
McCann et al., 2005 
180-207 Cr3 
Bovine αs2-casein 
180LKTVYQHQKAMKPWIQPKT
KV-IPTVRYL207 
3458 
+ charge 
Chymosin digest of bovine 
sodium caseinate 
Data not shown MIC not determined McCann et al., 2005 
175-207 Cr4 
Bovine αs2-casein 
175ALPQYLKTVYQHQKA-
MKPWIQP-KTKVIPYV-RYL207 
4031 
+ charge 
Chymosin digest of bovine 
sodium caseinate 
 B. subtilis, L. innocua, L. monocytogenes, E. coli, S. 
Typhimurium     
10.7µg/ml for  B. subtilis, L. 
innocua, L. monocytogenes, 
>171.2µg/ml for E. coli,  
21.4µg/ml for S. Typhimurium 
McCann et al., 2005 
164-207 Cr5/Cr6 
Bovine αs2-casein 
164LKKISQRYQKFALPQYLKTV
YQHQKAMKPWIQPKTKVIPYV
RYL207 
5453 
+ charge 
Chymosin digest of bovine 
sodium caseinate 
B. subtilis, L. innocua, L. monocytogenes, E. coli   4.8µg/ml against  B. subtilis, L. 
innocua, L. mono, >76.2µg/ml 
for E. coli 
McCann et al., 2005 
172-207 Cr7  Bovine αs2- casein 172QKFALPQYLKTVYQHQKAM
KPWIQPKTKVIPYVRYL207 
4436 
+ charge 
Chymosin digest of bovine 
sodium caseinate 
Data not shown MIC not determined McCann et al., 2005 
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Whey derived AMPs 
 
      
-Lactoglobulin f(15-20) LGDT2 15VAGTWY20 700 
- charge 
Hydrolysis of bovine  -
lactoglobulin with pepsin 
B. subtilis, M. luteus, S. aureus, Staphylococcus 
epidermidis, S. lentus   
MIC not determined Pellegrini et al., 
2001 
Benkerroum, 2010 
-Lactoglobulin f(25-40) LGDT4 25AASDISLLDAQSAPLR40 1630 
+ charge 
Hydrolysis of bovine  -
lactoglobulin with pepsin 
B. subtilis, S. lentus, S. zooepidemicus   MIC not determined Pellegrini et al., 
2001 
Benkerroum  2010 
-Lactoglobulin f(78-83) LGDT1 78IPAVFK83 670 
- charge 
Hydrolysis  of bovine  -
lactoglobulin with pepsin 
B. subtilis, S. lentus, S. zooepidemicus   MIC not determined Pellegrini et al., 
2001 
Benkerroum, 2010 
-Lactoglobulin f(92-100) LGDT3 92VLVLDTDYK100 1070 
amphipathic 
Hydrolysis of bovine  -
lactoglobulin with pepsin 
B. subtilis, M. luteus, S. aureus, S. epidermidis, S. 
lentus   
MIC not determined Pellegrini et al., 
2001 
Benkerroum, 2010 
Bovine α-lactalbumin f(1-5) LDT1 1EQLTK5 620 
- charge 
Hydrolysis of bovine  α-
lactalbumin with trypsin 
Bordetalla bronchiseptica, B. subtilis, M. luteus, S. 
epidermidis, S. luteus, S. zooepidemicus   
MIC not determined Pellegrini et al., 
1999 
Benkerroum, 2010 
Bovine α-lactalbumin f(17-31) S-S 
(109-114) LDT2 
GYGGVSPLEWVCTTF ALCSEK 2250 
- charge 
Hydrolysis of bovine  α-
lactalbumin with trypsin 
B. subtilis,Klebsiella.pneumoniae, M. luteus,S. 
aureus, S. epidermidis, S. luteus, Streptococcu 
zooepidemicus   
MIC not determined  Pellegrini et al., 
1999 
Benkerroum, 2010 
Bovine α-lactalbumin f(61-68)S-
S(75-80) LDC  
CKDDQNPH ISCDKF 1650 
- charge 
Hydrolysis of bovine  α-
lactalbumin with 
chymotrypsin 
B. bronchiseptica,  K.pneumoniae P. aeruginosa, B. 
subtilis,S. aureus, S. epidermidis, S. luteus, S. 
zooepidemicus   
MIC not determined Pellegrini et al., 
1999 
Benkerroum,  2010 
Lactophoricin 
derived from sequence of bovine milk 
component-3 of protease peptone 
1NTVKETIKYLKSLFSHAFEVVK
T23
 
2380 
+ charge 
Synthesized by Synergy 
423 peptide synthesizer  
S. aureus, L. innocua, Salmonella spp., 
Pseudomonas aeruginosa, E. coli 
>300µM Campagne et al., 
2004 
Lactoferricin B  17FKCRRWQWRMKKLGAPSITC
VRRAF41  
3125 
+ charge 
Pepsin enzymatic cleavage 
of lactoferrin 
Broad spectrum against of activity Gram positive 
and Gram negative including L. monocytogenes and 
E. coli  
0.6-45µg/ml Haukland et al., 
2001, Bellamy et al., 
1992 
Lactoferrampin 
Derived from N1 domain of bovine 
lactoferrin 
WKLLSKAQEKFGKNKSR 2047 
+ charge 
Synthesized by Fmoc-
chemistry on a MilliGen 
9050 peptide synthesizer 
B. subtilis, E. coli, P. aeruginosa   2.1-25 µM Van der Kraan et al., 
2004 
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5. Discussion 
This review discusses the potential applications of milk derived antimicrobials in the 
dairy industry, including their applications as functional foods. The market potential 
for functional foods is increasing rapidly; in 2008 the entire functional food market 
was worth an estimated US$80 billion (Vergari et al., 2011) and this figure is rapidly 
increasing with Global Industrial Analysts (GIA) estimating it will reach US$130 
billion by 2015. This market could include the addition of milk derived 
antimicrobials for use as a functional food due to their potential to reduce the 
severity of an infection or act as a prophylaxis.     
Milk derived antimicrobials display the advantage of having a broad spectrum of 
activity. In addition, they originate from a safe and inexpensive resource. For 
example, whey protein is a by-product of cheese making; consequently, there is 
enormous capacity for its use in the dairy industry. More research is required to 
determine the viability of integrating the antimicrobials discovered so far into food. 
There is clearly a large spectrum of milk derived antimicrobials, but more 
investigations need to be performed to unearth antimicrobials with higher MICs 
against pathogenic bacteria and greater/varying spectrums of activity. This is of 
particular significance at a time where the problem of antibiotic resistance is 
overwhelming (Cantón et al., 2011) and people are becoming more susceptible to 
infectious diseases (Rocourt et al., 2003). Another consideration is that antimicrobial 
factors in milk have been shown to work synergistically, thereby further enhancing 
their activity. The total antibacterial effect in milk is greater than the sum of the 
individual components. For example, López-Expósito et al., (2008) investigated the 
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synergistic effect of two milk derived peptides, bovine lactoferricin (Lfcin B) 
(lactoferrin f(17-41)) and bovine αs2-casein f(183-207), in conjunction with nisin or 
lactoferrin. Lfcin B is a potent milk derived antimicrobial peptide corresponding to a 
fragment of lactoferrin. In combination with lactoferrin it revealed a synergistic 
effect against E. coli and S. epidermidis. Bovine lactoferrin and nisin both increased 
their antimicrobial activity when used in combination with αs2-casein f(183-207).  
5.1 Identifying novel milk derived antimicrobials 
Identification of novel milk antimicrobials (Figure 1) focuses on the co-ordinated 
dissection of milk to uncover a new array of bioactive substances with the potential 
to positively impact on human health. This includes microbial fermentation with 
proteolytic bacteria or enzymatic hydrolysis with digestive enzymes such as trypsin 
and pepsin. In addition, knowledge in bioinformatics tools is required to identify 
milk derived antimicrobials. Metagenomic analysis may be necessary to determine 
the effects the milk components have on the bacteria in the human gut. Other 
sophisticated cell- and 'omics'- based technologies, e.g. proteomics, glycomics, 
glycoproteomics and lipidomics, may be utilized to identify fractions with 
prospective bioactivity and to clarify their mechanism(s) of action. Proteomics is the 
study of the whole set of proteins encoded by a genome and encompasses protein 
expression, structure and function. It has the ability to scientifically prove the safety 
of new products. Proteomic research offers opportunities for the dairy industry in 
process optimization and monitoring, quality and traceability, safety and nutritional 
evaluation (Pedreschi et al., 2011). 
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Fig.1 A schematic diagram of the processes involved in identification of novel milk 
derived antimicrobials 
Milk 
proteins
Proteolytic 
bacteria e.g. 
Lactobacillus
+
Bioinformatic based 
molecular approaches to 
identify peptides
Infection/immunity 
assays
(direct antagonism, cell culture)
Identify peptides in active 
fractions
(mass spectrometry, sequence 
analysis)
Characterize peptide
(chemically synthesize peptide of 
interest, confirm bioactivity, assess 
precise mode of action)
Generate 
hydrolysates/fractions
(membrane filtration, RP-HPLC)
Enzymatic hydrolysis of milk proteins
e.g. pepsin, chymosin, trypsin
Chemical synthesis of 
peptides of interest
Infection/immunity 
assays
(direct antagonism, cell culture)
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5.2 Technologies required for the production of food containing milk derived 
antimicrobials 
Until recently, the production of milk derived antimicrobials was limited due to a 
lack of appropriate large scale technologies (Korhonen et al., 2006). Novel 
techniques such as mass spectrometry, chromatographic techniques and membrane 
separation technology help solve this problem through enriching peptides with a 
specific molecular weight range (Korhonen et al., 2007). Mass spectrometry based 
techniques enable the characterization of human and animal milk components in 
fresh and processed milk (Casado et al., 2009). Ion exchange membrane 
chromatography can be used for the enrichment of peptide fractions from protein 
hydrosylates.  
Separation technologies are used to concentrate foods, as well as extract the relevant 
minor components. Spray drying is essential in order to convert fluid materials into 
solid or semi-solid particles (Murugesan et al., 2011) and it is the most often used 
encapsulation technique utilized by the food industry (Reineccius, 2004). To ensure 
accurate delivery of antimicrobials their bioavailability needs to be optimized. The 
formulation and stability of the peptide in certain food matrices and during digestion 
is vital to guarantee successful human delivery of the most promising milk derived 
bioactives. Microencapsulation or nanoencapsulation may provide solutions in 
enhancing stability of the peptide. Microencapsulation ensures protection of 
unstable, sensitive materials from environmental conditions, allowing controlled and 
targeted release of the materials. It can mask the odour or taste, is easier to handle 
and has better processing ability (Kuang et al., 2010). For example, enzymatic 
digestion can be used effectively to prepare bioactive preparations for formulation in 
infant functional food. However, it is necessary to inactivate the enzyme after a 
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certain time, which causes impurities in the final product. A fungal protease 
encapsulated with nanoparticles was shown to be a simple, rapid and efficient 
method for generating peptides from casein. Also, the use of sonication enhanced the 
production of the peptides by shortening the process (Madadlou et al., 2011). This 
study suggested it may help industrialization of enzymatic production of functional 
products from casein and milk. Microencapsulation is used to guarantee drug 
delivery in the pharmaceutical industry and these technologies could certainly be 
adapted for use in the dairy industry. 
Membrane–based technology such as nanofiltration, ultrafiltration and diafiltration 
procedures are also utilized to produce ingredients which contain specific bioactive 
peptides based on casein or whey protein hydrolysates (Korhonen, 2009). 
Nanofiltration and ultrafiltration concentrate the protein and diafiltration generates 
whey protein concentrate (WPC) (Casado et al., 2009). High throughput assays, for 
example Lux-tagging C. sakazakii so its growth can be easily monitored in IMF 
(Morrissey et al., 2011), and a diverse array of expertise in the latest cutting-edge 
technologies are needed to enhance production of new milk derived antimicrobials.  
A study design investigating the in vitro and in vivo models needs to be set up to 
validate health claims. This is imperative in order to satisfy the regulatory 
organizations. Regulatory issues are an important factor to consider in particular with 
reference to health claims. Finally, consumer acceptance is another issue of 
paramount importance. The health or wellness benefit must be very clear, convenient 
and contain fewer additives, taste must not be affected and price is also an issue. 
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6. Conclusion 
This review discusses the potential applications of milk derived antimicrobials for 
the dairy industry. These include the areas of food safety and functional food. It is 
evident there are a considerable number of promising applications. However, further 
research into the feasibility of utilizing these antimicrobials is essential. In addition 
progress in the development of new technologies will enhance discovery and 
production of new milk derived antimicrobials for the dairy industry. 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
 
 
 
 
           Thesis Introduction  
 
 
 
 
 
 
 
 
 
54 
 
 
This thesis was written with a view to publishing as many sections as possible. As 
several comprehensive reviews of Cronobacter spp. are available in the literature 
(Norberg et al., 2012, Yan et al., 2012 Healy et al., 2010), it was decided instead to 
focus the literature review on milk-derived antimicrobials. Short overviews of 
Cronobacter spp. and Lux-technology are also provided. 
 
Introduction - 1; Cronobacter spp. 
Cronobacter spp. (previously known as Enterobacter sakazakii) are Gram-negative, 
catalase positive, oxidase negative, motile by peritrichous flagellae, rod shaped, non-
spore forming bacteria belonging to the Enterobacteriaceae family. This ubiquitous 
micro-organism has been associated with severe neonatal infections; these include 
meningitis, meningoencephalitis, sepsis, and necrotising enterocolitis. It is also 
associated with serious sequelae including brain abscess and impaired sight and 
hearing (Muytjens et al., 1983). The bacterium was first implicated in a case of 
neonatal meningitis in 1958 when an outbreak resulted in the death of two infants in 
England (Urmenyi et al., 1961). Although the frequency of infection generally tends 
to be low, the prognosis is poor with case-mortality rates varying from 33-80% 
among infected infants (Lai, 2001). Consequently, Cronobacter spp. have been 
ranked as a ‘severe hazard for restricted populations, life threatening or substantial 
chronic sequelae or long duration’ by the International Commission for 
Microbiological Specifications for Foods, which places this pathogen in the same 
grouping as Listeria monocytogenes, Cryptosporidium parvum and Clostridium 
botulinum types A and B (ICMSF).         
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Taxonomy 
Cronobacter spp. was defined as ‘yellow pigmented Enterobacter cloacae’ until 
1980, when it was designated a new species, E. sakazakii by Farmer et al., (1980). 
The reclassification was based on differences in DNA-DNA hybridization, 
biochemical reactions, pigment production and antibiotic susceptibility. Analysis of 
both partial 16S ribosomal DNA (rDNA) and hsp60 housekeeping gene sequences 
revealed that E. sakazakii consists of at least four distinct clusters and it was 
hypothesized that clusters 2, 3 and 4 may represent original species (Iverson et al., 
2004b). Based on DNA-DNA hybridisation and phenotyping, E. sakazakii was 
subsequently proposed to be reclassified into a new genus, Cronobacter, composed 
of six distinct species: Cronobacter sakazakii, C. malonaticus, C. turicensis, C. 
muytjensii, C. dublinesis and a Cronobacter genomospecies group 1 (Iversen et al., 
2008). Two new species were recently added to the genus; C. universalis and C. 
condimenti, which replaced the original genomospecies 1 (Joseph et al., 2012a).   
Reservoir 
The natural environment of Cronobacter is not known, but these appear to be widely 
distributed microorganisms. They have been isolated from a number of environments 
including hospitals, dust from households and food production lines and soil (Kandhi 
et al., 2004, Khan et al., 1998). In addition, Cronobacter has been isolated from 
foods such as fruits, vegetables, herbs, cereals grains, cheese, fermented bread, tofu, 
sour tea, cured meat, minced beef, sausage meat and water (Friedemann, 2007, 
Iverson et al., 2004c Farmer et al., 1985). Schmid et al., (2009) characterized two C. 
sakazakii isolates from plant roots and the root colonization behaviour of nine 
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Cronobacter strains originating from clinical and plant sources was assessed. The 
results indicated that plants may be the natural habitat of Cronobacter spp. 
Growth in infant milk formula (IMF) 
Powdered IMF has been identified as one of the major contamination sources and 
transmission vehicles. This in particular poses a serious risk of infection for 
immature neonates whose immune systems are not fully developed (Mullane et al., 
2006). Low birth weight neonates (<2.5kg) and infants less than 28 days old are at 
increased risk compared to more mature infants (Caubilla-Barron et al., 2007). 
Definitive links between the presence of C. sakazakii in IMF and an outbreak of 
infection has been reported (CDC, 2002).  
Infant formulae are pasteurised during manufacturing and Cronobacter does not 
survive such heat treatment (Nararowec-White et al., 1997b). However IMF is not 
sterile and contamination with Cronobacter can occur if strict microbiological 
standards are not maintained. Two main routes of IMF contamination are considered: 
external and intrinsic contamination. External contamination is caused by poor 
handling; e.g., the reconstitution of IMF using equipment contaminated with 
Cronobacter. In intrinsic contamination, the ingredients added during processing, 
drying or packaging are contaminated. It has been suggested that plant-originated 
IMF ingredients that are not heat treated are potential sources of contamination 
(Healy et al., 2010).  
 Voluntary recalls of IMF contaminated with C. sakazakii has occurred in the United 
States, Europe and Asia which has led health care facilities, manufactures and 
governing bodies to improve hygienic practices and maintain higher microbiological 
standards (Chenu et al., 2009).    
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Detection methods 
Traditional methods for isolation and detection of Cronobacter from IMF have been 
shown to be quite time-consuming. Detection requires sequential growth steps in 
broth and selective agar media that can take 6-7 days to complete (FDA, 2002). 
There are also problems with specificity, especially when discriminating between 
Cronobacter spp. and other Enterobacter species (Lampel et al., 2009). Recently, the 
FDA has devised a new method for detection of Cronobacter in milk which is 
undergoing validation (Figure 1). This involves a real time PCR assay and 
chromogenic agars (Lampel et al., 2009). Lampel et al., (2009) tested the new 
method and found it drastically shortened the detection time to 24-48 hours. 
Sensitivity and specificity were also increased using the new method.        
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Fig 1. Schematic summary of new FDA method for isolating Cronobacter from IMF 
(adapted from Lampel et al., 2009). BPW (buffered peptone water), PBS (phosphate 
buffered saline), DFI (Druggan, Forsythe, Iversen), R&F® (Enterobacter sakazakii 
Chromogenic Plating Medium). 
 
Cronobacter spp. physiology 
Cronobacter spp. have the capability to adhere to hydrophilic and hydrophobic 
surfaces, produce extracellular polysaccharides and engage in cell-to-cell signalling 
with other bacteria in the form of biofilm production. Dancer et al., (2009b) 
illustrated Cronobacter spp. to be one of the most stress tolerant bacteria of all the 
Enterobacteriaceae with respect to pH, heat and low aw. However, the stress 
Samples
Incubate 24  2 h at 36  1 C 1:10 BPW
Centrifuge 3,000 g for 10 min, decant supernatant. 
Resuspend pellet in 200µl PBS
100µl
Real time PCR
DFI agar R&F agar
Incubate 18 to 24 h at 36  1 C
Two colonies from each plate are confirmed 
with real time PCR and Rapid ID 32E
Two colonies from each plate are confirmed for 
the presence of Cronobacter spp. using real time 
PCR and Rapid ID 32E 
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tolerance is strain and growth phase dependent. This innate stress tolerance may 
explain its presence in desiccated infant powder (Hunter et al., 2008). Iversen et al., 
(2004d) showed Cronobacter spp. grew between 6 to 45°C, with an optimal range of 
37-43°C.  
The bacterium has also been shown to persist under desiccated conditions in infant 
formula for over two years (Edelson-Mammel et al., 2005). Riedel et al., (2007) 
employed proteomics to identify differentially expressed proteins in response to two 
different osmotic stresses: desiccation and growth in hyperosmotic media. The 
results indicated that under high osmolarity conditions the central metabolic 
pathways, including amino acid biosynthesis and transport protein production, were 
shut down along with the downregulation of the motility apparatus. In contrast, an 
accumulation of structural proteins was observed which may function to preserve the 
proper functioning and integrity of the cell (Healy et al., 2009).  
Pathogenesis 
Information is lacking regarding the mechanisms of Cronobacter spp. pathogenesis 
compared to other food borne pathogens. The exact infectious dose is unknown, but 
experiments with neonatal CD-1 mice by Richardson et al., (2009) demonstrated that 
the infectious dose for the strain used in that study was 10
2
 CFU.  
Similar to other foodborne pathogens the bacteria is ingested and eventually reaches 
the gastrointestinal tract. Infants have a higher gastrointestinal pH than adults 
(Maffei et al., 1975) and this may facilitate survival of Cronobacter (Pagatto et al., 
2009). Following this the microorganism must translocate across the gastrointestinal 
epithelial cells. In mammalian tissue culture, the microorganism can attach to 
intestinal cells and survive internally in macrophages (Pagotto et al., 2003), therefore 
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permitting the bacteria to avoid host immune responses. However, the specific 
bacterial adhesions and host cell receptors involved in these processes are not 
known. Some strains of C. sakazakii produce capsular material but how this material 
contributes to macrophage evasion remains to be determined.  
Similar to Citrobacter diversus or Citrobacter freundii, Cronobacter appears to have 
a tropism for the central nervous system. C. sakazakii have been shown to adhere 
and invade human brain microvascular endothelial cell lines (HBMEC), highlighting 
their ability to cross the blood brain barrier (Townsend et al., 2008), which could 
result in meningitis, formation of brain abscesses and other neurological 
complications.  
Several studies have suggested that OmpA contributes substantially to the virulence 
potential of Cronobacter spp. (Kim et al., 2010, Mittal et al., 2009, Mohan Nair et 
al., 2007, Sinamsetty et al., 2008, Mohan Nair et al., 2007). Mohan Nair et al., 
(2009) described how OmpA binds fibronectin, facilitating the invasion of brain 
endothelial cells. Mittal et al., (2009) demonstrated that ompA expression affected 
the onset of meningitis in new born rats. OmpA positive Cronobacter isolates 
successfully crossed the intestinal barrier, multiplied in the blood and were able to 
subsequently transverse the blood brain barrier, whereas OmpA negative isolates 
could not bind to intestinal epithelial cells.                      
Genomics 
The genome sequence of C. sakazakii BAA-894 was published in 2010 (Kucerova et 
al., 2010). This revealed the genome is composed of one chromosome (4.36Mb) and 
two plasmids (pESAK2 31kb, 51% GC and pESAK3 131kb, 56% GC). Automated 
annotation of the genome identified 4392 genes covering 87% of the chromosome, 
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38 genes covering 83% of pESAK2 and 127 genes covering 87% of pESAK3.  Two 
further C. sakazakii genome sequences have since been published; C. sakazakii E899 
(Chen et al., 2011) and C. sakazakii ES15 (Shin et al., 2012). In addition, the 
genome sequence of C. turicensis has also been published (Stephan et al., 2011). 
Additional C. sakazakii genome sequencing projects are in progress 
(http://www.ncbi.nlm. nih.gov/genome/genomes/1170).  
Sequencing of these genomes will aid identification of virulence genes. Kucerova et 
al., (2010) identified genes predicted to be involved in invasion of HBMEC. They 
found a copper and silver resistance efflux system unique to Cronobacter spp. but 
homologous to a copper and silver resistance efflux system in E. coli, which may 
allow bacteria to invade HBMEC (Franke et al., 2003). Genomic sequencing will 
also assist in the comparative genomics of Cronobacter strains of varying virulence. 
Cronobacter spp. differ in their virulence potential with regards to invasion of 
intestinal cells, survival in macrophages and serum resistance (Townsend et al., 
2008, Townsend et al., 2007). Characterisation of the lipopolysaccharide (LPS) 
genes and resulting O-antigen could be significant in developing an identification 
system based on serotyping (Kucerova et al., 2010).  
A multilocus sequencing typing scheme has been established for the entire 
Cronobacter genus (Joseph et al., 2012c). One sequence type of particular relevance 
is C. sakazakii ST4, which appears to have a high propensity for causing neonatal 
meningitis (Joseph et al., 2011). Joseph et al., (2012b) compared the genome 
sequences of the seven Cronobacter species. Sets of universal core genes and 
accessory genes unique to each strain were identified. They found C. sakazakii to be 
unique in the Cronobacter genus due the presence of genes encoding the utilization 
of exogenous sialic acid. However, further improvement in draft genomes is needed 
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to identify virulence traits of strains with similar modes of infection (Joseph et al., 
2012b).    
Treatment and antimicrobial resistance 
C. sakazakii is naturally resistant to all macrolides, linomycin, clindamycin, 
streptogramins, rifampicin, fusidic acid and fosfomycin. It is susceptible to some 
antibiotics, including tetracyclines, aminoglycosides, several β-lactams, 
chloramphenicol, antifolates and quinolones (Stock et al., 2002). A combination of 
ampicillin and gentamycin or ampicillin and chloramphenicol has traditionally been 
used for the treatment of Cronobacter infection (Drudy et al., 2006). The acquisition 
of transposable elements, the production of β-lactamases and the presence of 
multiple antibiotic resistance genes may allow C. sakazakii to become resistant to 
ampicillin, gentamycin and chloramphenicol (Girlich et al., 2001).     
It is clear that Cronobacter spp. represents a serious risk to immature neonates fed 
with contaminated IMF. Future research on this pathogen should involve discovering 
approaches for limiting the presence of Cronobacter in IMF. This will include 
improving the detection and isolation methods, uncovering further information 
regarding its pathogenicity and finding inhibitors of Cronobacter spp.  
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Introduction – 2; Lux-tagging 
Bioluminescence is the manufacture of light by living organisms. The light emitted 
as a result of an enzymatic reaction catalyzed by the enzyme luciferase is encoded by 
lux genes. These genes have been identified in bacteria, fungi, crustaceans, jellyfish, 
worms and beetles (Widder, 2010). One of the most commonly employed 
bioluminescent systems is the Lux system from the Gram negative bacterium 
Photorhabdus luminescens (Waidmann et al., 2011). In the presence of oxygen the 
luciferase enzyme catalyzes the oxidation of reduced flavin mononucleotide 
(FMNH2) and a long chain aldehyde to yield flavin mononucleotide (FMN) and long 
chain fatty acid. This results in the emission of light at a wavelength of 490nm 
(Baker et al., 1992) (Figure 2A). The luciferase enzyme is encoded by luxAB genes 
and the fatty acid reductase complex for production of the aldehyde is encoded by 
the luxCDE genes (Meighen et al., 1991). These lux genes from Photorhabdus 
luminescens can be transferred and expressed in other bacteria. The resulting Lux-
tagged bacteria emit light (Figure 2B). 
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Fig 2. Schematic of the lux reaction (A). Non Lux-tagged and Lux-tagged strain on 
LB agar viewed with a Xenogen IVIS 100 Imager (B).   
 
The production of reduced flavin mononucleotide requires a functional electron 
transport chain, therefore only metabolically active cells can emit light (Alloush et 
al., 2006). In addition, bioluminescent readings are instantaneous and the output can 
be measured in real time.  This is an advantage as it provides a less labour intensive 
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and quicker method compared to traditional techniques such as performing viable 
plate counts. 
Lux-tagged bacterial strains have many potential food related applications such as 
studying the microbial ecology of food to determine if they can support bacterial 
growth, investigating injury and survival of pathogenic and spoilage 
microorganisms, reporters of virulence gene expression (e.g. toxins) in food, 
detection of pathogens, ability to form biofilms and biocide efficiency, identifying 
probiotic bacteria capable of reaching the gastrointestinal tract and monitoring starter 
culture activity (Griffiths, 2000). It is evident Lux technology provides a major 
advantage to the food industry due to its fast, sensitive and real-time ability to 
monitor the presence of bacteria in food.              
 
Aims of the thesis  
The aims of this thesis were to characterise a bank of Cronobacter strains for their 
ability to tolerate to the sub-optimal conditions of the gastrointestinal tract. A second 
aim was to examine growth of the pathogen in milk, employing Lux technology. The 
third aim of this thesis was to create a transposon mutagenesis library in a Lux-
tagged C. sakazakii strain and screen this library for mutants affected in growth in 
milk. The final aim was to identify genes involved in the tolerance of C. sakazakii to 
the milk derived antimicrobial peptide Lactoferricin B. 
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Chapter II 
 
 
Tolerance of Cronobacter strains to physiologically 
relevant stress conditions 
 
 
 
 
A manuscript based on this chapter is in preparation 
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Abstract 
Food-borne pathogens must overcome many barriers in the human gastrointestinal 
tract in order to infect and cause disease. Some Cronobacter strains can cause 
opportunistic infections in infants, and powdered infant formula is considered to be 
the primary transmission vehicle. The aim of the present study was to examine the 
ability of a collection of Cronobacter strains to tolerate sub-optimal conditions that 
may be encountered in the gastrointestinal tract. Strains were exposed to low pH, 
bile and salt. While all strains were capable of tolerating physiologically relevant 
conditions, noteworthy variations in tolerance was observed. Antibiotic disk assays 
revealed that all strains were sensitive to the antibiotics traditionally used to treat 
Cronobacter infections (ampicillin, gentamycin and chloramphenicol). 
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Introduction 
Cronobacter spp. (previously known as Enterobacter sakazakii) are a group of 
Gram-negative, motile, peritrichously flagellated, rod shaped, non-spore forming 
bacteria belonging to the Enterobacteriaceae family. They are catalase positive, 
oxidase negative, facultative anaerobes (Nazarowec-White et al., 1997a). Based on 
DNA-DNA hybridisation and phenotyping the genus Cronobacter was proposed to 
be composed of six distinct species; C. sakazakii, C. malonaticus, C. turicensis, C. 
muytjensii, C. dublinesis and a Cronobacter genomospecies group 1 (Iversen et al., 
2008). A new species was recently added to the genus; C. condimenti, and C. 
universalis now replaces the original Cronobacter genomospecies group 1 (Joseph et 
al., 2012a). To date, only strains of C. sakazakii, C. malonaticus and C. turicensis 
have been associated with neonatal infection.  
C. sakazakii is an opportunistic pathogen than can cause life threatening infections 
and powdered infant formula is considered to be the primary transmission vehicle. 
Outcomes of infection include meningitis, meningoencephalitis, sepsis, and 
necrotising enterocolitis (Muytjens et al., 1983). Although the incidence of C. 
sakazakii infection generally tends to be low, the prognosis is poor with case-
mortality rates varying from 33-80% (Lai, 2001). The exact infectious dose is 
unknown, but experiments by Richardson et al., (2009) with neonatal CD-1 mice 
demonstrated that the infectious dose for the strain used in that study was 10
2
 CFU. 
To date, the majority of research related to survival of C. sakazakii in vivo has 
focused on adhesion and invasion of cell lines and its ability to cross the blood brain 
barrier (Mohan Nair et al., 2009, Mittal et al., 2008, Singamsetty et al., 2008, 
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Townsend et al., 2008, Mange et al., 2006). The ability of the organism to tolerate 
conditions encountered in the gastrointestinal tract has not been investigated in great 
detail. In order to survive in this environment C. sakazakii must endure an array of 
sub-optimal conditions. The low pH of the stomach is the initial major barrier 
encountered by the pathogen. Once in the intestine the organism encounters low 
oxygen levels, elevated salt conditions, intestinal bile salts and weak acids. While 
some studies that investigate the ability of Cronobacter to tolerate environmental 
stress are available in the literature, these usually use a collection of strains but focus 
on one stress condition (e.g. Osaili et al., 2009) or use only a single C. sakazakii 
strain and examine several stresses (e.g. Hsiao et al., 2010). To our knowledge a 
single study that investigates the tolerance of a collection of Cronobacter strains to 
various physiologically relevant stresses is not available. Therefore, the aim of the 
present study was to address this lack of information using a collection of 
Cronobacter strains (thirteen C. sakazakii strains, one C. malonaticus and one C. 
muytjensii). For comparison purposes four Enterobacter strains (two E. cloacae, one 
E. gergorviae and one E. aerogenes) were also included in experiments. Antibiotic 
disk assays were carried out to examine the antibiotic tolerance of the strains. 
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Materials and Methods 
Bacterial strains and culture conditions 
Bacterial strains used in this study are listed in Table 1. Cronobacter, Enterobacter, 
Escherichia coli, Bacillus cereus, Pseudomonas aeruginosa and Salmonella 
Typhimurium strains were routinely grown in Luria-Bertani (LB) broth (Merck, 
Darmstadt, Germany) statically at 37°C. Listeria monocytogenes and Listeria 
innocua strains were grown in BHI (Brain Heart Infusion) (Oxoid, UK) statically at 
37°C. Lactococcus lactis HP was grown in M17 broth (Oxoid) supplemented with 
0.5% glucose (Sigma-Aldrich) statically at 30ºC. For certain experiments Brilliance 
Enterobacter sakazakii (DFI, Druggan, Forsythe and Iversen) agar (Oxoid, UK), 
TSA (Tryptic Soya Agar) (Oxoid), Mueller Hinton (Oxoid) broth,  Mueller Hinton 
agar and M9 (minimal media) (Sambrook et al., 2001) were used. For solid media 
1.5% agar was added. 
DNA extraction and manipulations 
Strains were grown overnight (~16 hrs) in LB broth. DNA was extracted from 1ml 
of overnight cultures as described by Hoffmann et al., (1987). PCR products were 
purified using the Invitrogen PCR purification kit. The concentration of nucleic acids 
was determined using an Invitrogen Qubit fluorometer (Eugene, Oregon, USA). PCR 
amplification was carried out using a G-storm cycler (Essex, UK). PCR products 
were separated on 1% (m/v) agarose gels and visualised with the DNR Bio-Imaging 
System (Jerusalem, Israel). 
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Table 1. Strains used in this study.  
 
 
Strains were obtained from the DPC, Dairy Products Research Centre, Moorepark, Fermoy, 
Co. Cork, Ireland and UCC, University College Cork culture collections. 
*These strains were originally obtained from M. Ardino, Centers for Disease Control and 
Prevention, Atlanta, United States. These strains were originally isolated as being C. 
sakazakii strains. rpoB genes were sequenced to confirm their correct identity. 
 
 
 
Strain  Isolated from Source Growth conditions 
DPC6522* Cronobacter  sakazakii Blood DPC LB at 37○C 
DPC6523* Cronobacter  sakazakii CSF DPC LB at 37○C 
DPC6524* Cronobacter  sakazakii Stool DPC LB at 37○C 
DPC6525* Cronobacter  sakazakii Urine DPC LB at 37○C 
DPC6526* Cronobacter  sakazakii Blood DPC LB at 37○C 
DPC6527* Cronobacter  sakazakii Blood DPC LB at 37○C 
DPC6528* Cronobacter  sakazakii CSF DPC LB at 37○C 
DPC6529* Cronobacter  sakazakii Tracheal aspirate DPC LB at 37○C 
DPC6530* Cronobacter  sakazakii Bronchial alveolar lavage DPC LB at 37○C 
DPC6531* Cronobacter malonaticus Brain Tumour DPC LB at 37○C 
ATCC51329 Cronobacter muytjensii  DPC LB at 37○C 
NCTC8155 Cronobacter sakazakii Tin of dried milk powder DPC LB at 37○C 
ATCC12868 Cronobacter sakazakii  DPC LB at 37○C 
ATCC29004 Cronobacter sakazakii  DPC LB at 37○C 
ATCC29544 Cronobacter sakazakii Child’s throat DPC LB at 37○C 
NCTC11434 Enterobacter gergorviae Human urinary tract DPC LB at 37○C 
NCTC11590 Enterobacter cloacae unknown DPC LB at 37○C 
NCTC11933 Enterobacter cloacae Human/clinical isolate DPC LB at 37○C 
NCTC10006 Enterobacter aerogenes sputum DPC LB at 37○C 
LO28 Listeria monocytogenes  UCC BHI at 37○C 
EGDe Listeria monocytogenes  UCC BHI at 37○C 
HP Lactococcus lactis  UCC GM17 at 30ºC 
 Listeria innocua  UCC BHI at 37
○C 
O157:H7 Escherichia coli  UCC LB at 37○C 
DH5-α Escherichia coli  UCC LB at 37○C 
 Bacillus cereus  UCC LB at 37
○C 
 Pseudomonas aeruginosa  UCC LB at 37
○C 
UK-1 Salmonella Typhimurium  UCC LB at 37○C 
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rpoB sequencing 
PCRs were performed on ten C. sakazakii strains using rpoB primers (Table 2). PCR 
products were purified with the Invitrogen PCR purification kit and sequenced by 
MWG Biotechnologies (Ebersberg, Germany). Homology searches were performed 
using BLAST on the National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.gov). 
Oxidase test  
An oxidase test was carried out on isolated colonies that were freshly grown 
overnight on TSA. An oxidase strip (Oxoid) was laid on the moist lid of the petri 
dish. A loopful of each strain was transferred to a strip. A positive result was 
indicated by the appearance of a deep purple colour within 10-30 seconds. Lack of a 
colour change indicated the colonies were oxidase negative. Pseudomonas 
aeruginosa (oxidase positive) and E. coli DH5-α (oxidase negative) were employed 
as controls.  
Pigment production 
The production of a yellow pigment was examined by streaking strains onto TSA 
and incubating at 25°C for 48-72 hrs (FDA, 2002). The presence of pigment genes 
was examined by PCR using primers based on the ESA_03347 gene (NC_009778.1)  
that has been shown to be involved in pigment production (Johler et al., 2010). 
Primer sequences are provided in Table 2. 
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Bacterial capsule formation 
The presence of capsule genes was examined by PCR using primers based on 
ESA_03359 (NC_009778.1) a homologue of kpsM which is involved in capsule 
biosynthesis (Healy et al., 2009). Primer sequences are provided in Table 2. 
 
Table 2. Primers and PCR conditions used in this study. 
Primer Sequence 5’→3’ Size of PCR 
product 
ESA_03347 F CATGGATAACGCCCTGCT 259 bp 
ESA_03347 R AACTGCGAAGTTTATGGCG  
ESA_03359 F  GTATTGAGCGAATACATCACG 206 bp 
ESA_03359 R GCGCTGCTGGCCATGACA  
ESA_01288 F AGCGTCTGTCCTCTGGTCTGC 271bp 
ESA_01288 R CAGACGCTGAGTGATTTCCG  
rpoB F  AACCAGTTCCGCGTTGG 760bp 
rpoB R CCTGAACAACACGCTCGGA  
 
 
Catalase test 
Strains were grown overnight on TSA agar and a loopful of colonies was transferred 
onto a glass slide. Two drops of H2O2 (hydrogen peroxide) (35% w/v) were added, 
the presence of bubbling indicated the strain was catalase positive. L. lactis HP 
(catalase negative) and E. coli DH5-α (catalase positive) were used as controls. 
Motility assay 
Motility was examined at 37°C using motility medium (tryptone 10g/l (Sigma 
Aldrich, Germany), NaCl 5g/l, and agar 5g/l) (Iversen et al., 2007). The media was 
stab inoculated with 5µl of overnight culture and incubated at 37°C for 48 h. The 
swimming behaviour of the cells was inspected visually and the zones of growth on 
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the plates were measured. Any zone bigger than 10 mm was considered positive. The 
presence of flagella genes was examined by PCR using primers based on 
ESA_01288/fliC (NC_009778.1) a putative flagellin gene. 
Protease assay 
Strains were grown overnight in LB broth and streaked onto skim milk agar i.e. LB 
agar supplemented with 1% (w/v) reconstituted skim milk. LB agar was autoclaved 
at 121°C for 15 min, while 10% (w/v) milk powder solution was autoclaved at 
110°C for 10 min. The autoclaved milk solution was mixed with LB agar to a final 
concentration of 1% while still hot (Jones et al., 2007). Streaked plates were 
incubated for 3 days at 37°C. Any strain giving a clear halo was considered positive. 
Bacillus cereus was used as a positive control and E. coli DH5-α was used as a 
negative control. 
Gram stain 
Gram staining was performed on the strains where Gram positive bacteria stain 
purple and Gram negative bacteria stain pink. A loopful of overnight culture was 
stained with 1% crystal violet, washed with H2O, subsequently flooded with  ram’s 
iodine, washed with 95% alcohol and counterstained with safranin. E. coli DH5-α 
(Gram negative) and Listeria innocua (Gram positive) were used as controls. 
H2O2 assay 
The sensitivity of each of the strains to H2O2 (hydrogen peroxide) (35% w/v) was 
tested. Strains were grown overnight in LB broth, diluted 1:10 in ¼ strength  inger’s 
solution (Merck, Darmstadt, Germany) and swabbed onto LB agar with sterile 
swabs. Sterile paper disks were subsequently placed on the surface of the plates. 
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10µl of H2O2 was pipetted onto each disk. The plates were incubated overnight at 
37°C and zones of inhibition were measured with a digital Vernier Calipers 
(Fisherbrand). 
Growth curves and survival assays 
Strains were grown in triplicate in LB broth and incubated overnight (~16 hrs) at 
37°C. 1ml of cultures were centrifuged at 8000 x g for 7 min, the supernatants were 
removed and cell pellets were resuspended in 1ml of  ¼ strength  inger’s solution 
(Merck, Darmstadt, Germany). 20µl of washed cells was added to 1ml LB broth, 
vortexed to mix and 200µl was transferred to a well of a 96-well plate (Genetix, 
UK). Growth at 37°C was monitored by measuring optical density (OD) at 620nm 
using a temperature controlled automatic plate reader (Thermo Scientific Multiscan 
FC). When required, viable plate counts were performed by serially diluting cultures 
in ¼ strength Ringer’s solution and enumeration on LB agar. Growth curves were 
performed in LB adjusted to pH 5.5, LB adjusted to pH 6.5, LB containing 0.3M 
NaCl (Sigma Aldrich, Germany), LB containing 5% NaCl and M9 (minimal media). 
The pH of the medium was lowered using 5M Lactic acid and the pH was 
determined using a pH meter (ORIEN 3 STAR, Thermo Scientific, Singapore). The 
pH was adjusted prior to autoclaving at 121°C for 15 min. A growth curve was 
performed in LB under anaerobic conditions using a GasPak 100 anaerobic system 
(BD, Sparks, MD, USA) and Anaerocult A sachets (Merck). Growth in LB 
containing 0.3% porcine bile (Sigma Aldrich, Germany) was also examined. Porcine 
bile was added before autoclaving at the required level and viable plate counts were 
taken after 3 h by serially diluting cultures in ¼ strength  inger’s solution and 
enumeration on LB agar.  
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For survival assays, strains were grown statically at 37°C for approximately 16 hrs. 
1ml of overnight cultures were centrifuged at 8000 x g for 7 min, the supernatants 
were discarded and the cell pellets were resuspended in 1ml ¼ strength  inger’s 
solution. 20µl was added to 1ml of test broth and incubated statically at 37°C for 1 h. 
Viable plate counts were performed by serially diluting in ¼ strength  inger’s 
solution and enumeration on LB agar in triplicate. Test broths included LB 
supplemented with 5% porcine bile, LB supplemented with 10% NaCl and LB 
adjusted to pH 3.2. LB broth containing bile was vortexed well before and after 
autoclaving at 121°C for 15 min. When required, the pH of the medium was adjusted 
using HCl (Hydrochloric acid) (1M) before autoclaving.  Results are presented as % 
survival, this was calculated as a percentage of viable cell counts after challenge 
expressed as a percentage of viable-cell counts at time zero, i.e. immediately prior to 
treatment.   
Antimicrobial susceptibility assay 
A disk diffusion assay was carried out following the instructions of the Clinical and 
Laboratory Standards Institute (CLSI, 2005). The antimicrobial susceptibility test 
disks (Oxoid, UK) included amoxicillin/clavulanic acid (30µg), ampicillin (10µg), 
cefotaxime (30µg), ceftriaxone (30µg), chloramphenicol (30µg), ciprofloxacin 
(5µg), gentamycin (10µg), nalidixic acid (30µg), kanamycin (30µg), tetracycline 
(30µg), cefalothin (30µg), trimethoprim-sulfamethoxazole (25µg) and cefuroxime 
(30µg). Cronobacter strains were streaked on TSA (Tryptic Soya Agar) and 
incubated at 37ºC for 24 hrs. Colonies were suspended in 3ml of Mueller Hinton 
broth. The suspensions were swabbed onto the entire surface of Mueller Hinton agar 
with sterile swabs after which the relevant antimicrobial disks were placed onto the 
surface of the plate with a sterile forceps. The plates were incubated upright at 37ºC 
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for 24 hrs under aerobic conditions. The diameters of zones of inhibition were 
measured using a digital Vernier Callipers (Fisherbrand) and interpreted according to 
the CLSI guidelines for Enterobacteriaceae (Staphylococcus spp. for erythromycin) 
(Clinical and Laboratory Standards Institute 2005).  
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Results and Discussion 
rpoB sequencing 
The Cronobacter and Enterobacter strains used in this study are listed in Table 1. Of 
the Cronobacter strains, five were obtained from culture collections and ten were 
isolated from clinical samples. In order to confirm that the clinical strains were 
indeed Cronobacter spp., rpoB genes were partially sequenced as performed by 
Stoop et al., (2009) and homology searches were performed using BLAST (Table 3). 
Of the ten strains, nine were identified as C. sakazakii and one was identified as C. 
malonaticus (DPC6531). 
 
Table 3. rpoB sequencing of the ten clinical Cronobacter strains. Homology 
searches were performed using BLAST on the National Centre for Biotechnology 
Information (NCBI) website.  
 
Strain Identity Accession Number 
DPC 6522 99% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6523 100% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6524 100% to C. sakazakii ATCC 25944  FJ717657 
DPC 6525 100% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6526 99% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6527 99% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6528 99% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6529 99% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6530 99% to ESA_03690 C. sakazakii BAA-894 CP000783.1 
DPC 6531 100% to C. malonaticus  LMG23826  FJ717659 
 
 
79 
 
Characterisation tests 
As expected, all of the strains were Gram negative, oxidase negative and catalase 
positive. When PCRs were performed with primers for the pigment gene 
(ESA_03347), products were amplified for all 15 Cronobacter strains. When plated 
onto TSA one of these strains, DPC6523 did not produce a yellow pigment. It is 
possible that the amount of pigment produced by DPC6523 is too low to be detected 
by visual inspection or that pigment is not produced by this strain under the 
conditions tested. As expected, the four Enterobacter strains (NCTC11434, 
NCTC11590, NCTC11933 and NCTC10006) did not produce yellow pigment on 
TSA agar and PCR products were not amplified with ESA_03347 primers. 
When PCRs were performed with primers for the capsule gene (ESA_03359), 
products were amplified for 14 of the 15 Cronobacter strains. Products were not 
amplified for strains ATCC29544 (Table 4). Two of our strains have previously been 
examined for capsule production by Hurrell et al., (2009). In agreement with the 
findings of that study we obtained a PCR product for ATCC12868 but not for 
ATCC29544.  PCR products were not amplified for any of the Enterobacter strains 
with the ESA_03359 primers.  
PCR products were amplified with primers for the motility gene (ESA_01288) for 
the 15 Cronobacter strains. 14 of the Cronobacter strains were positive on motility 
agar, ATCC51329 appeared to be non-motile on motility agar. This suggests that 
motility genes may not be expressed for this strain under the conditions used.  For 
the four Enterobacter strains, PCR products were not amplified for NCTC10006 and 
phenotypic examination of two strains (NCTC11590 and NCTC10006) suggested 
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they were non motile on motility agar. This indicates NCTC10006 may be non-
motile as it was negative for the molecular and phenotypic tests.  
A clear halo was obtained for all Cronobacter strains when streaked onto skim milk 
agar suggesting that they may be protease positive. Halos were not observed for any 
of the four Enterobacter strains. Strains were streaked on Brilliance Enterobacter 
sakazakii agar (DFI) (Oxoid) which contains 5-bromo-4-chloro-3-indolyl-α-D-
glucopyranoside, a compound that Cronobacter can hydrolyse with the enzyme α-
glucosidase to produce blue/green colonies (Iversen et al., 2004a).  On DFI agar all 
the Cronobacter strains produced blue/green colonies but the four Enterobacter 
strains did not. Iversen et al., (2004a) showed that none of the 31 E. cloacae strains 
and six E. aerogenes strains tested in their study pigmented blue/green on DFI.
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Table 4. Characterisation of the Cronobacter and Enterobacter strains used in this study. 
Strains Gram 
stain 
Oxidase Catalase Capsule 
ESA_03359a
 
 
Pigment production Motility Protease production Colony colour on DFI 
agar 
TSA at 25○C ESA_03347 b Motility agar ESA_01288c 
 
  DPC 6522 
_ 
 
_ 
 
+ + + + 
 
+ 
 
+ + Blue green 
 
DPC 6523 
 
_ 
 
_ 
 
+ 
 
+ 
 
_ 
 
+ 
+ 
 
+ + Light green 
 
DPC 6524 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ + 
 
+ 
 
+ + Blue green 
 
DPC 6525 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
DPC 6526 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
DPC 6527 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
DPC 6528 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
DPC 6529 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
DPC 6530 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
DPC 6531 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
ATCC51329 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
+ 
 
_ 
 
+ + Blue green 
 
NCTC8155 
 
_ 
 
_ 
 
+ 
 
+ 
 
+ 
+ 
 
+ 
 
+ + Blue green 
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ATCC12868 
 
_ 
 
_ 
 
+ + + 
 
+ 
 
 
+ 
 
+ + Blue green 
 
ATCC29004 
 
_ 
 
_ 
 
+ + + 
 
+ 
 
 
+ 
 
+ + Blue green 
 
ATCC29544 
_ 
 
_ 
 
+ 
_ 
 
+ 
 
+ 
 
 
+ 
 
+ + Blue green 
 
NCTC11434 
 
_ 
 
_ 
 
+ 
_ 
 
_ 
_ 
 
 
+ 
 
+ 
_ 
 
Yellow 
 
NCTC11590 
 
_ 
 
_ 
 
+ 
_ 
 
_ 
 
_ 
 
_ 
 
+ 
_ 
 
Yellow 
 
NCTC11933 
 
_ 
 
_ 
 
+ 
_ 
 
_ 
 
_ 
 
 
+ 
 
+ 
_ 
 
Yellow 
 
NCTC10006 
 
_ 
 
_ 
 
+ 
_ 
 
_ 
 
_ 
 
_ 
 
_ 
 
_ 
 
Yellow 
 
a
= Result of PCR performed with ESA_03359 primers. 
b
= Result of PCR performed with ESA_03347 primers.  
c
= Result of PCR performed with ESA_01288 primers. 
DFI= Brilliance Enterobacter sakazakii agar (Druggan Forsythe Iversen).
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pH conditions 
Following consumption, the acidity of the stomach is the first major barrier 
encountered by pathogens. The fasting gastric pH of the adult stomach is 1.5, which 
increases between 3.0 and 5.0 during feeding (Hill et al., 2002). Neonates are likely 
to exhibit higher gastric pH levels than adults, often reaching values above pH 4.0 
(Maffei et al., 1975). A range of pHs may also be encountered in the intestinal lumen 
(Kitagawa et al., 1966).   
In order to investigate the pH tolerance of strains a growth curve was performed in 
LB adjusted to pH 5.5 (Fig. 1a). All strains were capable of growth but variation in 
generation times was observed amongst the strains ranging from 27.36 min for 
DPC6524 to 42.59 min for ATCC29544 (see also Fig 2a and 2b). The shortest 
overall generation time was 21.32 min for the Enterobacter strain NCTC10006. 
Generation times for the remaining three Enterobacter strains ranged from 29 to 
32.66 min. A growth curve was also performed in LB adjusted to pH 6.5 which also 
showed variation between the strains (Fig 2c). When exposed to low pH (LB 
adjusted to pH 3.2, Fig. 1b) a variation in survival was observed for Cronobacter 
strains; the lowest survival rate was 1.89% for ATCC51329 and the highest survival 
rate was 72.29% for DPC6529. The Enterobacter strain NCTC10006 which had the 
shortest generation time for growth at pH 5.5 also displayed the highest tolerance at 
pH 3.2 as cell numbers were unaffected. Survival of the remaining Enterobacter 
strains ranged from 4% to 46%. Dancer et al., (2009b) demonstrated that C. 
sakazakii was more acid tolerant than most closely related enteric pathogens. 
Variability in acid tolerance between the strains was also noted. Survival of other 
gastrointestinal pathogens (L. monocytogenes, E. coli and S. Typhimurium) at pH 3.2 
was also investigated (Fig. 7a). The majority of strains were more acid sensitive than 
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the other the gastrointestinal pathogens tested in this study.  Strain DPC6529, and the 
Enterobacter strains NCTC11590 and NCTC1006 had similar survival rates to the 
gastrointestinal pathogens tested.  
 
Fig. 1 (a) Growth of strains in LB adjusted to pH 5.5 DPC6522 (■) DPC6523 (□) 
DPC652  (♦) DPC6525 (◊) DPC6526 (▲) DPC6527 (Δ) DPC 6528 (●) DPC6529 
(○) DPC6530 (X) DPC6531 (   ) ATCC51329 (▬), ATCC8155 (    ) ATCC12868 
( ) ATCC2900  (   ) ATCC295   (═)  CTC11 3  (  ),  CTC11590 (   ) 
NCTC11933 (   ) and NCTC10006 (   ). The presented graphs are representative of 
three independent experiments. Error bars were omitted for clarity (b) Survival of 
strains in LB adjusted to pH 3.2.  Viable plate counts were performed following 
one hour incubation by serially diluting in ¼ strength Ringer’s solution and 
enumeration on LB agar. % survival was calculated as a percentage of viable cell 
counts after challenge expressed as a percentage of viable-cell counts at time zero, 
i.e. immediately prior to treatment.   
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Fig. 2 (a) Time to detection (TTD) in LB adjusted to pH5.5. TTD is the time (h) 
at which the culture reaches an OD620nm of 0.5. (b) OD620nm  at T10 hours in LB 
adjusted to pH5.5. (c) Growth of strains in LB adjusted to pH 6.5. DPC6522 (■), 
DPC6523 (□), DPC652  (♦), DPC6525 (◊), DPC6526 (▲), DPC6527 (Δ), DPC6528 
(●), DPC6529 (○), DPC6530 (X), DPC6531 (   ), ATCC51329 (▬), ATCC8155       
(    ), ATCC12868 (+), ATCC29004 (   ), ATCC29544 ( = ), NCTC11434 (   ), 
NCTC11590 (   ), NCTC11933 (   ) and NCTC10006 (   ).  The presented graph is a 
representative of three independent experiments. Error bars were omitted for clarity.                                        
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NaCl 
Gastrointestinal pathogens must tolerate exposure to high osmolarity. Growth of 
strains in LB containing 0.3M (1.7%) NaCl was investigated as this concentration is 
considered an approximate surrogate for the level encountered in the upper small 
intestine (Sleator et al., 2007). Fig. 3a shows that all strains were capable of growth, 
however, differences were observed between the strains. For the Cronobacter strains 
the generation times ranged from 23.9 min for DPC6522 to 37.9 min for DPC6531. 
Of all of the strains, Enterobacter strain NCTC11933 had the longest generation 
time of 42.1 min. The generation times for the other Enterobacter strains ranged 
from 28 min to 34.95 min (see also Fig. 4a and 4b). Growth in LB containing 5% 
NaCl was also investigated (Fig. 4c). All strains were able to grow under this 
condition but there was disparity in growth between each of the strains. When 
exposed to 10% NaCl a variation in survival rates was observed between the strains 
(Fig. 4b). For the Cronobacter strains, the lowest overall survival rate was 19.7% for 
ATCC12868 and the highest survival rate was 72.92% for DPC6530. For the 
Enterobacter strains survival ranged from 36% to 57%. Overall, the C. sakazakii 
strains displayed a higher level of salt tolerance than concentrations approximating 
those that may be encountered in the small intestine. The survival capabilities of the 
majority of the collection of strains were similar to the other gastrointestinal 
pathogens tested (L. monocytogenes, E. coli and S. Typhimurium; Fig. 7b).  
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Fig. 3 (a) Growth of strains in LB containing 0.3M NaCl. DPC6522 (■), 
DPC6523 (□), DPC652  (♦), DPC6525 (◊), DPC6526 (▲), DPC6527 (Δ), DPC 
6528 (●), DPC6529 (○), DPC6530 (X), DPC6531 (  ), ATCC51329 (▬), 
ATCC51329 (▬), ATCC8155 (   ), ATCC12868 (+), ATCC29004 (    ), 
ATCC59244 (=), NCTC11434 (  ), NCTC11590 (   ),    NCTC11933 (   ) and 
NCTC10006 (   ). The presented graph is a representative of three independent 
experiments. Error bars were omitted for clarity. (b) Survival of strains in LB 
containing 10 % NaCl. Viable plate counts were performed following one hour 
incubation by serially diluting in ¼ strength Ringer’s solution and enumeration on 
LB agar. % survival was calculated as a percentage of viable cell counts after 
challenge expressed as a percentage of viable-cell counts at time zero. 
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Fig. 4 (a) Time to detection in LB containing 0.3M NaCl. TTD is the time (h) at 
which the culture reaches an OD620nm of 0.5. (b) OD620nm at T10 hours in LB 
containing 0.3M NaCl. (c) Growth of strains in LB plus 5% NaCl. DPC6522 (■), 
DPC6523 (□), DPC652  (♦), DPC6525 (◊), DPC6526 (▲), DPC6527 (Δ), DPC 
6528 (●), DPC6529 (○), DPC6530 (X), DPC6531 (   ), ATCC51329 (▬), 
ATCC8155 (    ), ATCC12868 (+), ATCC29004 (   ), ATCC29544 (=), NCTC11434 
(   ), NCTC11590 (   ), NCTC11933 (   ) and NCTC10006 (   ). The error bars 
represent the standard deviation of triplicate experiments. 
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Bile conditions  
Bile is a digestive secretion that plays a key role in the emulsification and 
solubilisation of lipids (Begley et al., 2005). It functions as part of the body’s 
defence system as bile salts have potent antimicrobial activity through their ability to 
emulsify the phospholipids, cholesterol and proteins of cell membranes causing cells 
to lyse. Therefore the ability of pathogens to tolerate bile is essential for their 
survival and colonization (Begley et al., 2005). Initially strains were streaked on agar 
containing 0.3% porcine bile (Sigma); this is a concentration which was chosen to 
approximate the average levels of bile encountered in vivo (Begley et al., 2005). All 
strains grew on agar containing 0.3% porcine bile with colony morphologies similar 
to growth on LB agar alone. Growth of the Cronobacter strains in LB broth 
supplemented with 0.3% bile after 3 h was also investigated. All strains were capable 
of growth; after 3 h the increase in log cfu/ml ranged from a 1.08 log increase for 
DPC6523 to a 1.63 log increase for DPC6524 (Fig. 5a). For the Enterobacter strains 
the lowest overall increase in log cfu/ml
 
was 0.46 for NCTC11434, the numbers of 
the remaining Enterobacter strains increased by ~1.5 log.  
When exposed to LB containing 5% porcine bile there was variation in survival rates 
between all the strains (Fig. 5b). For the Cronobacter strains the lowest survival rate 
was 24.98% for DPC6524. However, cell numbers were not affected for DPC6527 
and DPC6528. Survival of other gastrointestinal pathogens (L. monocytogenes, E. 
coli and S. Typhimurium) in LB containing 5% porcine bile was also investigated 
(Fig 7c). The survival capabilities of the majority of the collection of strains were 
similar to the gastrointestinal pathogens. To our knowledge there is only one study 
available in the literature that has examined the bile tolerance of C. sakazakii. As 
part of a larger study, Hsiao et al., (2010) showed that the C. sakazakii strain under 
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investigation (strain BCRC13988) was capable of growth in 0.5% and 2% bile 
solution (oxgall) over a 12 hour period. In our experiments, variation in bile 
tolerance was also observed for the Enterobacter strains tested; survival ranged from 
36% to 66.6% following exposure to 5% porcine bile. 
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Fig. 5 (a) Growth of strains in LB containing 0.3% bile. Plate counts were 
performed after three hours. (b) Survival of strains in LB containing 5% porcine 
bile. Viable plate counts were performed following the one hour incubation by 
serially diluting in ¼ strength Ringer’s solution and enumeration on LB agar. The 
error bars represent the standard deviation of triplicate experiments % survival was 
calculated as a percentage of viable cell counts after challenge expressed as a 
percentage of viable-cell counts at time zero.  
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Other physiologically relevant stress conditions  
In M9 (minimal media) variation in growth of strains was observed (Fig 6a). We also 
compared growth both aerobically and anaerobically (Fig 6b). The absence of O2 
affected the progress of the strains with an OD620nm approximately 50% that of the 
same strains grown anaerobically. For the H2O2 assay the strains were inhibited at 
various levels with zones ranging from 37-45.23mm (Table 5).  
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Fig. 6 (a) Growth of strains in M9 minimal media. DPC6522 (■), DPC6523 (□), DPC652  (♦), DPC6525 (◊), DPC6526 (▲), DPC6527 (Δ), 
DPC 6528 (●), DPC6529 (○), DPC6530 (X), DPC6531 (   ), ATCC51329 (▬), ATCC8155 (    ), ATCC12868 ( ), ATCC2900  (   ), 
ATCC29544 (=), NCTC11434 (   ), NCTC11590 (   ), NCTC11933 (   ) and NCTC10006 (   ). The presented graphs are representative of three 
independent experiments. Error bars were omitted for clarity. (b) Growth of strains incubated aerobically (  ) and anaerobically (   ). OD620nm 
was taken after 16 hour incubation at 37
○
C. The error bars represent the standard deviation of triplicate experiments. 
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Fig. 7. Survival of Cronobacter strains, L. monocytogenes LO28, L. monocytogenes EGDe, E. coli O157:H7, E. coli DH5-α, and Salmonella 
enterica serovar Typhimurium UK-1 (a) in LB adjusted to pH 3.2 (b) LB plus 10 % NaCl and (c) LB plus 5% porcine bile. Viable plate counts 
were performed following the one hour incubation by serially diluting in ¼ strength Ringer’s solution and enumeration on LB agar. % survival 
was calculated as a percentage of viable cell counts after challenge expressed as a percentage of viable-cell counts at time zero.  
(a) 
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Table 5. H2O2 disk assays. Zones were measured using a digital Vernier callipers. 
Results are in millimetres, and expressed as averages of triplicate experiments ± the 
standard deviation. 
 
Strains Zone size (mm) 
DPC6522 37.5±0.3 
DPC6523 38.3±0.4 
DPC6524 37.6±0.9 
DPC6525 38.0±3.8 
DPC6526 39.9±1.1 
DPC6527 37.3±2.1 
DPC6528 40.7±0.3 
DPC6529 37.8±2.8 
DPC6530 41.2±2.4 
DPC6531 37.0±1.9 
ATCC51329 36.5±0.9 
NCTC8155 46.1±1.4 
ATCC12868 37.4±1.2 
ATCC29004 40.8±0.2 
ATCC29544 38.6±1.1 
NCTC11434 45.2±0.9 
NCTC11590 42.1±1.1 
NCTC11933 43.0±1.2 
NCTC10006 38.6±3.0 
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Antimicrobial disk assays 
A combination of ampicillin and gentamycin or ampicillin and chloramphenicol has 
traditionally been used for the treatment of C. sakazakii infection (Drudy et al., 
2006). The acquisition of transposable elements, the presence of β-lactamases and 
the incidence of numerous antibiotic resistance genes may allow C. sakazakii to 
display resistance to ampicillin, gentamycin and cefotaxime (Girlich et al., 2001). 
Therefore it is important to investigate the use of other antimicrobials for the 
treatment of C. sakazakii infection. The results of the antibiotic disk assays of the 
strains are listed in Table 6. All of the Cronobacter strains were classified as 
sensitive to ampicillin. Three Enterobacter strains (NCTC11590, NCTC11933 and 
NCTC10006) displayed resistance to ampicillin according to the CLSI standards. All 
strains were sensitive to gentamycin. None of the C. sakazakii strains tested showed 
resistance to ampicillin or gentamycin and DPC6528 was the only Cronobacter 
strain to have intermediate sensitivity to chloramphenicol. Therefore the traditional 
treatment employed for C. sakazakii infection would be satisfactory for these strains. 
The other antibiotics tested were trimethoprim-sulfamethoxazole, ceftriaxone, 
cefotaxime, tetracycline, nalidixic acid, cefalothin, cefuroxime, ciprofloxacin, 
amoxicillin-clavulanic acid and kanamycin (Table 2). E. cloacae NCTC11590 
displayed resistance to ampicillin and amoxicillin-clavulanic acid and intermediate 
sensitivity to three other antimicrobials. E. cloacae have an intrinsic resistance to 
ampicillin and exhibit a high-frequency of mutation of resistance to extended 
spectrum and broad spectrum cephalosporins (Then, 1987).  
All of the Cronobacter isolates tested by Stock et al., (2002) displayed resistance to 
macrolides, linomycin, clindamycin, streptogramins, rifampicin, fusidic acid and 
fosfomycin. The study also found the Cronobacter strains were susceptible to some 
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antibiotics, including tetracyclines, aminoglycosides, several β-lactams, 
chloramphenicol, antifolates and quinolones. Kim et al., (2008) tested 113 E. 
sakazakii isolates for their antibiotic resistance and 31.8% were resistant to 
ampicillin and all of the isolates were resistant to at least one antibiotic. Al-Nabulsi 
et al., (2011) illustrated the C. sakazakii strains they tested were sensitive to 
gentamycin, kanamycin, ciprofloxacin and amoxicillin but displayed resistance to 
tetracycline. This paper noted strain variation in their antimicrobial susceptibilities, 
our study also illustrated differences between strains.  
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Table 6. Antibiotic disk assay. Zones were measured using a digital Vernier callipers. Results are in millimetres, and expressed as averages of 
triplicate experiments ± the standard deviations. 
Strains AMP 
10µg 
CN 
10µg 
CTX 
30µg 
TE 
30µg 
NA 
30µg 
C 
30µg 
STX  
25µg 
KF 
30µg 
CXM   
30µg 
CIP 
5µg 
AMC 
30µg 
K 
30µg 
CRO 
30µg 
DPC 6522 27.4±2.0 17.8±0.6 27.2±4.2 21.9±0.3 22.0±0.7 24.7±1.0 30.0±1.0 14.3±0.4* 22.6±0.4 25.0±1.3 28.4±1.5 16.5±1.7* 25.2±0.6 
DPC 6523 20.4±0.7 22.4±0.2 29.7±1.4 22.6±0.9 28.3±0.5 28.4±1.0 31.7±0.9 11.3±0.6* 20.5±0.1 20.8±1.0 25.0±1.0 17.6±0.9 22.9±1.3 
DPC 6524 26.4±0.3 18.2±0.9 31.0±1.1 31.00±1.1 18.2±0.8 22.7±2.2 33.8±0.5 24.1±0.2 20.4±0.9 21.7±0.4 29.7±0.6 16.8±0.7* 20.8±2.6 
DPC 6525 21.5±0.2 16.6±1.0 28.3±0.5 28.3±0.5 24.9±0.5 24.4±1.43 31.9±0.9 25.4±0.4 20.9±0.2 17.6±0.3* 26.0±0.5 16.1±0.3* 21.0±0.9 
DPC 6526 22.4±1.4 18.3±0.9 26.9±1.0 22.2±0.6 18.3±0.9 24.2±1.9 28.4±0.9 24.8±1.0 21.5±0.1 22.4±0.7 24.4±0.6 16.5±0.4* 24.7±0.4 
DPC 6527 26.8±0.3 19.4±0.3 27.0±1.0 24.3±1.3 24.5±1.0 25.0±1.7 29.1±1.3 26.3±0.3 20.5±0.4 21.3±1.0 29.0±0.9 16.4±1.2* 24.7±0.3 
DPC 6528 16.2±0.8 19.2±0.7 29.4±0.5 18.6±2.1 20.9±0.9 16.6±1.4* 24.9±1.4 22.6±0.4 17.8±0.6 17.8±0.4* 27.2±0.2 16.0±0.2* 24.7±0.7 
DPC 6529 17.0±0.4 18.6±1.1 27.4±0.6 25.0±0.3 24.4±0.0 23.4±0.2 23.9±0.06 22.9±1.1 18.1±1.1 20.5±2.4 23.0±0.2 16.4±0.8* 23.6±1.3 
DPC 6530 19.7±0.2 17.6±1.2 29.0±0.9 21.1±1.7 21.2±0.6 20.2±1.0 25.3±2.0 22.8±1.1 19.4±0.5 21.0±1.4 24.3±0.1 17.3±0.9 26.1±0.9 
DPC 6531 21.6±0.8 18.4±1.7 29.7±1.1 19.9±2.33 22.6±1 25.0±1.0 32.4±0.4 26.5±1.1 21.4±0.5 25.3±1.4 29.3±0.8 18.8±1.2 24.5±1.2 
ATCC51329 27.9±0.8 18.4±1.0 30.6±1.0 22.5±1.0 19.4±1.3 21.0±0.3 30.9±0.8 23.3±0.4 24.5±1.0 27.9±1.2 30.9±0.5 20.3±0.7 27.0±0.1 
NCTC8155 22.4±0.5 19.3±0.9 33.8±1.4 23.3±1.2 25.3±0.7 26.4±1.5 27.8±0.3 29.1±0.8 25.2±0.1 29.4±0.9 25.4±0.7 18.6±0.6 27.4±2.2 
ATCC12868 21.7±0.9 18.6±0.5 29.8±1.3 24.6±2.0 27.6±0.5 23.5±1.2 26.0±0.3 26.0±0.4 22.3±0.1 35.8±1.0 24.6±0.8 18.9±0.8 26.2±0.6 
ATCC29004 21.3±0.8 18.0±0.4 29.1±0.7 20.3±0.0 21.0±1.3 23.3±1.5 24.6±1.4 21.9±0.7 21.9±0.4 30.4±0.8 25.1±0.7 18.8±0.1 28.5±0.5 
ATCC25944 26.8±1.3 20.7±1.1 32.4±0.9 26.4±0.0* 24.0± 0.7 23.2±0.3 28.5±1.3 27.2±0.3 22.8±0.6 30.8±0.8 29.7±0.3 19.9±0.6 29.4±0.8 
NCTC11434 17.5±0.9 19.8±0.4 18.3±1.0* 22.7±0.5 13.5±0.5* 17.7±1.2 23.4±0.6 23.0±0.4 16.4±0.3* 29.5±0.5 20.0±0.1 21.2±1.2 20.2±1.1 
NCTC11590 5.9±0.0 17.3±1.0 22.8±0.3 16.1±0.6* 20.9±0.5 24.5±0.4 22.1±2.2 14.8±0.4* 23.3±0.6 25.4±0.4 9.4±0.2 15.6±0.8* 20.6±0.5 
NCTC11933 8.6±1.1 17.6±0.8 29.4±2.2 15.4±1.7* 22.5±0.9 19.3±0.6 25.5±0.2 20.8±0.9 18.5±0.2 27.3±0.6 9.9±0.3 16.4±0.8* 24.5±1.1 
NCTC10006 5.9±0.0 15.8±0.6 28.2±2.0 16.6±0.4* 20.9±0.2 22.7±1.3 21.3±0.4 17.1±0.6* 18.3±1.6 23.4±0.9 12.6±0.2 16.3±0.5* 27.1±0.2 
 
AMP=ampicillin, CN=gentamycin, CTX=cefotaxime, TE=tetracycline, NA=nalidixic acid, C=chloramphenicol, STX=trimethoprim-
sulfamethoxazole, KF=cefalothin, CXM=cefuroxime, CIP=ciprofloxacin, AMC=amoxicillin-clavulanic acid, K=kanamycin, CRO=ceftriaxone 
Zone sizes were interpreted according to the CLSI guidelines for Enterobacteriaceae (CLSI, 2005).  esults classified as “resistance” are 
highlighted in bold and those classified as “intermediate sensitivity” are indicated by an asterix.  
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In summary, the present study was initiated to examine the capability of sixteen 
Cronobacter strains to tolerate the physiologically relevant conditions of the 
gastrointestinal tract (low pH, salt and bile). While all strains were able to tolerate 
the conditions examined, noteworthy variations in tolerance were observed. It is 
therefore important that future studies aimed at investigating the mechanisms used 
by Cronobacter to survive within the gastrointestinal tract should include a 
collection of strains and not just focus on a single strain. 
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Abstract 
The objective of the present study was to create a collection of Lux-tagged 
Cronobacter strains to determine whether bioluminescence could be used to monitor 
growth in infant milk formulae (IMF). Nine Cronobacter strains (seven C. sakazakii, 
one C. malonaticus and one C. muytjensii) were transformed with plasmid p16Slux 
and integration of the plasmid at the desired site on the chromosome was confirmed 
by PCR. The integrated plasmid was shown to be stable in the absence of antibiotic 
selection and growth of the Lux-tagged strains was similar to their non-tagged 
counterparts. Growth of Lux-tagged strains was monitored in real-time in ten 
commercial brands of IMF by measuring light emission using a luminometer. While 
all of the IMF tested were able to support the growth of the Cronobacter strains, 
differences were observed between the brands. We also noted variations in the 
amount of light emitted by individual Cronobacter strains. Monitoring light emission 
by a combination of two strains that produced higher and lower than average RLU 
readings was found to be a good surrogate for the entire collection of Lux-tagged 
strains.   
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Introduction 
Cronobacter is a genus within the family Enterobacteriaceae and consists of seven 
species; C. sakazakii, C. malonaticus, C. turicensis, C. muytjensii, C. dublinesis, C. 
universalis and C. condimenti (Iversen et al., 2008, Joseph et al., 2012a). 
Cronobacter spp. have been isolated from a variety of environments and foods 
including water (Farmer et al., 1985), soil (Khan et al., 1998) dust from households 
and food production lines (Khandhi et al., 2004), fruits, vegetables, herbs, cereals 
and grains (Friedemann, 2007).  
C. sakazakii is an opportunistic infant pathogen that causes necrotizing enterocolitis, 
sepsis and meningitis (Chenu et al., 2009). Although the frequency of infection 
generally tends to be low, the prognosis is poor with case-mortality rates varying 
from 33-80% (Lai, 2001). Powdered infant milk formula (IMF) is thought to be the 
primary transmission vehicle of C. sakazakii (Healy et al., 2010). IMF is not 
manufactured as a sterile product but conforms to international microbiological 
specification guidelines. According to the Codex Alimentarius Commission (CAC) 
guidelines issued in 2008 each batch of IMF must be tested to ensure that it is free 
from C. sakazakii by testing thirty 10g samples (CAC).  However, C. sakazakii has 
been isolated from retailed IMF by several research groups. For example, Iversen et 
al., (2004c) investigated the presence of Cronobacter in IMF and other food 
products and isolated the bacterium from 2 of 82 IMF tested (2.4%). Nazarowec-
White et al., (1997b) analyzed 120 cans of IMF from 5 different companies in 
Canada and found 6.7% contained Cronobacter spp. Muytjens et al., (1998) isolated 
Cronobacter from 20 of 141 IMF (14%) tested. It has been noted that Cronobacter 
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spp. are heterogeneously distributed throughout batches of IMF (Jogenburger et al., 
2011) which may explain why Cronobacter may not always be detected by IMF 
manufacturers prior to sale.  
Schmid et al., (2009) suggest that plants may be the natural habitat of Cronobacter 
spp. and that plant-derived IMF supplements (e.g. starches and proteins), particularly 
those that are not subjected to an additional heating step, are potential sources of 
contamination in the factory setting. Furthermore equipment employed in the IMF 
manufacturing facility (dryers, bag filling platform, packing vacuums, blenders, 
production and particularly air filters) are also possible sources of contamination 
(Mullane et al., 2008, Mullane et al., 2007).  
IMF manufacturers may be interested in developing novel compositions or 
ingredients that limit or inhibit the growth of C. sakazakii. As IMF is opaque, 
bacterial growth cannot be examined by measuring optical density and is usually 
analyzed by performing direct plate counts (Nair et al., 2004) or indirectly by 
measuring pH changes (Chang et al., 2009) or alterations in electrical impedance 
(Yang et al., 2008). These processes can be time-consuming and laborious. 
Morrissey et al., (2011) transformed a C. sakazakii strain with luciferase (lux) genes 
using plasmid p16Slux and monitored growth of the bacterium in milk and infant 
formulae by measuring bioluminescence. Reproducible results were obtained in real-
time even when low initial inoculums were used. Light could also be detected in the 
presence of competing bacteria. Overall the study suggests that this method of 
following growth of C. sakazakii offers advantages to the conventional methods that 
are routinely used and may be utilized in high-throughput studies aimed at 
identifying anti-C. sakazakii agents or developing novel IMF compositions 
(Morrissey et al., 2011). 
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Similar to other bacterial genera, not all strains of C. sakazakii are genetically or 
phenotypically identical (Caubilla-Barron et al., 2007, Healy et al., 2009, Ye et al., 
2011). Therefore, it is important that studies aimed at developing novel IMF should 
not focus solely on one strain but should include a collection of strains from different 
sources. These strains must be individually Lux-tagged if the previously mentioned 
bioluminescence-based experiments are to be employed. As Cronobacter strains are 
not naturally competent, methods such as electroporation or CaCl2 transformation 
are required to transform strains with plasmids. Differences in outer cell structure of 
Cronobacter strains (e.g. the presence of a capsule) may affect the uptake of 
plasmids. It is therefore possible that not all strains may be as easy to manipulate as 
the strain employed by Morrissey et al., (2011) or that plasmid p16Slux may not be 
stable in all strains.   
The primary aim of this study was to Lux-tag a collection of Cronobacter strains 
from a variety of environmental sources and determine if their growth could be 
monitored in IMF by measuring bioluminescence. A second aim was to examine 
whether growth of a cocktail of strains would be a good indicator of the average 
growth of Cronobacter strains in IMF.    
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Materials and Methods 
Bacterial strains and culture conditions  
The Cronobacter strains used in this study are listed in Table 1. Strains were 
routinely grown in Luria-Bertani (LB) broth (Merck, Darmstadt, Germany) statically 
at 37°C. For solid media 1.5% agar was added. Lux-tagged Cronobacter strains were 
grown with shaking at 37ºC in LB broth supplemented with 500μg/ml erythromycin. 
Escherichia coli DH10B::p16Slux was grown at 30°C shaking in LB supplemented 
with 500μg/ml erythromycin. Erythromycin (Sigma, Germany) was made up as a 
concentrated stock in ethanol and added to cooled autoclaved media. For certain 
experiments Brilliance Enterobacter sakazakii (DFI, Druggan, Forsythe and Iversen) 
agar (Oxoid, UK) was used.   
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Table 1. Bacterial strains used in this study.  
Strain  Relevant 
Information 
Source/ 
reference 
DH10B::p16Slux E.coli Erythromycin resistant Riedel et 
al., 2007 
NCTC8155 Cronobacter  sakazakii 
 
Isolated from a tin of 
dried milk powder 
 
DPC6522 
 
Cronobacter  sakazakii 
 
Isolated from blood M Ardino 
DPC6526 
 
Cronobacter  sakazakii 
 
Isolated from blood M Ardino 
DPC6527 
 
Cronobacter  sakazakii 
 
Isolated from blood M Ardino 
DPC6529 
 
Cronobacter  sakazakii 
 
Isolated from tracheal 
aspirate 
M Ardino 
DPC6531a 
 
Cronobacter  malonaticus Isolated from a brain 
tumor 
M Ardino 
ATCC51329b 
 
Cronobacter  muytjensii 
 
  
ATCC12868 
 
Cronobacter  sakazakii   
ATCC29004 
 
Cronobacter  sakazakii   
ATCC29544 
 
Cronobacter  sakazakii Isolated from a child’s 
throat 
 
NCTC8155::p16Slux Cronobacter  sakazakii  Morrissey 
et al., 
2011 DPC6522::p16Slux 
 
Cronobacter sakazakii  This study 
DPC6526::p16Slux 
 
Cronobacter sakazakii  This study 
DPC6527::p16Slux 
 
Cronobacter  sakazakii 
 
 This study 
DPC6529::p16Slux 
 
Cronobacter  sakazakii  This study 
DPC6531::p16Slux 
 
Cronobacter  malonaticus  This study 
ATCC51329::p16Slux 
 
Cronobacter  muytjensii 
 
 This study 
ATCC12868::p16Slux Cronobacter  sakazakii  This study 
        ATCC29004::p16Slux 
 
        Cronobacter  sakazakii 
 
 This study 
        ATCC295445::p16Slux 
 
        Cronobacter  sakazakii  This study 
a
This strain was classified as C. sakazakii but rpoB sequencing revealed it was a C. malonaticus. 
b
This strain was deposited as C. sakazakii but was re-classified as C. muytjensii by Iversen et al., 
(2008). 
All strains were obtained from the DPC, Dairy Products Research Centre, Moorepark, Fermoy, Co. 
Cork, Ireland. Strains DPC6522, DPC6526, DPC6527, DPC6529 and DPC6531 were originally 
obtained from M. Ardino, Centers for Disease Control and Prevention, Atlanta, United States. 
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Creation of competent Cronobacter cells and electroporations  
Strains were grown statically overnight in LB for approximately 16 hrs. A 1% 
inoculum was transferred to fresh LB broth and incubated with shaking for 
approximately 3 hrs at 37°C until an OD620nm of ~0.6 was reached. Cultures were 
chilled on ice for 15 min after which they were centrifuged at 900 x g for 10 min at 
4°C. The supernatants were discarded, and the cells were resuspended in ice cold 
sterile distilled water and re-centrifuged. This was repeated three times, after which 
the cells were resuspended in 10% ice cold glycerol and re-centrifuged. The 
supernatants were removed and cells were resuspended in 500µl of 10% glycerol. 
50µl aliquots were transferred to cold sterile 1.5ml microcentrifuge tubes and stored 
at -80°C. For electroporations, 2µl of p16Slux plasmid preparation (~1µg) was added 
to 50µl of competent cells in a 2mm cuvette (Molecular BioProducts, San Diego 
CA). Cells were shocked using a Harvard Apparatus ECM 630 Electro Cell 
Manipulator (MA, USA) with settings of 2.5kV, 200Ω and 25µF. The cells were 
resuspended in 1ml LB and incubated shaking at 30°C for 1 h. Transformants were 
selected by plating onto LB agar containing erythromycin (500µg/ml). Plates were 
incubated at 30°C for 48 hrs. Colonies were checked for light emission using the 
Xenogen IVIS100 imaging system (Xenogen, Alameda, CA). Bioluminescence was 
measured in relative light units (photons/sec/cm) with a binning of sixteen and an 
exposure time of one min. In order to integrate the plasmid into the chromosome, 
strains were grown overnight in LB containing 500µg/ml erythromycin at 30°C, 
diluted 1:1000 into fresh LB containing erythromycin and grown overnight at 42°C. 
Dilutions were subsequently plated on LB agar containing 500µg/ml erythromycin 
and incubated at 42°C overnight. 
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Molecular biology experiments 
Plasmid p16Slux was extracted from its E. coli host strain using the Invitrogen Quick 
plasmid miniprep kit. It was subsequently alcohol precipitated using Pellet Paint Co-
Precipitant (Novagen, Merck).  Integration of p16Slux into the chromosome of 
Cronobacter strains was confirmed by PCR using primers 16S_fwd_new 
(ACACTGGAACTGAGACACGGTCCAGACTCC) and 16S_int_rev 
(TTGTAAAACGACGGCCAGTGAGCGCGCG). Amplification of the target region 
was achieved with 30 cycles of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C 
for 1 min. PCR amplification was carried out using a G-storm cycler (Essex, UK). A 
1,163-bp PCR product was amplified when p16Slux was integrated at the correct site 
in the chromosome. The amplified PCR products were separated on 1% (m/v) 
agarose gels and visualized with the DNR Bio-Imaging System (Jerusalem, Israel). 
Monitoring growth of Cronobacter strains in LB broth by measuring optical 
density and in IMF by measuring bioluminescence 
Strains were grown in triplicate in LB broth and incubated overnight (~16 hrs) at 
37°C. Cells were centrifuged at 8000 x g, washed and resuspended in 1ml ¼ strength 
 inger’s solution ( erck, Darmstadt,  ermany). 20µl of washed cells was added to 
1ml of LB broth, vortexed to mix and 200µl was transferred to a 96-well plate 
(Genetix, UK). Growth was monitored by measuring optical density (OD) at 620nm 
using a temperature controlled automatic plate reader (Thermo Scientific Multiscan 
FC). Viable plate counts were performed at selected time points by serially diluting 
samples in ¼ strength  inger’s solution and enumeration on LB agar. Ten brands of 
IMF were purchased in a local supermarket. IMF was aseptically weighed and added 
to sterile distilled water (10% wt/vol) and mixed by swirling manually for 5 min. In 
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order to monitor bioluminescence, a 2% inoculum of washed Lux-tagged cells was 
added to fresh IMF and 200µl of this was transferred to a 96-well white plate (Nunc, 
Thermo Fisher Scientific, Roskilde, Denmark). Bioluminescence was measured 
every hour in relative light units (RLU) using a Luminoskan luminometer automatic 
plate reader (Thermo Fisher Scientific, Roskilde, Denmark). When viable plate 
counts were required, cultures were serially diluted in ¼ strength  inger’s solution 
and enumerated on DFI agar.   
Plasmid stability 
The Lux-tagged Cronobacter strains were grown overnight (~16 hrs) in duplicate in 
LB broth containing erythromycin (500µg/ml) at 37°C. 1ml of overnight was 
centrifuged at 8000 x g for 7 min, washed and resuspended in 1ml ¼ strength 
 inger’s solution ( erck, Darmstadt,  ermany). 200µl was transferred into 10ml of 
fresh LB broth without antibiotic. Tubes were incubated at 37°C for approximately 8 
hrs after which 200µl of culture was transferred into 10ml of fresh broth and 
incubated at 37°C overnight (~16 hrs). This passaging was repeated for a further 
three days. At every passage 100µl aliquots were serially diluted in ¼ strength 
 inger’s solution and 100µl was spread onto LB agar. Plates were incubated at 
37°C. 50 random colonies from each passage were scored for antibiotic resistance by 
patching them onto LB agar and LB agar supplemented with 500µg/ml 
erythromycin.  
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Results 
Growth of C. sakazakii NCTC8155::p16Slux in IMF 
Growth of the Lux-tagged C. sakazakii strain employed by Morrissey et al., (2011) 
NCTC8155::p16Slux was examined in ten different brands of IMF. As previously 
observed, growth of the strain could be easily monitored by measuring 
bioluminescence. Variations in RLU readings were observed amongst the different 
brands of IMF (Fig. 1). For example at T24 hrs the readings obtained for IMF7 was 
five times higher than IMF3 (102.1 RLU versus 18.16 RLU, respectively). 
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Figure 1. Growth of NCTC8155::p16Slux in ten different powdered infant formulae: 
IMF1 (◊), IMF2 (□), IMF3 (▲). IMF  (●), IMF5 (○), IMF6 (+), IMF7 (Δ), IMF8 
(■), IMF9 (    ) and IMF10 (♦). The initial inoculum was approximately 1x104 cfu/ml 
with RLU taken over a 24 h period at 37°C. Bioluminescence was measured using a 
Luminoskan luminometer. Error bars represent the standard deviations of triplicate 
experiments.  
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Creation and analysis of Lux-tagged Cronobacter strains 
Plasmid p16Slux was used to Lux-tag nine strains of Cronobacter (seven C. 
sakazakii, one C. malonaticus and one C. muytjensii) (Table 1). This plasmid 
contains the Lux operon derived from Photorhabdus luminescens under the control 
of a constitutive promoter, Phelp (highly expressed Listeria promoter) (Fig. 2A). It 
facilitates homologous recombination based integration into a 16S rRNA gene of 
Gram negative bacteria (Riedel et al., 2007). After initial transformation with 
p16Slux, bacteria were maintained under permissive conditions (30°C), which 
allowed for plasmid replication. Changing to the non-permissive temperature (42°C) 
selects for strains in which p16Slux integrates into the bacterial chromosome. Using 
primers based on the integration site, PCR amplification of a 1,163 bp product in the 
Lux-tagged strains confirmed integration of p16Slux into the correct location (Fig. 
2B). Lux-tagged strains emitted light when viewed with the IVIS100 imaging system 
confirming expression of the lux genes. The Lux-tagged C. sakazakii strain created 
in Morrissey et al., (2011) is also included (NCTC8155::p16Slux) (Fig. 2C).  
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Figure 2. (A) Map of p16Slux showing the Phelp promoter, DH10B 16S rRNA gene 
and Lux operon (lux A-E). (B) Gel picture of PCR reactions performed to ensure 
integration of p16Slux into the chromosome. M molecular marker (1Kb, Promega); 
Lane 1, DPC6522; Lane 2, DPC6522::p16Slux; Lane 3, DPC6526; Lane 4, 
DPC6526::p16Slux; Lane 5, DPC6527; Lane 6, DPC6527::p16Slux; Lane 7 
DPC6529; Lane 8, DPC6529::p16Slux; Lane 9, DPC6531; Lane 10, 
DPC6531::p16Slux; Lane 11, ATCC51329; Lane 12, ATCC51329::p16Slux; Lane 
13, NCTC8155; Lane 14, NCTC8155::p16Slux; Lane 15, ATCC12868; Lane 16, 
ATCC12868::p16Slux; Lane 17,  ATCC29004; Lane 18, ATCC29004::p16Slux; 
Lane 19, ATCC29544; Lane 20, ATCC29544::p16Slux; Lane 21, negative control 
(water). (C) C. sakazakii Lux-tagged strains streaked onto LB plus 500µg/ml 
erythromycin agar plates and viewed with an IVIS imager.        
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Growth curves of the non-tagged strains and their Lux-tagged counterparts were 
carried out in LB broth to examine if integration of the plasmid affected growth 
under standard laboratory conditions (Fig 3 A-J) and generation times are given in 
Table 2. Of the ten strains examined, statistically significant differences in 
generation times were observed for two strains. The generation times of Lux-tagged 
C. sakazakii strains DPC6526 and DPC6529 were longer than their non-Lux-tagged 
counterparts (Table 2). Although statistically significant it was noted that these 
differences were slight, so overall, integration of plasmid p16Slux does not have a 
major impact on the growth of strains. 
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Figure 3. Growth curves in LB broth at 37°C over 24 hours (A) DPC6522::p16Slux (□) and DPC6522 (■), (B) DPC6526::p16Slux (□) and 
DPC6526 (■), (C) DPC6527::p16Slux (□) and DPC6527 (■), (D) DPC6529::p16Slux (□) and DPC6529 (■), (E) DPC6531::p16Slux (□) and 
DPC6531 (■), (F) ATCC51329::p16Slux (□) and ATCC51329 (■),  (G) NCTC8155::p16Slux (□) and  CTC8155 (■), (H) ATCC29004 (□) and 
ATCC29004::p16Slux (■) (I) ATCC12868::p16Slux (□) and ATCC12868 (■), (J) ATCC29544::p16Slux (□) and ATCC29544 (■).  Data are 
represented as mean OD620nm ± standard deviations for three biological repeat.
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Table 2. Generation times of non-tagged versus Lux-tagged strains. Results are 
expressed as averages of triplicate experiments ± the standard deviation.   
Strain Generation 
time (min) 
Lux-tagged strain Generation 
time (min) 
p value 
DPC6522 28.23 ± 0.93 DPC6522::p16Slux 30.94 ± 0.94 0.053 
DPC6526* 31 ± 1.68 DPC6526::p16Slux 33.11 ± 0.77 0.02 
DPC6527 29.94 ± 4.2 DPC6527::p16Slux 35.95 ± 2.5 0.117 
DPC6529* 27.4 ± 0.3 DPC6529::p16Slux 28.6 ± 0.4 0.019 
DPC6531 35.77 ± 1.1 DPC6531::p16Slux 34.81 ± 1.9 0.49 
ATCC51329 35.682 ± 1.4 ATCC51329::p16Slux 36.4 ± 0.85 0.48 
NCTC8155 28.11 ± 2.8 NCTC8155::p16Slux 32 ± 1.49 0.51 
ATCC12868 35.06 ± 1.6 ATCC12868::p16Slux 37.39 ± 0.8 0.1189 
ATCC29004 38.58 ± 1.15 ATCC29004::p16Slux 37.404  ± 2.11 0.46 
ATCC29544 32.4 ± 1.06 ATCC29544::p16Slux 30.2 ± 3.2 0.36 
* According to the student t-test for these strains the p value is <0.05, therefore 
the difference in growth rates is statistically significant. Analysis of the scientific 
data was carried out using basic statistical software in Excel.  
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The stability of p16Slux was examined by continuously passaging the Lux-tagged 
strains in LB broth in the absence of erythromycin and scoring for antibiotic 
resistance. The plasmid was shown to be 100% stable over two transfers for all of the 
strains and 98% stable over four transfers for all of the strains (Fig. 4). Some 
instability was observed over longer time periods. For example, while 
ATCC29544::p16Slux was 97% stable over six transfers, DPC6531::p16Slux was 
only 74% stable over the same time period (Fig. 4).  
 
 
 
 
Figure 4. Stability of p16Slux for each strain. Percentage of erythromycin resistant 
colonies following daily passaging of Lux-tagged strains in the absence of antibiotic 
selection.  vernight (■), passage 1 (  ), passage 2 (  ), passage 3 ( ), passage 4 ( ), 
passage 5 ( ) and passage 6 ( ). Data are represented as mean % of erythromycin 
resistant colonies ± standard deviations for three biological repeats. 
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Growth of Lux-tagged strains in IMF 
Growth curves were performed with the ten Lux-tagged strains in two IMF, IMF5 
and IMF8. These two IMF were chosen as in earlier experiments with 
NCTC8155:p16Slux higher RLU readings than average were obtained for IMF5 and 
lower than average RLU readings were obtained for IMF8 (Fig. 1). These two IMF 
brands are produced by different manufacturers. While lowest RLU readings and 
plate counts were obtained for NCTC8155:p16Slux in IMF10 this IMF was not 
selected for further experiments as it is a lactose free formula and growth of 
Cronobacter is limited. Growth of Lux-tagged strains in IMF5 and IMF8 is 
portrayed in Fig. 5A and Fig. 5B, respectively. Similar to the results obtained with 
NCTC8155::p16Slux, growth of the Lux-tagged strains in both IMF could be easily 
and reproducibly monitored by measuring bioluminescence.  
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     A            B 
 
 
Figure 5. Growth curves of Lux-tagged strains in IMF5 (A) and IMF8 (B) 
DPC6522::p16Slux (◊), DPC6526::p16Slux (□), DPC6527::p16Slux (▲) 
DPC6529::p16Slux (=), DPC6531::p16Slux (○), ATCC51329::p16Slux (+), 
NCTC8155::p16Slux (Δ), ATCC12868::p16Slux (■), ATCC2900 ::p16Slux (▬) 
and ATCC29544::p16Slux (♦) at 20°C over 24 h. Bioluminescence was measured 
using a Luminoskan luminometer. Error bars represent the standard deviations of 
triplicate experiments. 
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Growth of individual Lux-tagged Cronobacter strains and a cocktail of Lux-
tagged strains in IMF8 
Growth of the ten Lux-tagged Cronobacter strains in IMF8 was reanalyzed and the 
average RLU of all ten strains was calculated (Fig. 6A and 6B).  Plate counts were 
performed at 16 hrs for DPC6522::p16Slux for which RLU were higher than the 
average of the ten strains (~94 RLU) and ATCC12868::p16Slux for which RLU 
were lower than the average of the ten strains (~40 RLU). Cell numbers for both 
strains were ~1x10
7 
cfu/ml. 
In addition to the individual Lux-tagged strains a cocktail of the ten strains was 
included (Fig. 6A). This was carried out in order to determine if growth of a 
collection of Cronobacter strains (cocktail) could be used as an approach to 
predicting Cronobacter growth as an alternative to employing ten strains 
individually. The RLU values obtained for the cocktail of the Lux-tagged strains was 
similar to the average RLU obtained for the ten individual strains.  
The experiment was repeated with DPC6522::p16Slux alone, ATCC12868::p16Slux 
alone, a cocktail of all 10 Lux-tagged strains and a mix of DPC6522::p16Slux and 
ATCC12868::p16Slux (Fig. 6B). The cocktail of the ten strains and the cocktail of 
the two strains were comparable. Therefore these two strains could potentially be 
used instead of the cocktail of ten Lux-tagged Cronobacter strains as an accurate 
indicator of the bacterial growth in IMF.  
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      A         B
 
Figure 6. (A). Growth of Lux-tagged Cronobacter strains at 20°C over 24 h in 
IMF8. Also included are a cocktail of the ten strains and the average of the ten Lux-
tagged Cronobacter strains. DPC6522::p16Slux (◊), DPC6526::p16Slux (□), 
DPC6527::p16Slux (▲) DPC6529::p16Slux (=), DPC6531::p16Slux (○), 
ATCC51329::p16Slux (+), NCTC8155::p16Slux (Δ), ATCC12868::p16Slux (■), 
ATCC29004::p16Slux (▬), ATCC29544::p16Slux (♦), cocktail of the ten Lux-
tagged strains (×) and average RLU of the 10 lux-tagged strains (     ). (B) Using a 
cocktail of two stains was also investigated DPC6522::p16Slux (◊). 
ATCC12868::p16Slux (■), mix of DPC6522::p16Slux and ATCC12868::p16Slux (●) 
and a cocktail of the ten Lux-tagged strains (×). Bioluminescence was measured 
using a Luminoskan luminometer. Error bars represent the standard deviations of 
triplicate experiments. 
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Discussion 
Initial experiments examined growth of C. sakazakii NCTC8155::p16Slux, the Lux-
tagged strain used by Morrissey et al., (2011), in ten different brands of IMF 
produced by four different manufacturers. It was found that growth of the strain 
could be easily and reproducibly monitored in real-time by monitoring light 
emission. Differences in RLU readings were observed between formulae and 
differences in viable plate counts were also noted (data not shown).  The lowest RLU 
readings were obtained for IMF10 which was the only lactose free IMF. In addition 
to variations in nutrient composition between formulae it is also possible that the 
growth of C. sakazakii could be affected by the resident microflora in IMF. This 
microflora consists mainly of Bacillus spp. which may outgrow C. sakazakii or 
produce inhibitory substances such as bacteriocins. 
Healy et al., (2009) employed microarray comparative genome indexing (CGI) to 
analyze the genomic content of 78 Cronobacter strains and highlighted the genomic 
similarities and differences between strains. The phenotypic diversity of 
Cronobacter strains has also been demonstrated (Caubilla-Barron et al., 2007, Ye et 
al., 2011); therefore not all strains of Cronobacter are identical and may proliferate 
at different rates in different IMF. As IMF manufacturers strive to create new and 
improved formulae, it is likely that they will want to investigate the extent to which 
these new compositions support the growth of C. sakazakii. It is important that more 
than one strain is included in these experiments so if bioluminescence-based assays 
are to be used a collection of Lux-tagged Cronobacter strains will be required. While 
attempts by previous researchers have failed to Lux-tag C. sakazakii (Forsythe, 
113 
 
2009), we were able to successfully Lux-tag all seven C. sakazakii strains we 
selected at random from our culture collection using plasmid p16Slux. A C. 
malonaticus strain and a C. muytjensii strain were also successfully tagged. While 
integration of the plasmid had a slight effect on the generation times of two of the ten 
stains, expression of the luciferase and accessory proteins and the process of light 
emission did not seem to be a huge burden on bacterial metabolism. The integrated 
plasmid was stable when cells were cultured in the absence of antibiotic over short 
time periods.  
It was observed that growth of the Lux-tagged strains could be easily monitored in 
real-time in IMF by measuring bioluminescence. Differences in RLU readings were 
observed between strains and these differences did not always directly correlate with 
differences in cell counts. For example in IMF8 after 16 hrs the RLU reading for 
DPC6522::p16Slux was twice the reading for ATCC12868::p16Slux (~94 RLU vs 
~40 RLU) while cell counts for both strains were the same (~1x10
7 
cfu/ml). The light 
reaction involves the oxidation of reduced riboflavin phosphate (FMNH2) the 
concentration of which depends on the metabolic activity of the cell (Bachmann et 
al., 2007, Meighan, 1991). It is possible that the different Cronobacter strains used 
in our study produce different amounts of FMNH2 which affects RLU output. 
Therefore, our experiments show that the growth of Lux-tagged Cronobacter strains 
can be easily followed by measuring light emission and bioluminescence-based 
experiments can be employed to determine if an infant formula composition supports 
their growth. Although RLU readings obtained for different strains cannot be directly 
translated into viable cell numbers uniformly for all strains, cell numbers and RLU 
readings for individual strains can be directly correlated.  
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Experiments with mixes of strains demonstrated that a cocktail of two Lux-tagged 
Cronobacter strains provides a good representation of the average growth of all ten 
strains in IMF. This means that rather than performing future growth analyses in 
IMF with all ten strains, the use of two strains would reduce the amount of work and 
samples required. 
In conclusion, we have successfully Lux-tagged a collection of Cronobacter strains 
and demonstrated that growth in IMF could be monitored by measuring 
bioluminescence. In addition to examining the effects of various infant formula 
compositions on growth of Cronobacter, a bank of Lux-tagged strains may have 
other potential applications. For example, the strains may be of use in examining 
biofilm formation in experiments similar to those performed in L. monocytogenes 
(Begley et al., 2009). Milk components have been shown to influence biofilm 
formation by C. sakazakii (Dancer et al., 2009a) and biofilms contribute to 
persistence of the pathogen on food contact surfaces (Iversen et al., 2004d). Lux-
tagged strains may also be employed to investigate biocide efficiency or examine 
growth and survival in in vitro (i.e. cell culture) and in vivo models of infection 
(Griffiths, 2000). 
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Abstract 
Cronobacter sakazakii is a rare cause of neonatal meningitis, septicaemia and enterocolitis. 
Contaminated infant milk formulae (IMF) have been epidemiologically linked as a source of 
C. sakazakii infection in several clinical cases. Lux-tagged C. sakazakii strains emit light 
and their growth can be monitored in real-time in IMF by measuring bioluminescence. A 
transposon mutagenesis library was created in a Lux-tagged strain of C. sakazakii. This 
library was screened for mutants with impaired growth in milk. It was found the majority of 
genes disrupted in these mutants were associated with amino acid metabolism (valine, 
isoleucine, glutamic acid, methionine and arginine). Addition of the relevant amino acid 
fully restored growth of the mutant to wild type levels of growth in milk. Complementation 
of mutants with an intact copy of the disrupted gene on a plasmid also resulted in restoration 
of growth in milk. Our results highlight the importance of genes involved in amino acid 
metabolism for growth in this environment. A better understanding of how the bacterium 
grows in milk may ultimately aid in the development of more effective preservation 
techniques to limit growth of this pathogen in milk. 
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Introduction 
Cronobacter sakazakii is an opportunistic pathogen, associated with the ingestion of 
contaminated powdered infant milk formula (IMF). It is a Gram negative, peritrichously 
motile, non-spore forming, facultative anaerobic bacteria. Although rare, infections by this 
organism have a case fatality rate between 33-80% (Lai, 2001). The organism is ubiquitous 
and can survive for long periods of time (up to two years) in a desiccated state (Edelson-
Mammel et al., 2005). These features may provide C. sakazakii with a competitive 
advantage, contributing to its presence in dry environments such as IMF. In addition, IMF is 
not sterile therefore contamination with C. sakazakii can occur if strict microbiological 
guidelines are not adequately followed. Isolation of the pathogen from commercially 
available IMF can range from 2.4 to 14% (Iversen et al., 2004c, Nazarowec-White et al., 
1997b, Muytjens et al., 1988). The FDA method for detection of C. sakazakii in IMF has 
been revised to include molecular biology tests as well as microbiological analyses (Lampel 
et al., 2009). Future studies with this more sensitive method may provide more accurate data 
on the true incidence of C. sakazakii in IMF.  
However, it is evident that contamination of IMF with C. sakazakii occurs. In November and 
December of 2011, four infants were infected with C. sakazakii resulting in two deaths in the 
United States (CDC, 2012). This resulted in a voluntary recall of suspect IMF. Therefore C. 
sakazakii is undoubtedly of major concern to infant formula manufacturers and public 
health.  
Much of the research on growth of bacteria in milk focuses on lactic acid bacteria (LAB) 
such as Streptococcus thermophilus and Lactococcus lactis. These studies include 
investigation of the proteomic signature of LAB in milk (e.g. Herve-Jimenez et al., 2008, 
Gitton et al., 2005) or identifying genes essential for growth of LAB in milk (e.g. Arioli et 
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al., 2009, Dudley et al., 2001). Less information is available concerning the growth of 
pathogenic bacteria in milk. Examples of such studies include investigation of the gene 
expression profiling of L. monocytogenes in milk (Liu et al., 2008) and examining proteomic 
changes of Escherichia coli in milk compared to laboratory media (Lippolis et al., 2009). To 
our knowledge, genes required for growth of C. sakazakii in milk have not yet been 
identified. A better understanding of the molecular mechanisms this pathogen utilizes to 
grow in milk may assist in developing more effective preservation techniques.   
As milk is opaque it does not lend itself to growth measurements by optical density. The 
traditional processes used to measure bacterial growth in milk can be lengthy and time-
consuming (e.g. direct plate counts, monitoring pH variation and changes in electrical 
impedance). Morrissey et al., (2011) transformed a C. sakazakii strain with luciferase (lux) 
genes employing the plasmid p16Slux and monitored growth of the bacterium in milk and 
infant formulae by measuring bioluminescence (light emission). This process provides real 
time tracking of C. sakazakii growth in milk and monitoring growth of the Lux-tagged C. 
sakazakii strain was shown to be reproducible.   
The aim of the current study was to create a transposon mutagenesis library in a Lux-tagged 
strain of C. sakazakii and screen this library for mutants affected in their growth potential in 
milk.  
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Materials and methods 
Bacterial strains and culture conditions. 
Strains used in this study are listed in Table 1. They were routinely grown in Luria-Bertani 
(LB) broth (Merck, Darmstadt, Germany) statically at 37°C for ~16 hours unless otherwise 
stated. For solid media 1.5% agar was added. For certain experiments Brilliance 
Enterobacter sakazakii (DFI, Druggan, Forsythe and Iversen) agar (Oxoid, UK) was used. 
Reconstituted skim milk (RSM) (Carbery) was prepared by dissolving (10% wt/vol) powder 
in distilled water and autoclaving at 110°C for 10 minutes. IMF was aseptically weighed and 
added to sterile distilled water (10% wt/vol) and mixed by swirling manually for 5 min. If 
required antibiotics were added at the following final concentrations: erythromycin, 
500μg/ml, kanamycin, 50µg/ml and chloramphenicol, 10µg/ml. Erythromycin (Sigma, 
Germany) and chloramphenicol (Sigma) were made up as a concentrated stock in ethanol. 
Kanamycin (Sigma) was filter sterilized and made up as a concentrated stock in sterile 
distilled water. When necessary antibiotics were added to cooled autoclaved media.  The 
amino acids; glutamic acid (Sigma), isoleucine (Sigma), valine (Sigma), arginine (Sigma) 
and methionine (Sigma) were made up as concentrated stocks in sterile distilled water and 
added to cooled autoclaved media. Stocks of glutamic acid were filter sterilized. Stocks of 
isoleucine, valine, arginine and methionine were autoclaved at 121°C for 15 min.  
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Table 1. Bacterial strains, plasmid and transposon used in this study 
 
 
*WT=wild type 
Ery
r 
= Erythromycin resistance 
Cm
r
= Chloramphenicol resistance 
Km
r 
= Kanamycin resistance 
Strain or plasmid Relevant genotype or characteristic(s) Source or reference 
WT* Cronobacter  sakazakii 6529::p16Slux Ery
r 
Chapter 3 
DH5-α E. coli UCC culture collection 
pNZ44 E. coli-L. lactis high-copy-number shuttle vector, Cm
r 
containing 
constitutive P44 promoter from L. lactis chromosome 
McGrath et al., 2001 
EZ-Tn5 <kan-2> (Tn) Km
r
, mini-Tn5 transposon
 
 Epicentre,  Madison, WI   
M1 WT with an insertion in ESA_03607  Km
r 
 Ery
r
 This study 
M2 WT with an insertion in ESA_00653  Km
r 
 Ery
r
 This study 
M3 WT with an insertion in ESA_03781 Km
r 
 Ery
r
 This study 
M4 WT with an insertion in ESA_01561  Km
r 
 Ery
r
 This study 
M5 WT with an insertion in ESA_03810  Km
r 
 Ery
r
 This study 
M6 WT with an insertion in ESA_03820  Km
r 
 Ery
r
 This study 
M7 WT with an insertion in ESA_00904  Km
r 
 Ery
r
 This study 
M1Comp M1 harbouring pNZ44+ESA_03607  Cm
r
 This study 
M3Comp M3 harbouring pNZ44+ESA_03781  Cm
r
 This study 
M5Comp M5 harbouring pNZ44+ESA_03810  Cm
r
 This study 
M6Comp M6 harbouring pNZ44+ESA_03820  Cm
r
 This study 
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Transposon mutagenesis  
A transposon mutagenesis library was constructed using the EZ-Tn5 <KAN-2>Tnp 
Transposome kit (Epicentre, Madison, WI) according to protocols provided by the 
manufacturer. Briefly, C. sakazakii DPC6529::p16Slux was grown overnight in LB plus 
500µg/ml erythromycin for approximately 16 h statically. A 1% inoculation was transferred 
to fresh LB incubated shaking for ~3 hours at 37°C until an OD of ~0.6 was reached. The 
cells were centrifuged at 900 x g for 10 minutes at 4°C, the supernatant was discarded, and 
cells were resuspended in ice cold sterile distilled water and re-centrifuged. This was 
repeated three times, after which the cells were resuspended in 10% ice cold glycerol and 
centrifuged again. The supernatant was removed and cells were resuspended in 500µl of ice 
cold 10% glycerol. 50µl aliquots were transferred to cold sterile 1.5ml centrifuge tubes and 
stored at -80°C.  
For electroporations, 1µl of transposon DNA was added to 50µl of competent cells on ice in 
a 2mm cuvette (Molecular BioProducts, San Diego CA). The electroporation conditions 
were 2.5kV, 200Ω and 25µF using a Harvard Apparatus EC  630 Electro Cell anipulator 
(MA, USA). To aid recovery the cells were resuspended in 1ml super optimal broth with 
catabolite repression (SOC) and incubated shaking for 1 hour at 37°C. Cells were diluted 
1:100 in prewarmed SOC medium. To select for transposon insertion clones, aliquots of 
100µl were plated onto LB plates containing 50µg/ml kanamycin and plates were incubated 
overnight at 37°C. Single mutants were picked and transferred to individual wells of 96-well 
plates (Genetix, UK), containing 150µl/well of LB supplemented with 7.5% glycerol and 
50µg/ml kanamycin.  Plates were incubated overnight at 37°C for approximately 16 hours 
and subsequently stored at -80°C. 
Screening of transposon mutants  
The -80°C stock plates were thawed and replicated into 96-well plates (Genetix) containing 
LB broth plus 50µg/ml kanamycin using a 96-pin replicator (Genetix). These were incubated 
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at 37°C for approximately 16 hours. Subsequently mutants were serially diluted in ¼ 
strength Ringers solution and an initial inoculum of ~1x10
5 
cfu/ml was added to RSM in a 
96-well white plate (Nunc, Thermo Fisher Scientific, Roskilde, Denmark). Bioluminescence 
was measured every hour in relative light units (RLU) using a Luminoskan luminometer 
automatic plate reader (Thermo Fisher Scientific, Roskilde, Denmark). 1046 transposon 
mutants were screened for their growth progress in milk. When viable plate counts at 
selected time points were required, cultures were serially diluted in ¼ strength  inger’s 
solution and enumerated on LB agar. When required, light emission was examined using the 
Xenogen IVIS100 imaging system (Xenogen, Alameda, CA). Bioluminescence was 
measured in relative light units (photons/sec/cm) with a binning of sixteen and an exposure 
time of one minute.     
  
  
DNA extraction and manipulations 
Strains were grown overnight (~16 hrs) in LB broth. DNA was extracted from 1ml of 
overnight cultures using the Invitrogen PureLink Genomic DNA Mini Kit following the 
manufacturer’s instructions. Plasmids were extracted using the Invitrogen Quick plasmid 
miniprep kit. PCR products were purified using the Invitrogen PCR purification kit. Colony 
PCRs were performed following lysis of cells with IGEPAL CA-630 (Sigma). The 
concentration of nucleic acids was determined using an Invitrogen Qubit fluorometer 
(Eugene, Oregon, USA). PCR amplification was carried out using a G-storm cycler (Essex, 
UK). PCR products were separated on 1% (m v
-1
) agarose gels and visualised with the DNR 
Bio-Imaging System (Jerusalem, Israel). Enzymes and respective buffers were obtained 
from Roche (Basel, Switzerland).  
Identification of transposon insertion sites 
The transposon insertion site for each mutant was identified by single primer PCR. DNA 
fragments were amplified from chromosomal DNA of the transposon mutants using primer 
Tn5PCRR (Table 2) with the reaction conditions described by Karlyshev et al., (2000). The 
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conditions were 1 min at 94°C, 20 cycles of 94°C for 30s, 50°C for 30s and 72°C for 3 min, 
30 cycles of 94°C for 30s, 30°C for 30s and 72°C for 2 min, 30 cycles of 94°C for 30s, 50°C 
for 30s and 72°C for 2 min, followed by a 7 min extension at 72°C. PCR products were 
purified and sequenced using primer KAN-2 RP1 (Table 2) by MWG Biotechnologies 
(Ebersberg, Germany). 
BLASTn (Basic Local Alignment Search Tool) searches were performed with the obtained 
sequences (http://blast.ncbi.nlm.nih.gov/) to identify homologous genes. Homologous 
regions in the genome of the sequenced C. sakazakii BAA-894 strain (accession number 
NC_009778) were analysed and the information obtained was used to generate Figure 4. 
Proteins were analysed for the presence of conserved domains using the conserved domain 
database (http://www.ncbi.nlm.nih.gov/cdd/).  
 
 
Table 2 Primers used in this study 
Primer Sequence 5’→3’ 
Kan-2 RP1 GCAATGTAACATCAGAGATTTTCAG 
Tn5PCRR CGAGCAAGACGTTTCCCGTTG 
ESA_03607 F GCTCTAGAAGGCGCAGTAAGAGGTCAC*
 
ESA_03607 R AACTGCAGAACGTCAGACGAAACGGTC
† 
ESA_03781 F GGGGTACCGACACGGACAACATCACGAG
‡ 
ESA_03781 R GCTCTAGAGGGTGGGTAGTGAAACG*
 
ESA_03810 F GCTCTAGACTGAGGTCTGTCAACAGTG*
 
ESA_03810 R AACTGCAGCATCCACCGTGATATTCAGG
† 
ESA_03820 F GCTCTAGAACGACACAGCGATTGATG*
 
ESA_03820 R GGGGTACCGTCATCCTCGCAATAGCA
‡ 
pNZ44 F CTAATGTCACTAACCTGCCCCGTTAG 
pNZ44 R GGCTATCAATCAAAGCAACACGTG 
 
Recognition sites of restriction enzymes are highlighted in bold and underlined. 
* XbaI 
† 
PstI 
‡ 
KpnI  
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Monitoring growth of selected mutant strains in LB broth by measuring optical density 
and in IMF by measuring bioluminescence.  
Mutants were grown in triplicate in LB broth and incubated overnight (~16 h) at 37°C. Cells 
were centrifuged at 8000 x g, washed and resuspended in ¼ strength  inger’s solution 
(Merck, Darmstadt, Germany). For growth curves, the washed cells were serially diluted and 
an initial inoculum of ~1x10
5 
cfu/ml was added to LB broth, 200µl of this was transferred to 
a 96-well plate (Genetix, UK). Growth was monitored by measuring optical density (OD) at 
620nm using a Thermo Scientific Multiscan FC plate reader where a reading was taken once 
an hour for 24 h. Viable plate counts were performed at selected time points by serially 
diluting samples in ¼ strength  inger’s solution and enumeration on LB agar. In order to 
monitor bioluminescence in IMF washed cells were serially diluted in ¼ strength  inger’s 
solution and an initial inoculum of ~1x10
5 
cfu/ml was added to fresh IMF, 200µl of this was 
transferred to a 96-well white plate (Nunc, Thermo Fisher Scientific, Roskilde, Denmark). 
Bioluminescence was measured every hour in relative light units (RLU) using a Luminoskan 
luminometer automatic plate reader (Thermo Fisher Scientific, Roskilde, Denmark). When 
viable plate counts were required, cultures were serially diluted in ¼ strength  inger’s 
solution and enumerated on DFI agar.   
Complementation of transposon mutants 
For complementation of the mutants, the functional genes from C. sakazakii 
DPC6529::p16Slux were amplified by PCR using primers listed in Table 2. An annealing 
temperature of 50°C and extension time of 1 min was used. PCR products were subsequently 
purified and digested with the relevant restriction enzymes. Each PCR product was ligated to 
similarly digested pNZ44 (McGrath et al., 2001). The resulting ligation mix was 
transformed into electrocompetent E. coli DH5α cells. Transformants were selected on LB 
agar containing 10µg/ml chloramphenicol and incubated overnight at 37°C. Colony PCRs 
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were performed using pNZ44 forward and reverse primers. Selected colonies were grown 
overnight in LB supplemented with 10µg/ml chloramphenicol. Plasmids were extracted and 
electroporated into electrocompetent C. sakazakii cells. Transformants were selected on LB 
agar containing 10µg/ml chloramphenicol and incubated overnight at 37°C.  
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Results 
Creation and screening of the transposon mutant library 
A C. sakazakii DPC6529::p16Slux transposon mutant library was successfully created. The 
library was screened for mutants affected in their growth potential in milk using a 
bioluminescence based approach (Figure 1).  
 
 
Fig 1. Method used to create and screen the Transposon mutagenesis bank.  
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Of 1046 mutants screened 35 were chosen for further analysis due to the lack or relatively 
low amount of light emitted by these strains in RSM in the initial screen. The number of 
mutants was further reduced in three ways. Firstly, the amount of light emitted by the 
mutants during growth in LB broth was examined. Any mutants emitting no or very low 
amounts of light were excluded from further investigations. Secondly, these mutants were 
streaked on LB agar and the colonies were checked for light emission using the Xenogen 
IVIS100 imaging system. Some mutants emitted no light or some light after a 5 minute 
exposure. These mutants were again omitted from further analyses. Thirdly, additional 
elimination of the mutants involved measuring growth (OD620nm) of each mutant in LB broth 
in order to determine if growth of these mutants was impaired in standard laboratory 
medium. Out of the 35 mutants, 28 were eliminated by this process.  
Growth analyses of mutants from initial screen 
The remaining seven mutants were selected for further analysis. These mutants emitted 
approximately the same amount of light as the wild type in LB broth but emitted lower 
amounts of light than the wild type in RSM (Figure 2 A and B). In addition, all seven 
mutants displayed growth similar to the wild type strain when grown in LB broth at 37°C, 
indicating that disruptions of the genes in questions were not essential for growth under 
these conditions (data not shown). Plate counts after six hours in LB and RSM corroborated 
these results. The transposon mutants had lower plate counts in RSM than the wild type and 
the same plate counts as the wild type in LB. In RSM plate counts at T6 were: WT (~2x10
8
 
cfu/ml), M1 (~9x10
7
 cfu/ml), M2 (~9x10
7
 cfu/ml), M3 (~5x10
7
 cfu/ml), M4 (~13x10
7
 
cfu/ml), M5 (~9x10
7
 cfu/ml), M6 (~4x10
7
 cfu/ml) and M7 (~3.5x10
7
 cfu/ml).      
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Fig 2. (A) Growth of mutants in RSM. (B) Growth of mutants in LB. WT (■), M1 (♦), 
M2 (∆), M3 (●), M4 (□), M5 (◊), M6 (∆) and M7 (○). Bioluminescence was measured using 
a Luminoskan luminometer. Error bars represent the standard deviations of triplicate 
experiments. 
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Growth of mutants in IMF 
The seven mutants were grown in different infant milk formulae (IMF2 and IMF6) produced 
by two different manufacturers (Figure 3 A and B). Growth of five of the mutants was 
negatively affected in IMF compared to the wild type. M7 emitted more light in both IMF 
than was previously observed in RSM. However, growth still appeared to be delayed for this 
mutant compared to the wild type indicated by a longer lag phase. M4 emitted similar 
amounts of light to the wild type in IMF6 and plate counts were also the same as the wild 
type. However, this was not the case for this mutant in IMF2 where emission of light was 
similar to its previous growth in RSM.  
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
 
 
 
Fig 3. Growth of mutants in IMF 2 (A) and IMF 6 (B). WT (■), M1 (♦), M2 (∆), M3 (●), 
M4 (□), M5 (◊), M6 (∆) and M7 (○). Bioluminescence was measured using a Luminoskan 
luminometer. Error bars represent the standard deviations of triplicate experiments. 
 
 
Bioinformatic analysis 
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The site of the transposon insertion was identified by performing a single primer PCR 
followed by sequencing of the resultant products (Table 3). Locations of transposon 
insertion sites are shown in Figure 4. Conserved domains of each of the proteins are 
illustrated in Figure 5. 
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Table 3. Overview of the transposon mutants with inhibited growth in RSM   
 
 
Tn 
Mutant 
Tn 
insertion 
site 
Protein accession number, 
Size of protein 
Proposed function of encoding protein 
M1 ESA_03607 
 
YP_001439653 
472 aa 
GltD, NADPH-dependent glutamate synthase, it catalyzes the single-step conversion of L-glutamine and α-ketoglutarate into two molecules of L-glutamate. 
M2 ESA_00653 
 
YP_001436772 
356 aa 
 
Hypothetical protein, phosph-2-dehydro-3-deoxyheptonate aldolase, it catalyzes the formation of 3-deoxy-D-arabino-hept-2-ulosonate 7 phosphate from 
phosphoenolpyruvate and D-erythrose 4-phosphate. 
M3 ESA_03781 
 
YP_001439809 
491 aa 
IlvC, ketol-acid reductoisomerase, 
it catalyzes the formation of (R)-2,3-dihydroxy-3-methylbutanoate from (S)-2-hydroxy-2-methyl-3-oxobutanoate in valine and isoleucine biosynthesis. 
M4 ESA_01561 
 
YP_001437651 
531 aa 
TrpD, bifunctional glutamine amidotransferase/anthranilate phosphoribosyltransferase, 
TrpD forms a heterotetramer with TrpE and the complex catalyzes the formation of anthranilate from chorismate and glutamine; also catalyzes the formation of N-(5-
phospho-D-ribosyl)-anthranilate from athranilate and 5-phospho-alpha-D-ribose 1-diphosphate, it functions in tryptophan biosynthesis 
M5 ESA_03810 ABU78996 
381 aa 
ArgE, acetylornithine deacetylase,  
it catalyzes the formation of L-ornithine from N(2)-acetyl-L-ornithine in arginine biosynthesis 
M6 ESA_03820 
 
YP_001439842 
301 aa 
 
MetF 5,10-methylenetetrahydrofolate reductase, this is reduced to 5-methyltetrahydrofolate by methylenetetrahydrofolate reductase, a cytoplasmic, NAD(P)-dependent 
enzyme. 5-methyltetrahydrofolate is utilized by methionine synthase. 
M7 ESA_00904 ABU76174 
505 aa 
 
Amidophosphoribosyltransferase, it catalyzes first step of the de novo purine nucleotide biosynthetic pathway. 
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Fig 4. Genomic organisation of insertion sites in transposon mutants with delayed growth 
in RSM (M1-M7). The diagram was drawn approximately to scale using C. sakazakii 
BAA_894 genome sequence data. Open reading frames (shaded in grey) are genes with 
transposon insertion. Black arrowheads represent the approximate location of the transposon 
insertion. White open reading frames are flanking genes. Lollipops indicate predicted 
terminator locations. 
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Fig 5. Conserved domains present in the putative proteins encoded by the disrupted genes in 
M1-M7. Proteins were analysed for the presence of conserved domains using the conserved 
domain database (http://www.ncbi.nlm.nih.gov/cdd/). 
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Mutant M1. In M1 the transposon disrupted gene ESA_03607. Bioinformatic analysis 
revealed the product of this gene has 92% maximum identity to the glutamate synthase 
subunit beta of E. coli S88. Glutamate synthase catalyzes the single-step conversion of L-
glutamine and α-ketoglutarate into two molecules of L-glutamate. Glutamate synthase is a 
tetramer of dimers, with each dimer having one large and one small subunit (GltB and GltD, 
respectively) (Kumar et al., 2010). Conserved domain searches illustrate the protein has a 
GltD domain with an e-value of zero.  
Mutant M2. In M2 the transposon inserted into ESA_00653. This gene encodes a 
hypothetical protein. In silico analysis suggests that it may be a 3-deoxy-D-arabino-
heptulosonate-7-phospahte synthase (DAHP synthase). This protein shows 90% identity to a 
DAHP synthase in Klebsiella variicola At22. DAHP synthase catalyzes the formation of 3-
deoxy-D-arabino-heptulosonate-7-phosphate from phosphoenolpyruvate and D-erythrose-4-
phosphate and is tyrosine sensitive (Ma et al., 2012). A conserved domain search revealed a 
DAHP synthetase I family (e-value=1.04
-110
).  
Mutant M3. The transposon disrupted gene ESA_03781 in M3. Bioinformatic analysis 
indicates this gene encodes a ketol-acid reductoisomerase (IlvC). Conserved domain 
searches show an IlvC (ketol-acid reductoisomerase) domain (e-value=9.68
-32
).  IlvC 
catalyzes the formation of (R)-2,3-dihydroxy-3-methylbutanoate from (S)-2,3-hydroxy-2-
methyl-3-oxobutanoate and is involved  in valine biosynthesis. It also catalyses the 
formation of (R)-2,3-dihydroxy-3-methylpentoate from (S)-2,3-hydroxy-2-methyl-3-
oxopentoate in isoleucine biosynthesis (Tyagi et al., 2005). Homology searches reveal 95% 
identity to ketol-acid reductoisomerase of Escherichia coli 536.  
Mutnat M4. ESA_01561 was disrupted in M4. The product of this gene displays homology 
to a bifunctional glutamine amidotransferase/anthranilate phosphoribosyltransferase (TrpD) 
in Shigella flexneri 5a str (91% maximum identity). It forms a heterodimer with TrpE and 
this complex catalyzes the formation of anthranilate from chorismate and glutamine (Ramos 
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et al., 2008). A search of the conserved domains reveal a glutamine aminotransferase (e-
value=3.35
-77
) and an anthranilate phosphoribosyltransferase (e-value=3.85
-102
).  
Mutant M5. In M5 the transposon inserted into ESA_03810. Bioinformatic analysis 
suggests this gene encodes an acetylornithine deacetylase (ArgE). The protein is 91% 
homologous (maximum identity) to ArgE in Salmonella enterica subsp. enterica serovar 
Typhi str. P-stx-12. This catalyzes the formation of L-ornithine from (N)-2-acetyl-L-
ornithine in arginine biosynthesis (McGregor et al., 2007). A search for conserved domains 
reveal the presence of an acetylornithine deacetylase subfamily domain (e-value=1.29
-161
).  
Mutant M6. In M6 the transposon disrupted gene ESA_03820. In silico analysis suggests 
this gene encodes a 5,10-methylenetetrahydrofolate reductase (MetF). This protein shows 
95% identity with MetF in Salmonella enterica subsp. enterica serovar Choleraesuis str. SC-
B67. In addition, conserved domain searches illustrate a 5,10-methylenetetrahydrofolate 
reductase with an e-value of zero. MetF reduces 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate. It is a cytoplasmic, NAD(P)-dependent enzyme. MetF is also used in 
the methylation of homocysteine to form methionine (Sheppard et al., 1999).  
Mutnat M7. ESA_00904 was disrupted in M7. Bioinformatic analysis indicates this product 
of this gene has 95% maximum identity to an amidophosphoribosyltransferase in 
Escherichia coli str. K-12 substr. MG1655. This protein catalyzes the first step of the de 
novo purine nucleotide biosynthetic pathway (Bera et al., 2000). A search of the conserved 
domain revealed the presence of an amidophosphoribosyltransferase domain (e-value=0).  
Growth of mutants in milk supplemented with amino acids 
In silico analyses suggested that the disrupted genes in four of the mutants are putatively 
associated with amino acid metabolism. It was therefore decided to investigate if 
supplementation with the relevant amino acid would restore growth of these mutants. 
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For M1, glutamic acid was added to RSM. For M3 isoleucine and valine was added to RSM. 
For M5 arginine was added to RSM. For M6 methionine was added to RSM. These 
concentrations fully restored the mutants to wild type levels of growth in RSM (Figure 6 A, 
B, C and D).  
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Fig 6. Growth of mutants supplemented with amino acids (A) WT (■), M1 plus 
8.76mg/ml glutamic acid (○), M1 (●). (B) WT (■), M3 plus 1.6mg/ml isoleucine and 
2mg/ml valine (○), M3 (●). (C) WT (■), M5 plus 1mg/ml arginine (○), M5 (●). (D) WT (■), 
M6 plus 0.16mg/ml methionine (○) M6 (●). Bioluminescence was measured using a 
Luminoskan luminometer. Error bars represent the standard deviations of triplicate 
experiments. 
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Complementation of Transposon mutants 
These four transposon mutants were subsequently complemented with full functional copies 
of the disrupted genes to determine if this would also restore growth to wild type levels in 
RSM. Equal initial inoculums of each strain (wild type, transposon mutants and 
complemented strains) were added to RSM. Fig 7 shows the bioluminescence readings 
obtained at 12 hours. RLU readings obtained were as follows: WT 1.34x10
9 
± 0.43 RLU, M1 
5.5x10
8 
± 0.6 RLU, M1Comp 1.33x10
9 
± 0.43 RLU, M3 6.23x10
7 
± 0.13 RLU, M3Comp 
1.49x10
9 
± 0.07 RLU, M5 3.36x10
8 
± 0.66 RLU, M5Comp 1.3x10
9 
± 0.2 RLU, M6 3x10
8 
± 
0.5 RLU, M6Comp 1.2x10
9 
± 0.2 RLU) (Figure 7 A, B, C and D). When compared to the 
wild-type, all RLU readings for the transposon mutants were significantly lower whereas 
readings for complemented strains were not significantly different (as determined by 
Student’s t-test). 
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Fig 7. Growth of complemented Tn mutants in RSM using an IVIS 100 imager after 12 
hours of growth (A) M1 and M1Comp, (B) M3 and M3Comp, (C) M5 and M5Comp, (D) 
M6 and M6Comp.  
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Discussion 
To date, much of the research into the genes required for growth of bacteria in milk has 
focused on LAB e.g. L. lactis and S. thermophilus. Less information is available on genes 
essential for growth of pathogenic bacteria in milk. Lippolis et al., (2008) investigated the 
proteomic variation in E. coli when grown in fresh milk versus LB. This study observed 
changes in the adaptation of E. coli when grown in milk. The strain used was isolated from a 
clinical case of bovine mastitis. The authors suggest that some of the protein changes 
required for growth of the pathogenic strain of E. coli in milk (compared to a non-mastitis 
causing strain) could be identified and subsequently be used for therapeutic interventions.   
Liu et al., (2008) investigated the gene expression profiling of L. monocytogenes during 
growth in ultra high-temperature-processed skim milk at 4°C using microarray technology. 
The upregulated genes included genes encoding transport and binding proteins, cell division, 
amino acid biosynthesis, energy metabolism, protein synthesis, transcriptional regulators and 
hypothetical proteins. This study proposed identification of these genes could ultimately 
facilitate food processors to develop more effective preservation strategies to control levels 
of L. monocytogenes in milk.  
With regards to C. sakazakii, information is lacking regarding the genes required for growth 
of this pathogen in milk. The current study was initiated to address this lack of knowledge. 
A transposon library was successfully created in a Lux-tagged C. sakazakii strain. 
Transposon mutant libraries have previously been created in naturally light-emitting strains 
of bacteria. For example, Martin et al., (1989) created a bank of 30,000 transposon insertion 
mutants to identify the loci-encoding functions required for luminescence in Vibrio harveyi. 
Graf et al., (1994) screened 2,462 transposon insertion mutations for motility in V. fischeri. 
Ciche et al., (2001) screened 2,800 transposon insertion mutants for the ability of 
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Photorhabdus luminescence to support nematode growth and reproduction. However, to our 
knowledge our study is the first report of creating a transposon mutant library in a 
constructed Lux-tagged strain. 
Our initial screen identified 35 mutants emitting little or no light in RSM. Some of these Tn 
mutants were eliminated from further studies by examining their growth in LB broth and by 
plating them on LB agar and checking the amount of light they emitted compared to the wild 
type. In mutants with a bioluminescence defect it is possible the transposon either inserted 
into a gene in p16Slux or inserted in a gene in the light emitting reaction. Luciferase 
catalyzes the reaction of molecular oxygen, reduced flavin mononucleotide (FMNH2) and a 
long chained aldehyde generating the resulting carboxylic acid, FMN, water and light (490 
nm) (Bachmann et al., 2007). Therefore a transposon insertion in this reaction would affect 
the emission of bioluminescence.  
Many of the functions necessary for growth of LAB in milk involve the supply of amino 
acids (Arioli et al., 2007, Monnet et al., 2005, Dudley et al., 2001, Garault et al., 2000). 
There is a limited availability of free essential amino acids in milk (Tan et al., 1993). For 
this reason LAB have an intricate proteolytic system to convert milk casein to free amino 
acids and peptides for growth (Law et al., 1997). Therefore a mutation in any of the genes 
that function to metabolise amino acids may cause reduced growth of the bacteria in milk. In 
our study the majority of the mutants we identified disrupted genes linked to amino acid 
metabolism: ESA_03607 (glutamic acid metabolism), ESA_03781 (isoleucine and valine 
biosynthesis), ESA_01561 (tryptophan biosynthesis), ESA_03810 (arginine metabolism). 
ESA_00653 is thought to play a role in the shikimate pathway (Ma et al., 2012) which is 
used to generate the aromatic amino acids (phenylalanine, tyrosine and tryptophan). 
ESA_03820 is believed to be involved in methane metabolism. However, it may also play a 
role in methionine metabolism as the reaction it catalyzes provides a methyl donor to 
homocysteine, a precursor to methionine (Sheppard et al., 1999). ESA_00904 is the only 
gene without a direct link to amino acid metabolism and may be involved in purine 
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biosynthesis. Derzelle et al., (2005) investigated the proteome of S. thermophilus in milk and 
a homolog of ESA_00904 annotated as purF was upregulated when grown in milk. The same 
gene was upregulated in the proteome profile of L. lactis grown in milk (Gitton et al., 2005).
   
Growth of the seven mutants was also investigated in IMF. IMF can be considered to be 
more nutritious then RSM due to the additional ingredients (e.g. lactose, 
galactooligosaccharides, vitamins and minerals). This may explain why growth of two of the 
mutants improved (M4 and M7) in IMF compared to their previous growth in RSM. 
However, growth of the majority of mutants was affected in IMF.          
Growth of four mutants was restored to wild type levels when the relevant amino acid was 
added (M1, M3, M5 and M6), further highlighting the importance of these genes for 
progress of the bacteria in milk.   
ESA_03607 
This gene encodes a putative a glutamate synthase small subunit (GltD). In C. sakazakii 
GltBD may form part of an operon (Figure 4) flanked by an aceltylglutamase kinase. Letort 
et al., (2001) demonstrate omission of both glutamate and glutamine in minimal media 
prevented growth of S. thermophilus. In the proteomic signature of L. lactis in milk, Gitton 
et al., (2005) found upregulation of gltD. Lippolis et al., (2008) investigated the proteomic 
changes in E. coli when grown in fresh milk versus laboratory media and found levels of 
gltB increased when grown in milk compared to laboratory media. Monnet et al., (2005) 
found glnA essential for growth of S. thermophilus in milk. Glutamine synthetase (encoded 
by glnA) catalyzes the formation of glutamine from glutamate and ammonia. The product of 
glnBD catalyzes the formation of glutamate from glutamine, therefore the two pathways are 
related and a mutation in glnB or glnD could reasonably cause reduced growth of the 
bacteria in milk. 
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ESA_03781 
This gene is predicted to encode a ketol-acid reductoisomerase (IlvC) which may play a role 
in valine and isoleucine biosynthesis; these are both branched chain amino acids. Garault et 
al., (2000) reported branched-chain amino acid biosynthesis is required for optimum growth 
of S. thermophilus in milk. This paper identified two mutants with reduced growth in milk 
(ilvB and ilvC). In C. sakazakii BAA-894 the organisation of the ilvC gene is similar to E. 
coli as it is flanked by ilvY. However, in C. sakazakii there is a small (138 base pairs) open 
reading frame (ORF) between these genes. Gitton et al., (2005) and Derzelle et al., (2005) 
found ilvC to be upregulated in L. lactis and S. thermophilus when grown in milk. It was 
also upregulated in E. coli when grown in fresh milk (Lippolis et al., 2009).  
ESA_03810 
In C. sakazakii this gene is proposed to function as an acetylornithine deacetylase (ArgE) 
and may play a role in arginine biosynthesis. ArgE catalyzes the formation of ornithine 
which is an obligatory element in the 8 enzymatic steps in the biosynthesis of arginine 
(McGregor et al., 2007). Arioli et al., (2009) found carbamoylsynthetase (carB) activity is 
essential for growth of S. thermophilus in milk. This enzyme has a role in pyrimidine 
metabolism and is a precursor for the biosynthesis of arginine.  Arioli et al., (2009) restored 
growth of their carB mutant by addition of arginine and uracil. Growth of M5 also returned 
to wild type levels by addition of arginine (Figure 6 C).  
ESA_03820  
In C. sakazakii the product of this gene is suggested to function as a 
methylenetetrahydrofolate reductase (MetF). Similar to E. coli the genes are putatively 
organised in a gene cluster metJBLF (Sheppard et al., 1999). Although homologs of metF 
have not been directly linked to growth in milk it is believed to play a role in methionine 
biosynthesis and this amino acid is advantageous for progress of S. thermophilus in a 
minimal chemically defined medium (Letort et al., 2001). In addition, Herve-Jimenez et al., 
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(2008) showed metF is expressed during late phase growth of S. thermophilus in milk. 
Lippolis et al., (2009) also demonstrated this gene was upregulated during growth of E. coli 
in milk.  
The four mutants (M1, M3, M5 and M6) were subsequently complemented. They were 
chosen as their growth was affected in both RSM and IMF and they were directly linked to 
amino acid metabolism. As shown in Figure 7 restoration of the complemented mutants was 
comparable to wild type levels of growth in milk.    
In conclusion, a transposon mutagenesis bank was successfully created in a Lux-tagged 
strain of C. sakazakii. This bank was screened for mutants with delayed growth in milk and 
potential candidates were subsequently identified using single primer PCR and bioinformatic 
analysis. The disrupted genes compare with previous results obtained in LAB strains, as the 
majority were found to be involved in amino acid biosynthesis. In these mutants addition of 
the relevant amino acids fully restored the strain to levels similar to wild type growth in 
milk. Complemented mutants also displayed growth in milk comparable to the wild type 
strain. Considering that infant formula is the primary transmission vehicle for C. sakazakii, 
understanding how this pathogen grows in milk is imperative. Identification of these genes 
may aid in finding targets for more effective control strategies. This could reduce the 
incidence of infection and decrease the number of high-cost recalls of IMF. 
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Chapter V 
 
 
Identification of Cronobacter sakazakii genes involved 
in the tolerance to Lactoferricin B 
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Abstract 
Cronobacter sakazakii is an opportunistic pathogen associated with life-threatening 
infections, predominantly in neonates. Infection has been linked to the consumption 
of contaminated infant milk formula (IMF). Lactoferricin B (Lfcin B) is a milk 
derived antimicrobial peptide obtained from the pepsin cleavage of lactoferrin. It has 
been shown to be active against a broad range of pathogens including C. sakazakii. A 
transposon mutagenesis library was created in a strain of C. sakazakii and screened 
for mutants with increased sensitivity to Lfcin B. Mutations were identified and the 
genes involved were characterised by their proposed functions (encoding proteins 
involved in transport, DNA recombination and repair, central metabolic reactions 
and stress response). Lfcin B has the potential to be added to IMF as a preservative 
in order to inhibit C. sakazakii. Therefore, identification of the molecular 
mechanisms of C. sakazakii tolerance to Lfcin B is essential to potentiate the activity 
of this milk derived antimicrobial peptide.            
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Introduction 
Cronobacter sakazakii is an opportunistic pathogen that causes rare but life 
threatening cases of meningitis, necrotizing enterocolitis and septicaemia in neonates 
(Nazarowec-White et al., 1997a). Powdered infant milk formula (IMF) is often 
implicated as the primary source of infection. In addition IMF is not sterile therefore 
contamination with C. sakazakii can occur if strict microbiological guidelines are not 
practiced. This is a problem for IMF manufacturers due to the high mortality rate and 
the substantial cost of recalls.  
Lactoferricin B (bovine lactoferricin) (Lfcin B) is a 25-residue disulfide cross-linked, 
cationic peptide corresponding to amino acid residues 17-41 of the N-terminal of 
bovine lactoferrin (Figure 1). It can be produced by gastric pepsin digestion of 
bovine lactoferrin and possesses antimicrobial activity against a wide variety of 
microorganisms including Gram positive and Gram negative bacteria, fungi, 
protozoa and viruses (Bellamy et al., 1992, Orsi 2004, Gifford et al., 2005). Shorter 
derivatives of Lfcin B have also exhibited antimicrobial activity (Liu et al., 2011, 
Ulvante et al., 2001). An 11-mer derivative representing residues 4-14 in Lfcin B, 
has been recognized as being necessary for the antibacterial effect (Kang et al., 
1996). The primary sequence of Lfcin B contains mainly hydrophobic and positively 
charged residues. This may facilitate interaction with the negatively charged 
elements in the bacterial envelope, such as lipopolysaccharide (LPS) in Gram-
negative bacteria and lipotechoic acid in Gram-positive bacteria.  
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Fig 1. Amino acid sequence of lactoferricin B. Basic amino acids are highlighted in 
bold.  
 
 
Due to its broad range of action, it has been suggested that Lfcin B interacts directly 
with membranes instead of with a specific receptor (Arseneault et al., 2010). The 
antibacterial effect is believed to be accomplished via a pore forming mechanism 
(Hwang et al., 1998). Lfcin B also exerts an intracellular effect, in that Ulvante et al., 
(2004) observed that sublethal concentrations of Lfcin B inhibited DNA, RNA and 
protein synthesis of Escherichia coli and induced filamentation during an SOS 
response in bacteria. Tu et al., (2011) employed an E. coli proteome chip to identify 
the intracellular targets of Lfcin B. Sixteen proteins were identified and the majority 
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interact with proteins that affected the tricarboxylic acid (TCA) cycle. 
Phosphoenolpyruvate carboxylase was identified as a target of Lfcin B, suggesting 
that one of its mechanisms of action may be connected to pyruvate metabolism. A 
pyruvate assay was carried out in E. coli with and without Lfcin B and it was shown 
that abnormal accumulation of pyruvate occurred when E. coli was incubated with 
Lfcin B (Tu et al., 2011).     
Wakabayashi et al, (2008) investigated the susceptibility of four C. sakazakii strains 
to lactoferrin derived compounds, including Lfcin B.  IC’s were determined and 
revealed all strains of C. sakazakii showed susceptibility to Lfcin B, with  IC’s 
ranging from 5.1µM-9.1µM.        
IMF manufacturers are frequently creating new ingredients and formulations that can 
be added to milk to improve the safety and health benefits of their IMF; therefore an 
inhibitor of C. sakazakii would certainly be of interest. Bovine lactoferrin is added as 
an ingredient to some infant formulae in Japan, Indonesia and Korea (Tomita et al., 
2009).  The Morinaga milk company was the first IMF manufacturer to add bovine 
lactoferrin to its infant formulae (Tamura, 2004). The expected effects are anti-
infection, improvement of oro-gastrointestinal microflora, immunomodulation, anti-
inflammation and anti-oxidation. Tomita et al., (2009) also stated that bovine 
lactoferrin pepsin hydrolysate containing Lfcin B is added to some peptide based 
infant formulae. As Lfcin B is already added to some IMF, there is potential for 
further research into the possibility of utilizing Lfcin B as a preservative in IMF.   
The aim of the current study was to create a transposon mutagenesis library in C. 
sakazakii and to use it to identify genes involved in the tolerance of C. sakazakii to 
Lfcin B. A better understanding of these mechanisms of bacterial resistance is 
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essential to progress efforts to exploit milk derived antimicrobials for application as 
a preservative or for therapeutic interventions. For example developing compounds 
that target one of the resistance mechanisms could enhance the activity of the milk 
derived antimicrobial.    
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Materials and methods 
Bacterial strains and culture conditions 
Strains used in this study are listed in Table 1. They were routinely grown in Luria-
Bertani (LB) broth (Merck, Darmstadt, Germany) statically at 37°C for ~16 h unless 
otherwise stated. For solid media 1.5% agar was added. For certain experiments 
Brilliance Enterobacter sakazakii (DFI, Druggan, Forsythe and Iversen) agar (Oxoid, 
UK), TSA (Tryptic Soya Agar) (Oxoid), Mueller Hinton (Oxoid) broth and Mueller 
Hinton agar were used. If required kanamycin (50µg/ml) was added to cooled 
autoclaved media. Kanamycin (Sigma-Aldrich) was filter sterilized and made up as a 
concentrated stock in sterile distilled water.  
Test antimicrobials 
Lactoferricin B (Sigma-Aldrich L1290) was dissolved in sterile HPLC grade water 
to give a stock solution of 1mM. Aliquots of stock solution were stored at -80°C 
until required.       
Nisin powder (2.5%, balance sodium chloride and denatured milk solids) (Sigma-
Aldrich) was suspended in sterile HPLC grade water to give a stock solution of 
10mg/ml.  
Ampicillin (Sigma-Aldrich) was filter sterilized and made up as a concentrated stock 
in sterile HPLC grade water (50mg/ml). 
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Table 1. Bacterial strains and transposon used in this study   
 
Strains or 
transposon 
Relevant genotype or characteristic(s) Source or 
reference 
EZ-Tn5<kan-2> (Tn) Km
r
, mini-Tn5 transposon Epicentre, Madison, WI 
6522 Cronobacter  sakazakii DPC 
6523 Cronobacter  sakazakii DPC 
6524 Cronobacter  sakazakii DPC 
6525 Cronobacter  sakazakii DPC 
6526 Cronobacter  sakazakii DPC 
6527 Cronobacter  sakazakii DPC 
6528 Cronobacter  sakazakii DPC 
6529 (WT) Cronobacter  sakazakii DPC 
6530 Cronobacter  sakazakii DPC 
6531 Cronobacter malonaticus DPC 
ATCC51329 Cronobacter muytjensii DPC 
NCTC8155 Cronobacter sakazakii DPC 
ATCC12868 Cronobacter sakazakii DPC 
ATCC29004 Cronobacter sakazakii DPC 
ATCC29544 Cronobacter sakazakii DPC 
NCTC11434 Enterobacter gergorviae DPC 
NCTC11590 Enterobacter cloacae DPC 
NCTC11933 Enterobacter cloacae DPC 
NCTC10006 Enterobacter aerogenes DPC 
DH5-α E. coli  UCC 
L1 WT with an insertion in ESA_04322 Km
r This study 
L2 WT with an insertion in a gene of unknown function Km
r This study 
L3 WT with an insertion in a gene of unknown function Km
r This study 
L4 WT with an insertion in CTU_32540 Km
r This study 
L5 WT with an insertion in ESA_03985 Km
r This study 
L6 WT with an insertion in ESA_00567 Km
r This study 
L7 WT with an insertion in ESA_01660 Km
r This study 
L8 WT with an insertion in ESA_00894 Km
r This study 
L9 WT with an insertion in ESA_00177 Km
r This study 
L10 WT with an insertion in ESA_02808 Km
r This study 
 
Km
r
 = kanamycin resistance 
Strains were obtained from the DPC, Dairy Products Research Centre, Moorpark, 
Fermoy, Co. Cork, Ireland and UCC, University College Cork culture collections. 
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Limits of tolerance to Lfcin B 
DPC6529 (WT) was grown in triplicate and incubated overnight in LB broth for 
approximately 16 hours. To grow to log phase, a 2% inoculum was added to fresh 
LB broth for 2.5 hrs until an OD of ~0.3 was reached. 1ml of cells were centrifuged 
at 8000 x g for 7 min, the supernatants were removed and resuspended in 1ml of 
10mM sodium phosphate buffer (pH7.4)  The washed log phase cells were serially 
diluted in 10mM sodium phosphate buffer to give a final concentration of ~5x10
5 
cfu/ml of bacteria. Bactericidal assays were performed according to Ericksen et al., 
(2005). Briefly 50µl of washed cells was transferred to a 96 well plate (Genetix, 
UK). 50µl of Lfcin B (Sigma) with final concentrations ranging from 125µM to 
3.9µM was also transferred to the 96-well plate. The plate was incubated at 37°C 
over the next 2 hours, after which 100µl of double strength (2X) LB broth was added 
to each of the wells. Growth was monitored by measuring optical density (OD) at 
620nm for the next 24 hours using a temperature controlled automatic plate reader 
(Thermo Scientific Multiscan FC). Limits of tolerance were also determined for 
stationary phase cells with the same initial inoculum as the log phase cells. 
Transposon mutagenesis  
A transposon mutagenesis library was constructed using the EZ-Tn5 <KAN-2>Tnp 
Transposome kit (Epicentre, Madison, WI) according to protocols provided by the 
supplier. Briefly, DPC6529 was grown overnight in LB for ~16 h statically. A 1% 
inoculation was transferred to fresh LB incubated shaking for ~3 hours at 37°C until 
and OD of ~0.6 was reached. The cells were centrifuged at 900 x g for 10 minutes at 
4°C, the supernatant was discarded, and cells were resuspended in ice cold sterile 
distilled water and re-centrifuged. This was repeated 3 times, after which the cells 
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were resuspended in 10% ice cold glycerol and centrifuged again. The supernatant 
was removed and cells were resuspended in 500µl of ice cold 10% glycerol. 50µl 
aliquots were transferred to cold sterile 1.5ml centrifuge tubes and stored at -80°C.  
For electroporations, 1µl of transposon DNA was added to 50µl of competent cells 
on ice in a 2mm cuvette (Molecular BioProducts, San Diego CA). The 
electroporation conditions were 2.5kV, 200Ω and 25µF with a Harvard Apparatus 
ECM 630 Electro Cell Manipulator (MA, USA). To aid recovery the cells were 
resuspended in 1ml super optimal broth with catabolite repression (SOC) and 
incubated shaking for 1 hour at 37°C. Cells were diluted 1:100 in prewarmed SOC 
medium. To select for transposon insertion clones, aliquots of 100µl were plated 
onto LB plates containing 50µg/ml kanamycin and plates were incubated overnight 
at 37°C. Single colonies were picked and transferred to individual wells of 96-well 
plates (Genetix, UK), containing 150µl/well of LB, supplemented with 7.5% 
glycerol and 50µg/ml kanamycin. Plates were incubated overnight at 37°C for 
approximately 16 hours and subsequently stored at -80°C.  
Screening of Transposon mutants 
The -80°C stock plates were thawed and replicated into 96-well plates (Genetix) 
containing LB broth plus 50µg/ml kanamycin using a 96-pin replicator (Genetix). 
These were incubated at 37°C for ~16 hours. Subsequently, mutants were serially 
diluted in 10mM sodium phosphate buffer (pH 7.4) to give a final concentration of 
~5x10
5 
cfu/ml of bacteria. 50µl of cells was transferred to a 96-well plate (Genetix, 
UK) and 50µl of Lfcin B (15.62μ ) (Sigma) was added to each well. The plate was 
incubated at 37°C over the next 2 hours. Following this, 100µl of double strength 
(2X) LB broth was added to each of the wells. Growth was monitored by measuring 
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optical density (OD) at 620nm for the next 24 hours using a temperature controlled 
automatic plate reader (Thermo Scientific Multiscan FC). Viable plate counts were 
performed at selected time points by serially diluting samples in ¼ strength  inger’s 
solution and enumeration on LB agar.  
DNA extraction, manipulations and sequencing 
Strains were grown overnight (~16 hrs) in LB broth. DNA was extracted from 1ml 
of overnight cultures using the Invitrogen PureLink Genomic DNA Mini Kit 
following the manufacturer’s instructions. PC  amplification was carried out using a 
G-storm cycler (Essex, UK). The amplified PCR products were separated on 1% 
(m/v) agarose gels and visualised with the DNR Bio-Imaging System (Jerusalem, 
Israel). PCR products were purified using Invitrogen PCR purification kit. The 
concentration of nucleic acids was determined using an Invitrogen Qubit fluorometer 
(Eugene, Oregon, USA).  
Identification of transposon insertion sites 
The transposon insertion site for each mutant was identified using a single primer 
PCR approach. DNA fragments were amplified from chromosomal DNA of the 
transposon mutants using primer Tn5PCRR or Tn5PCRF (Table 2) with the reaction 
conditions described by Karlyshev et al., (2000). The conditions were 1 min at 94°C, 
20 cycles of 94°C for 30s, 50°C for 30s and 72°C for 3 min, 30 cycles of 94°C for 
30s, 30°C for 30s and 72°C for 2 min, 30 cycles of 94°C for 30s, 50°C for 30s and 
72°C for 2 min, followed by a 7 min extension at 72°C. PCR products were purified 
and sequenced with primer KAN-2 RP1 or KAN-2 FP1 (Table 2) by MWG 
Biotechnologies. BLASTn (Basic Local Alignment Search Tool) searches were 
performed with the obtained sequences (http://blast.ncbi.nlm.nih.gov/) to identify 
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homologous genes. Homologous regions in the genome of the sequenced C. 
sakazakii BAA-894 strain (accession number NC_009778) were analysed and the 
information obtained was used to generate Figure 5. Proteins were analysed for the 
presence of conserved domains using the conserved domain database 
(http://www.ncbi.nlm.nih.gov/cdd/). The location of each protein in bacterial cells 
was predicted using PSORT (http://psort.hgc.jp/form.html).                 
 
 
Table 2. Primers used in this study 
Primer Sequence 5’→3’ 
Kan-2 FP1 ACCTACAACAAAGCTCTCATCAACC 
Kan-2 RP1 GCAATGTAACATCAGAGATTTTCAG 
Tn5PCRF GCTGAGTTGAAGGATCAGATC 
Tn5PCRR CGAGCAAGACGTTTCCCGTTG 
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Survival assays 
For survival assays, strains were grown statically at 37°C for approximately 16 hrs. 
1ml aliquots of overnight cultures were centrifuged at 8000 x g for 7 min, the 
supernatants were discarded and the cell pellets were resuspended in 1ml 10mM 
sodium phosphate buffer and diluted in sodium phosphate buffer to give a final 
concentration of ~5x10
5 
cfu/ml. 50µl was added to 50µl of Lfcin B incubated 
statically at 37°C for 1 hour. Viable plate counts were performed by serially diluting 
in ¼ strength  inger’s solution and enumeration on LB agar in triplicate. 
Well assays 
The antibacterial activity of Lfcin B and nisin was measured by radial diffusion 
assay according to the method described by Derache et al., (2009). Cultures of 
DPC6529 (WT) and transposon mutants were incubated at room temperature 
(~20°C) overnight. The cells were centrifuged at 8,000 x g for 7 min, supernatants 
were removed and cell pellets were resuspended in 1ml sodium phosphate buffer. 
100µl of washed cells was added to 15ml 10mM sodium phosphate buffer containing 
0.03g of LB, 1% wt/vol ultra-pure agarose (Invitrogen) and 0.02% Tween 20 and 
poured into a petri dish. Once solid a 4.6mm diameter well was bored into the media. 
10µl of the antimicrobial was added to the well. Peptide and control solutions were 
allowed to diffuse into the gel containing bacteria by incubating the plates for 3 
hours at 37°C. The gel was then overlaid with 15ml 10mM sodium phosphate buffer 
containing double strength (2X) LB, plus 1% wt/vol ultra-pure agarose. After 
overnight incubation at 37°C, the diameter of the clear zone surrounding each well 
was measured. 
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Ampicillin disk diffusion assay 
A disk diffusion assay was carried out following the instructions of the Clinical and 
Laboratory Standards Institute (CLSI, 2005) using ampicillin disks (10µg; Oxoid). 
6529 (WT) and transposon mutants were streaked on TSA (Tryptic Soya Agar) and 
incubated at 37°C for 24 h. Colonies were suspended in 3ml of Mueller Hinton 
broth. The suspensions were swabbed onto the entire surface of Mueller Hinton agar 
with sterile swabs after which the antimicrobial disk (ampicillin, 10µg) (Oxoid, UK) 
was placed onto the surface of the plate with a sterile forceps. The plates were 
incubated upright at 37°C for 24 hours under aerobic conditions. The diameters of 
zones of inhibition were measured using a digital Vernier Callipers (Fisherbrand) 
and interpreted according to the CLSI guidelines for Enterobacteriaceae (Clinical 
and Laboratory Standards Institute 2005).  
MIC (minimum inhibitory concentration) determination 
MICs were determined in LB broth. A two-fold serial dilution of ampicillin was 
added to the wells of a 96-well plate containing C. sakazakii at a concentration of 
~5x10
5
 CFU/ml. Following a two hour incubation at 37°C, 100µl double strength LB 
broth was added. After 24 h of incubation at 37°C the plates were read, and the 
MICs were determined as the lowest concentration of ampicillin which resulted in 
the absence of apparent growth of the bacteria. MIC determinations were carried out 
in triplicate. 
Pigment production 
Strains were streaked onto TSA and incubated at 25°C for 72 hours after which the 
colonies were visually inspected for the production of a yellow pigment. 
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Results 
Growth of Cronobacter strains in LB plus Lfcin B  
To investigate the variation between Cronobacter strains, log phase cells of sixteen 
Cronobacter (fourteen C. sakazakii, one C. malonaticus and one C. muytjensii) were 
grown in LB plus 7.8µM Lfcin B with an initial inoculum of ~5x10
5 
cfu/ml. For 
comparative purposes two Enterobacter cloacae, one Enterobacter gergorviae and 
one Enterobacter aerogenes were included (Figure 2). There were differences 
between the susceptibility of individual strains to Lfcin B; e.g. ATCC29544 was the 
most affected strain. DPC6529 was chosen as the target strain for mutagenesis as it 
was one of the easiest of the Cronobacter strains to genetically manipulate and it was 
one of the more stress resistant of the Cronobacter strains. It was clear all strains 
were affected by Lfcin B due to their delayed growth compared to the wild type 
strain.  
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Fig 2. Growth curve of strains in LB containing 7.8 µM Lfcin B. DPC6522 (■), 
DPC6523 (□), DPC652  (♦), DPC6525 (◊), DPC6526 (▲), DPC6527 (Δ), DPC 
6528 (●), DPC6529 (WT) (○), DPC6530 (X), DPC6531 (   ), ATCC51329 (▬), 
ATCC8155 (    ), ATCC12868 (+), ATCC29004 (   ), ATCC29544 (=) NCTC11434 
(   ), NCTC11590 (  ),  NCTC11933   (   ), NCTC10006 (  ), and DPC6529 (WT) 
containing no Lfcin B (– – ).     
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Limits of tolerance of stationary phase and log phase cells to Lfcin B 
The limits of tolerance to Lfcin B of DPC6529 were determined using stationary 
phase cells (Figure 3A) and log phase cells (Figure 3B) using an initial inoculum of 
~5x10
5 
cfu/ml. This was carried out to establish whether stationary and log phase 
cells display the same tolerance to Lfcin B. The log phase cells were more sensitive 
than stationary phase cells to Lfcin B. For example, concentrations of 125µM and 
62.5µM prevented growth of log phase cells but stationary phase cells were able to 
grow at these concentrations.   
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Fig 3. (A) Growth curve of stationary phase inoculum C. sakazakii DPC6529 
(WT) in LB supplemented with Lfcin B. 125µ  (♦). 62.5µ  (■), 31.25µ  (▲), 
15.62µ  (□), 7.8µ  (◊) and wt without Lfcin B (∆). (B) Growth curve of log 
phase inoculum C. sakazakii DPC6529 (WT) in LB supplemented with Lfcin B.  
125µ  (♦). 62.5µ  (■), 31.25µ  (▲), 15.62µ  (□), 7.8µ  (◊), 3.9 µ  (x) and wt 
without Lfcin B (∆). Error bars represent the standard deviation of triplicate 
experiments.    
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Creation and screening of the transposon mutant library 
A C. sakazakii DPC6529 random transposon mutant library was created. Mutants 
with increased sensitivity to Lfcin B were identified using the approach outlined in 
Figure 4. From the limits of tolerance of stationary phase cells to Lfcin B (Figure 
3A) it was decided to use a concentration of 15.62µM Lfcin B for screening of the 
transposon mutant bank as this was a concentration that had a limiting effect on 
growth of C. sakazakii 6529 but did not prevent growth.  
Of 1029 mutants screened ten were chosen for further analysis due to their longer lag 
phase compared to the wild type strain when grown in LB plus Lfcin B (data not 
shown). All ten mutants displayed growth similar to the wild type strain when grown 
in LB at 37°C. Any differences were not statistically significant (Student’s t-test 
p<0.05). This indicates that the functions encoded by the genes in question were not 
essential for growth under normal physiological conditions. The exact location of the 
transposon insertion site was identified by a single primer PCR approach, followed 
by sequencing of the insertion site (Table 3). When plated on TSA, all mutants 
produced a yellow pigment and all mutants produced blue/green colonies on DFI 
agar.   
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Fig 4. Method used to create and screen the transposon mutagenesis bank. 
electroporate
TransposomeTn5
+Tn5
Genomic DNA
Purified 
genomic DNA
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Table 3. Overview of Lfcin B transposon mutants isolated in this study  
 
 
Tn mutant Tn insertion 
site 
Primer used Protein accession 
number, 
Size of protein 
Proposed function of encoded protein PSORT localisation 
prediction 
L1 ESA_04322 Tn5PCRR ABU_79501 
702 aa 
4-α-glucanotransferase, MalQ, it acts to release glucose from maltodextrins  Bacterial cytoplasm 
L2 No sequence 
similarity 
Tn5PCRR  - Unknown function - 
L3 No sequence 
similarity 
Tn5PCRR  - Unknown function - 
L4 CTU_32540 Tn5PCRR CBA_33120 
339 aa 
Integrase gene product involved in DNA integration and recombination Bacterial cytoplasm 
L5 ESA_03985 
 
Tn5PCRR ABU_79171 
253 aa 
Uncharacterized protein conserved in bacteria, BsmA Bacterial cytoplasm 
L6 ESA_00567   
 
Tn5PCRR ABU_75857 
354 aa 
RecA (recombinase A), it catalyzes the hydrolysis of ATP in the presence of 
single-stranded DNA, the ATP-dependent uptake of single-stranded DNA by 
duplex DNA, and the ATP-dependent hybridization of homologous single-
stranded DNAs 
Bacterial cytoplasm 
L7 ESA_01660 Tn5PCRR ABU_76914 
115 aa 
Putative anti-adapter protein IraM. It inhibits rpoS proteolysis by regulating rssB 
activity, thereby increasing the stability of the sigma stress factor rpoS during 
magnesium starvation. May also be involved in the early steps of isoprenoid 
biosynthesis, possibly through its role as rssB regulator 
Bacterial cytoplasm 
L8 ESA_00894 Tn5PCRR ABU_76164 
924 aa 
Subtilisin-like serine protease  Inner or outer 
membrane protein 
L9 ESA_00177 Tn5PCRF ABU_75478 
379 aa 
Hypothetical protein, putative iron-sulfur cluster binding protein Bacterial cytoplasm 
L10 ESA_02808 Tn5PCRR ABU_78038 
1049 aa 
Hypothetical protein, multidrug efflux system protein AcrB Plasma membrane 
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Bioinformatic analysis 
Location of the transposon insertion sites are illustrated in Figure 5. Conserved 
domains of each of the proteins are illustrated in Figure 6. For two of the transposon 
mutants (L2 and L3) there was no sequence similarity to any protein in the NCBI 
datasite, therefore they were assigned as having unknown function.    
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Fig 5. Genomic organisation of the transposon insertion sites (L1-L10) in 
mutants with delayed growth in Lfcin B. The diagram was drawn approximately to 
scale using C. sakazakii BAA-894 genome sequence data except for CTU_32540 
which was drawn using the C. turicensis z3032 genome sequence data. Open reading 
frames (shaded in grey) are genes with transposon insertion. Black arrowheads 
represent the approximate location of the transposon insertion. White open reading 
frames are flanking genes. Lollipops indicate predicted terminator locations. 
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Fig 6. Conserved domains present in the putative proteins encoded by the disrupted genes in 
L1-L10. Proteins were analysed for the presence of conserved domains using the conserved 
domain database (http://www.ncbi.nlm.nih.gov/cdd/). 
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Mutant L1. In L1 the transposon disrupted gene ESA_04322. In silico analysis 
suggests this gene encodes a 4-α-glucanotransferase (MalQ). This protein has a 
maximum identity of 77% to MalQ in E. coli IAI39. It is known that MalQ catalyzes 
a chemical reaction that transfers a segment of a 1,  α-glucan to new position in an 
acceptor carbohydrate which may be glucose or a 1,  α-glucan (Park et al., 2011). A 
search of the conserved domain showed a 4-α-glucanotransferase superfamily 
domain with an e-value of zero. PSORT predicted this protein is located in the 
bacterial cytoplasm.  
Mutant L4. In L4 the transposon inserted into CTU_32540. A BLASTn of the 
sequence of this gene revealed no sequence similarity to the C. sakazakii BAA-894 
genome. A tBLASTx illustrated 91% identity to an integrase gene product of C. 
turicensis z3032. Bioinformatic analysis revealed 92% maximum identity to a phage 
integrase protein in Salmonella enterica subsp. enterica serovar Typhimurium str. 
ST4/74.  A conserved domain search revealed a Phage HP1 integrase with an e-value 
of 5.82
-66
. HP1 integrase results in the site-specific recombination of bacteriophage 
HP1 genome (Hickman et al., 1997). PSORT predicted this gene product is located 
in the bacterial cytoplasm.  
Mutant L5. The transposon disrupted gene ESA_03985 in L5. This gene encodes an 
uncharacterised protein conserved in bacteria which has 63% maximum identity to 
BsmA in Pseudomonas fluorescens F113. From the conserved domain search, a 
BsmA superfamily was identified with an e-value of 3.98
-70
. This is a biofilm 
formation and stress response factor (Weber et al., 2010). PSORT predicted this 
protein is located in the bacterial cytoplasm.   
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Mutant L6. ESA_00567 was disrupted in L6. In silico analysis suggests this gene 
encodes a recombinase A (RecA). The protein shows high % identity (95%) to 
recombinase A of Escherichia coli str. K-12 substr. MG1655. This bacterial enzyme 
has roles in homologous recombination, DNA repair and induction of the SOS 
response (Stohl et al., 2003). RecA couples ATP hydrolysis to DNA strand 
exchange. When a cell's DNA is damaged, RecA undergoes activation, which 
facilitates the autocleavage of LexA, and this allows the SOS genes to be expressed 
(Little et al., 1980). PSORT predicted this gene product is located in the bacterial 
cytoplasm. 
Mutant L7. In L7 the transposon inserted into ESA_01660. This gene encodes a 
hypothetical protein which shares homology with the anti-adaptor protein IraM in E. 
coli B185 (23% maximum identity). A search of the conserved domains showed an 
anti-adapter protein family with an e-value of 1.21
-45
. IraM inhibits rpoS proteolysis 
by regulating rssB activity, thereby increasing the stability of the sigma stress factor 
rpoS during magnesium starvation (Bougdour et al., 2008). It may also be involved 
in the early steps of isoprenoid biosynthesis, possibly through its role as rssB 
regulator (Hemmi et al., 1998). PSORT predicted this protein is located in the 
bacterial cytoplasm. 
Mutant L8. In L8 the transposon disrupted gene ESA_00894. Bioinformatic analysis 
indicates this gene encodes a hypothetical protein. Conserved domain searches of 
this protein reveal a peptidase S8 family domain in autotransporter serine proteases 
(e-value 4.17
-78
) and an autotransporter beta-domain (e-value=7.71
-19
). A homology 
search showed 41% maximum identity to the serine protease of Xanthomonas 
axonopodis pv. citri str. 306. PSORT predicted this gene product has a location in 
the inner or outer membrane. 
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Mutant L9. The transposon disrupted gene ESA_00177 in L9. This gene encodes a 
hypothetical protein which has 91% maximum identity to a putative iron-sulfur 
cluster binding protein in E. coli MS 16-3. A search of the conserved domains show 
a domain of unknown function which occurs in iron-sulfur cluster-binding proteins 
(e-value=3.59
-31
). PSORT predicted this protein is located in the bacterial cytoplasm.   
Mutant L10. ESA_02808 was disrupted in L10. In silico analysis suggests this gene 
encodes a hypothetical protein with 89% maximum identity to an acriflavine 
resistance protein (AcrB) in E. coli K-12 substr. MG1655. This is part of multidrug 
efflux pump, where AcrB is the transporter that works in combination with AcrA, a 
periplasmic accessory protein (Husain et al., 2010). The gene product of ESA_02807 
has 85% maximum identity to AcrA in E. coli K-12 subst. MG1655, therefore it is 
possible they form part of the AcrAB multidrug efflux pump. PSORT predicted this 
gene product is located in the plasma membrane.  
 
Further analysis of mutants 
% survival in Lfcin B 
A kill curve of the stationary phase mutants in 15.62µM Lfcin B showed variation 
between strains (Figure 7A). The wild type showed 24.5% survival in the presence 
of Lfcin B. The highest survival for the Lfcin B mutants was L9 with 21.8% 
survival. The rest of the mutant strains were significantly more sensitive than the 
wild type (Student’s t-test p<0.05). The lowest survival was 4.6% for L7. A kill 
curve of the log phase mutants in 7.8µM Lfcin B also showed variation between 
strains (Figure 7B). The wild type strain plus Lfcin B had 10% survival. The highest 
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survival of the Lfcin B mutants was L5 with 8.3% survival. The rest of the mutant 
strains were significantly more sensitive than the wild type (Student’s t-test p<0.05). 
The lowest survival was 0.13% for L7. This strain had the lowest survival outcome 
for both stationary and log phase cells.   
  
A       B 
 
 
Fig 7. (A) % Survival of stationary phase inoculum WT cells in sodium 
phosphate buffer containing 15.62µM Lfcin B. (B) % survival of log phase 
inoculum WT cells in sodium phosphate buffer containing 7.8µM Lfcin B. Viable 
plate counts were performed following one hour incubation by serially diluting in ¼ 
strength  inger’s solution and enumeration on LB agar. % survival was calculated as 
a percentage of viable cell counts after challenge expressed as a percentage of 
viable-cell counts at time zero, i.e. immediately prior to treatment.  
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Well assays  
Well assays with 10mg/ml nisin (Table 4) showed variations in zone size between 
the Lfcin B mutants. Five strains were significantly more sensitive than the wild type 
(Student’s t-test p<0.05) (mutants L2, L3, L6 L7 and L8).  L6 had the largest zone of 
inhibition. Well assays with 10µl of 1mM Lfcin B was done singly. The largest zone 
of inhibition was L10 and the smallest zone of inhibition was mutant L9.  
Ampicillin sensitivity 
Ampicillin disk assays (Table 4) revealed the 50% of the Lfcin B mutants were 
statistically more sensitive than the wild type (mutants L3, L6, L7, L9 and L10) 
(Student’s t-test p<0.05). L10 had the largest zone of inhibition. This may be 
because this mutant is predicted to be a drug efflux pump (AcrB). MICs for all the 
strains was 10µg/ml except for L10 which had an MIC of 5µg/ml. A bactericidal 
assay with the Lfcin B mutants plus 8µg/ml ampicillin (Figure 8) also showed 
variation between the strains with L5 displaying similar growth to the wild type and 
again L10 was the most sensitive strain.       
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Table 4. Further characterization of the WT and transposon mutants isolated in this 
study 
 
Tn mutant Nisin (well assay) 
10mg/ml (mm) 
AMP 10µg 
(mm) 
Amp 
MIC 
Pigment 
production 
Growth on DFI 
L1 16.00±0.50 20.60±0.60 10 ug/ml + Blue green colonies 
L2 16.10±0.10 21.40±0.60 10 ug/ml + Blue green colonies 
L3 16.13±0.23 22.30±0.30 10 ug/ml + Blue green colonies 
L4 15.70±0.20 20.76±0.80 10 ug/ml + Blue green colonies 
L5 15.70±0.30 20.60±0.60 10 ug/ml + Blue green colonies 
L6 16.50±0.50 22.03±0.40 10 ug/ml + Blue green colonies 
L7 15.93±0.07 22.15±0.05 10 ug/ml + Blue green colonies 
L8 16.47±0.20 21.9±0.90 10 ug/ml + Blue green colonies 
L9 15.95±0.45 21.85±0.35 10 ug/ml + Blue green colonies 
 L10 15.25±0.25 24.06±0.26  5 ug/ml + Blue green colonies 
WT 15.56±0.13 20.65±0.50 10 ug/ml + Blue green colonies 
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Fig 8. Growth curve of wt and Lfcin B mutants in LB containing 8µg/ml 
ampicillin. wt (∆), L1 (▲), L2 (■), L3 (□), L  (♦), L5 (◊), L6 (○), L7 (●), L8 (x), L9 
(+) and L10 (   ). 
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Discussion 
C. sakazakii is an opportunistic foodborne pathogen in neonates and infants. The 
fatality rate has been reported to vary between 33-80% (Lai, 2001). Although C. 
sakazakii has been isolated from a wide variety of food, contaminated IMF has been 
epidemiologically linked to cases of C. sakazakii infection in infants (Weir, 2002). 
This is undoubtedly a major concern for IMF manufacturers. In the US, in November 
and December of 2011 there were four cases of C. sakazakii infection in infants in 
which two infants died (CDC, 2012). A voluntary recall of IMF was initiated. 
Therefore it is evident C. sakazakii is a continuing problem. Antimicrobial peptides 
(AMPs) such as Lfcin B are of interest to IMF manufacturers due their safety, 
effectiveness and broad spectrum of activity. As Lfcin B is a milk derived AMP it 
could act as a preservative by providing protection against C. sakazakii infection and 
increase the safety of the IMF.    
It was apparent that log phase cells were more sensitive to Lfcin B than stationary 
phase cells. This may be due to stationary phase cells expressing more stress 
response genes (Nair et al., 2004). There are also differences in cell membrane 
composition of stationary phase cells compared to log phase cells (Pagán et al., 
2000), for example cyclopropane fatty acids can accumulate (Cronan, 1968), which 
is thought to aid in the bacterial stress response (Chang et al., 1999). There was also 
variation between the collection of Cronobacter strains in their sensitivity to Lfcin 
B, albeit that all strains were affected to some degree. This is significant for IMF 
manufacturers as it highlights the importance of employing a collection of 
Cronobacter strains instead of a single strain when assessing suitable inhibitory 
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concentrations for IMF. A selection of strains will give a more realistic readout of 
the effectiveness of a Cronobacter inhibitor that could be added to IMF.   
In this study we identified ten mutants with delayed progress when grown in the 
presence of Lfcin B. Two mutants (mutants L2 and L3) were designated has having 
unknown function as they had no sequence similarity to any protein in the NCBI 
datasite. Currently the genome sequences of three C. sakazakii strains have been 
published; however, there are at least fifteen more C. sakazakii sequencing projects 
in progress (http://www.ncbi.nlm.nih.gov/genome/genomes/1170) and publication of 
this data may aid identification of these unassigned genes.  
ESA_04322 
The product of this gene is homologous to a 4-α-glucanotransferase (MalQ). In C. 
sakazakii it may form part of an operon with ESA_04321, the product of this gene 
shares homology with MalP, a maltodextrin phosphorylase. Therefore it may be a 
maltose inducible operon. A gene product downstream from MalQ is homologous to 
a major cold shock protein (ESA_04323) and may form part of the same operon. In 
E. coli this operon yields glucose and glucose-1-P that enter glycolysis (Park et al., 
2011). Tu et al., (2011) confirmed MalP binds to Lfcin B. Therefore it is plausible 
that a mutation in this operon has an effect on the sensitivity of the strain to Lfcin B.            
CTU_32540 
The proposed function of the product of this gene is an integrase protein, which has a 
role in DNA integration and recombination. This protein may form part of an operon 
with hypothetical proteins on either side. Integrase proteins have also been shown to 
form part of pathogenicity islands for integration to the chromosome (Dobrindt et 
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al., 2004). This integrase may be important in the pathogenicity of the strain. Its role 
in Lfcin B tolerance is not known at this point, nor do we have any reasonable 
hypothesis to propose.  
ESA_03985 
This gene product shares homology to a BsmA protein. The gene was previously 
designated yjfO. Weber et al., (2010) characterised and proposed renaming of the 
gene. A mutation in this gene altered the biofilm structure and cell motility and the 
ability of the bacteria to respond to pH and oxidative stress. Antimicrobial peptides 
have been shown to induce a stress response in bacteria e.g. upregulation of the 
PhoPQ two-component regulatory system (McPhee et al., 2003). This may explain 
why a mutation in this stress response gene resulted in increased sensitivity to Lfcin 
B. 
ESA_00567 
In C. sakazakii the proposed product of this gene is a recombinase A (RecA). In E. 
coli, DNA damaging agents trigger the SOS response; this involves induction of 
RecA expression (Thi et al., 2011). The protein catalyzes an ATP-dependent DNA 
strand exchange reaction that is the central step in repair of dsDNA breaks in 
homologous recombination. A mutation in RecA has previously been shown to have 
increased sensitivity to antibiotics (Liu et al., 2010); therefore it is conceivable that a 
mutation in this gene also resulted in increased sensitivity to antimicrobial peptides 
such as Lfcin B. In C. sakazakii it may form part of an operon with downstream 
putative recX and alaS genes.   
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ESA_01660 
In C. sakazakii this gene is suggested to encode for a putative antiadapter protein 
IraM. This protein is believed to be essential for the stabilization of RpoS during 
magnesium starvation by regulating RssB activity (Bougdour et al., 2008). This 
study also showed IraM is regulated by the two component system PhoPQ. Due to its 
connection with the general stress response regulator RpoS, it may explain why a 
mutation in IraM displayed increased sensitivity to Lfcin B. Of all the mutants this 
was be the most susceptible to Lfcin B, with the lowest % survival in log and 
stationary phase cells. 
ESA_00894 
In C. sakazakii the proposed function of this gene product is a subtilisin serine 
protease. It doesn’t appear to have a homolog in E. coli and the nearest non-
Cronobacter homolog is in Rhodanobacter fulvus with a maximum identity of 45%. 
Along with a peptidase S8 family domain, a search of the conserved domain revealed 
an autotransporter β-domain, this family corresponds to the presumed integral 
membrane β-barrel domain that transports proteins and is also a member of the porin 
superfamily. PSORT predicted the location of the gene product as an inner or outer 
membrane protein and Lfcin B is thought to have an effect on the cell membrane of 
the bacteria (Murdock et al., 2010, Ulvante et al., 2001). Due to its link to membrane 
transport, this may explain why a mutation in this gene displayed increased 
sensitivity to Lfcin B. However, the exact function is not clear at this point. 
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ESA_00177  
In C. sakazakii the product of this gene is suggested to be a putative iron-sulfur 
cluster binding protein (YjeS). Iron sulfur proteins are present in all living organisms 
and have a variety of functions these include electron transport, redox and non-redox 
catalysis, stabilization of proteins and sensing for regulatory processes (Ollagnier-de-
Choudens et al., 2001). This protein has not been fully characterized and its exact 
function is not known. Of the Lfcin B mutants L9 had the smallest zone of inhibition 
and the highest % survival of the stationary phase cells. Although it is affected by 
Lfcin B it is the least susceptible of the mutants. 
ESA_02808 
The product of this gene is proposed to function as a drug efflux pump, acriflavin 
resistance protein (AcrB). It may form an operon with AcrA. In E. coli this drug 
efflux pump consists of AcrAB-TolC and displays resistance to a wide variety of 
compounds. AcrA is an inner membrane lipoprotein, TolC is an outer membrane 
channel and AcrB captures the drug molecules and pumps them through TolC to the 
medium (Husain et al., 2010). Lfcin B could be one of the compounds this drug-
efflux pump can transport.  Therefore it is plausible that a mutation in this gene 
would be more affected by Lfcin B. In addition it had the largest zone of inhibition 
to Lfcin B compared to the rest of the mutants.    
Further analysis of the Lfcin B mutants was undertaken to determine if they are also 
affected by other antimicrobials. Nisin is a 34 amino acid bacteriocin produced by 
Lactococcus lactis. It forms pores in the cytoplasmic membrane resulting in 
depolarization in the cell membrane and eventually cell death (Hasper et al., 2006). 
Lfcin B also has an effect on the cell membrane of susceptible bacteria; Lfcin B has 
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been shown to cause depolarization of the membrane and fusion of negatively 
charged liposomes (Ulvatne et al., 2001). All strains including the wild type were 
sensitive to nisin, the most sensitive being mutant L6 (the RecA mutant, which is 
essential for the repair and maintenance of DNA). Gunderson et al., (2006) isolated 
antimicrobial peptides that caused DNA segregation, abnormalities, filamentation 
and DNA damage, which resulted in induction of the SOS response. As RecA needs 
to be induced to trigger the SOS response, it is possible a mutation in this gene could 
render the bacterium more susceptible to other antimicrobial peptides including 
nisin.  
The sensitivity of the mutants to ampicillin was also investigated. Ampicillin is a β-
lactam antibiotic that affects cell wall synthesis. Of the disk diffusion assays, the 
most sensitive of the mutants was mutant L10 which also had the lowest MIC of the 
strains; this result is understandable as the gene product has homology to a drug 
efflux pump. Growth of the strains in LB plus 8µg/ml ampicillin showed variation 
between the strains, with mutant L5 growing similarly to the wild type and with a 
zone of inhibition similar to the wild type in the ampicillin disk diffusion assay. This 
gene product has homology to BsmA which is a biofilm formation and stress 
response factor. However it is the least affected of the Lfcin B mutants to ampicillin.  
This study created a transposon mutagenesis library in C. sakazakii which were 
screened for their susceptibility to Lfcin B. The identified genes varied in their 
proposed function, for some their role in Lfcin B tolerance was not known and will 
require further investigation. Other genes could be linked to functions with a 
proposed role in Lfcin B tolerance. Identifying these genes is important to improve 
the efficacy of Lfcin B and also to identify possible targets for effective therapeutic 
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delivery. This study could also be of interest to IMF manufacturers due to problems 
associated with C. sakazakii in IMF.  
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Thesis summary 
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Cronobacter spp. are opportunistic pathogens associated with the ingestion of 
contaminated infant milk formula (IMF). This poses a constant challenge to IMF 
manufacturers, making it essential to understand the factors that affect survival and 
growth of Cronobacter in order to develop more effective control strategies. 
However, this is problematic due to tolerance of the pathogen to certain 
environmental stresses, in particular osmotic stress and drying, with some capsulated 
strains surviving for periods up to 2.5 years in dehydrated powdered infant formula 
(Edelson-Mammel et al., 2005). This may provide Cronobacter with a competitive 
advantage in powdered IMF.  
Chapter 2 of this thesis examines the ability of a collection of sixteen Cronobacter 
strains to cope with sub-optimal conditions of the gastrointestinal tract (low pH, salt 
and bile). The majority of studies on the capability of Cronobacter to tolerate 
environmental stresses focus on a single stress using a collection of strains, or a 
single strain is tested against a variety of stresses. In our study, while all strains were 
able to endure the stress conditions tested, noteworthy differences in tolerance were 
observed. It is therefore essential that future research on survival of Cronobacter to 
gastrointestinal stress conditions should include a bank of strains rather than just a 
single strain. 
Chapter 3 of this thesis investigated whether bioluminescence could be used to 
monitor growth of Cronobacter in IMF. As milk is opaque it does not lend itself to 
optical density measurements. Nine Cronobacter strains (from the collection of 
strains in chapter 2) were Lux-tagged, which enabled their growth to be easily 
monitored in real time by means of light emission (bioluminescence). Differences in 
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RLU readings were observed between strains, but these differences did not always 
directly correlate with differences in cell counts. Experiments with mixes of strains 
demonstrated that a cocktail of two Lux-tagged Cronobacter strains provides a good 
representation of the average growth of all ten strains in IMF. This means that rather 
than performing future growth analyses in IMF with all ten strains, the use of two 
strains would reduce the amount of work and samples required. This bank of Lux-
tagged strains could be employed to examine the effects of various infant formula 
compositions on the growth of Cronobacter. The bank of Lux-tagged strains may 
have other potential applications, for example, examining biofilm formation or 
biocide efficiency.     
Chapter 4 describes the creation of a transposon mutagenesis library in a Lux-tagged 
strain of C. sakazakii. Although transposon mutagenesis libraries have been created 
in naturally light emitting strains of bacteria this is the first time to our knowledge a 
transposon mutagenesis library has been created in a constructed Lux-tagged strain. 
This library was screened for mutants with growth affected in milk. These mutants 
were identified and the majority were found to be involved in amino acid 
metabolism. This information could contribute further to our understanding of how 
C. sakazakii grows in milk. This knowledge is essential to aid identification of 
potential inhibitors of the pathogen in IMF.    
Chapter 5 of this thesis describes the creation of a transposon mutagenesis library in 
C. sakazakii. This library was screened for mutants with increased sensitivity to the 
milk derived antimicrobial peptide, Lactoferricin B (Lfcin B). This antimicrobial 
peptide could be added to IMF as a preservative to inhibit C. sakazakii. A variety of 
genes were identified that varied in their proposed function (encoding proteins 
involved in transport, DNA recombination and repair, central metabolic reactions 
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and stress response). Identification of these genes is important to potentiate the 
affectivity of Lfcin B.  
In conclusion, this body of work found that Cronobacter strains vary in their ability 
to tolerate sub-optimal stress conditions. From Lux-tagging a collection of strains it 
was established that RLU readings may differ from strain to strain despite cell 
number counts. Therefore, it is essential that more than one Cronobacter strain is 
employed for investigating the efficiency of a potential anti-Cronobacter product. 
Amino acid metabolism genes were determined to be needed for the growth of C. 
sakazakii in milk. An array of genes including an antibiotic efflux pump were found 
to be significant in the tolerance of C. sakazakii to Lfcin B. Identification of such 
genes could facilitate approaches to help improve the efficacy of Lfcin B in turn, 
may aid control of this life-threatening opportunistic pathogen.              
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Identification of genes involved in the antibiotic tolerance of 
Cronobacter sakazakii 
This project was initiated by an undergraduate student as her final year lab project. I 
continued the work with the aim of generating enough data for a peer-reviewed 
publication. 
 
Introduction 
The spread of antibiotic resistant bacteria is a significant public health concern. C. 
sakazakii infections have traditionally been treated with a combination of ampicillin 
and gentamycin or ampicillin and chloramphenicol (Drudy et al., 2006). However, 
ampicillin, chloramphenicol and gentamycin resistant Cronobacter spp. have arisen 
due to acquisition transposable elements, production of β-lactamases and the 
presence of several antibiotic resistance operons (Girlich et al., 2001). Even though 
the antibiotic resistance of Cronobacter spp. is less of a problem than for other food 
borne pathogens, antibiotic resistant strains may become increasingly common due 
to drug overuse or external and internal stresses linked to environmental conditions 
(Lee et al., 2012b).  
Molloy et al., (2009) isolated 33 Cronobacter spp. from farming and domestic 
environments, food production animals and retail foods. Antibiotic resistant profiling 
indicated that all the Cronobacter strains were sensitive to seven of the eight 
antibiotics tested, but 51% of the isolates were resistant to cephalothin. This is a first 
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generation cephalosporin traditionally used for treatment of neonatal infections, but 
increased resistance has resulted in the recommended use of third generation 
cephalosporins (Gurtler et al., 2005).  
Kilonzo-Nthenge et al., (2012) isolated Cronobacter spp. from domestic kitchens. 
Antibiotic resistant profiling on these strains revealed 33% were resistant to 
ampicillin, 19% resistant to chloramphenicol and none resistant to gentamycin. 
Overall, C. sakazakii isolates were resistant to two or more of the ten antibiotics 
tested. Lee et al., (2012b) investigated the antibiotic susceptibility of 66 Cronobacter 
spp. isolated from various foods in Korea. The majority of C. sakazakii strains were 
susceptible to ampicillin (98.2%), tetracycline (98.2%) and chloramphenicol (96.6%) 
but 12% were resistant and 75.8% displayed intermediate sensitivity to streptomycin. 
In addition, a clinical case has been documented in which multiple antibiotics were 
ineffective in the treatment of a Cronobacter infection and required prolonged broad 
spectrum treatment (Dennison et al., 2002). These studies highlight an increase in 
antimicrobial resistance, with third generation cephalosporins now required to treat 
some infections. It is crucial antibiotic resistant strains of C. sakazakii do not 
proliferate. This is especially significant as stronger or different combinations of 
antibiotics may cause serious damage to a neonate.  
Currently, the genes used by C. sakazakii to tolerate antibiotics are unknown. This 
study was initiated to address this lack of knowledge. 
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Materials and methods 
Creation and screening of a transposon mutagenesis bank  
A C. sakazakii transposon mutagenesis library was created as per Chapter V of this 
thesis. The library was screened for mutants that were impaired in growth on LB 
agar supplemented with ampicillin, chloramphenicol or gentamycin. Ampicillin 
(Sigma-Aldrich) was filter sterilized and made up as a concentrated stock in sterile 
HPLC grade water (32mg/ml). Chloramphenicol was made up as a concentrated 
stock in ethanol (32mg/ml) and gentamycin was purchased as a concentrated liquid 
stock (50mg/ml) (Gibco). The transposon library was replicated from 96-well plates 
onto Q-trays (Genetix, UK) of LB agar, and LB agar supplemented with antibiotics; 
2µg/ml ampicillin, 2µg/ml chloramphenicol or 0.09375µg/ml gentamycin. Plates 
were examined after 2  and  8 hours and mutants which didn’t grow or grew poorly 
were selected for DNA extraction, PCR and sequencing.  
MICs determination 
MICs were determined as per Chapter V of this thesis. Briefly, a two-fold serial 
dilution of the antibiotic was added to the wells of a 96-well plate containing C. 
sakazakii at a concentration of ~5x10
5
 cfu/ml. Following a two hour incubation at 
37°C, 100µl double strength LB broth was added. After 24 h of incubation at 37°C 
the plates were read, and the MICs were determined as the lowest concentration of 
antibiotic which resulted in the absence of apparent growth of the bacteria. MIC 
determinations were carried out in triplicate. 
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DNA extraction, manipulations and sequencing 
DNA extraction and single primer PCRs were set up as per Chapter IV of this thesis 
using Tn5 PCRR (CGAGCAAGACGTTTCCCGTTG) and sequencing was 
performed with KAN-2 RP-1 (GCAATGTAACATCAGAGATTTTCAG). 
Bioinformatic analysis was performed as per chapter three of this thesis. 
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Results and Discussion  
Approximately 1,920 mutants were screened for antibiotic tolerance. Thirty 
antibiotic sensitive mutants were identified. Some of these mutants were sensitive to 
more than one antibiotic. In total 23 were sensitive to ampicillin, six were sensitive 
to chloramphenicol and six were sensitive to gentamycin (Table 1). In order to 
confirm the initial findings, mutants were grown overnight in 10ml LB, and 10l 
aliquots were spotted onto LB and LB supplemented with antibiotics (Figure 1). The 
transposon insertion sites were identified using a single primer approach (Table 1). 
MICs for each of the antibiotic sensitive mutants are also shown in Table 1. The wild 
type strain had an MIC of 20µg/ml against chloramphenicol, 10µg/ml against 
ampicillin and 0.0625µg/ml against gentamycin. 
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A             B  
 
C              D 
 
Figure 1. 10l of overnight cultures of thirty antibiotic sensitive mutants and wild 
type strain were spotted onto LB agar (A), LB agar plus 2.5µg/ml ampicillin (B), LB 
agar plus 2µg/ml chloramphenicol (C) and LB agar plus 0.09375µg/ml gentamycin 
(D). The two spots at the bottom of each plate represent the wild type strain.   
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Table 1. Overview of the antibiotic sensitive transposon mutants.  
Mutant Antibiotic sensitivity MIC Tn insertion site Proposed function of encoded protein 
Ampicillin sensitive mutants 
A-1 Ampicillin 10µg/ml ESA_03633 Hypothetical protein, predicted membrane protein  
A-2 Ampicillin 5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
A-4 Ampicillin 5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
A-5 Ampicillin 5µg/ml ESA_03191 Membrane carboxypeptidase penicillin binding protein 
1b MrcB 
A-7 Ampicillin 10µg/ml ESA_03828 ATP-dependent protease peptidase subunit, HslU 
A-8 Ampicillin 10µg/ml Intergenic region between two genes 44 
bp before ESA_00124, may form part of 
an operon 
Hypothetical protein 
A-10 Ampicillin 5µg/ml ESA_03188 Iron-hydroxamate transporter substrate-binding subunit 
FhuD 
A-11 Ampicillin 10µg/ml No sequence similarity Unknown function 
A-12 Ampicillin 5µg/ml ESA_02437 Phosphoserine aminotransferase 
A-13 Ampicillin 5µg/ml ESA_03325 Hypothetical protein 
 
A-14 Ampicillin 5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
A-16 Ampicillin 5µg/ml ESA_04118 Preprotein translocase subunit, SecA 
A-17 Ampicillin  10µg/ml 
 
Intergenic region between two genes 44 
bp before ESA_00124  may form part of 
an operon 
Hypothetical protein 
A-21 Ampicillin 5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
A-23 Ampicillin 
 
5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
A-25 Ampicillin 10µg/ml ESA_03741 Putative chloramphenical resistance permease RarD 
A-26 Ampicillin 5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
A-29 Ampicillin 5µg/ml ESA_03346 Hypothetical protein, lytic murein transglycosylase 
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Chloramphenicol sensitive mutants 
A-15 Chloramphenicol 10µg/ml Intergenic region 96 bp before tolC, may 
form part of an operon 
 
Gentamycin sensitive mutants 
A-3 Gentamycin 0.03125µg/ml ESA_00036 Potassium transporter peripheral membrane component, 
TrkA 
A-19 Gentamycin 0.0625µg/ml ESA_04003/ESA_04005 Hypothetical protein 
F0F1 ATP synthase subunit epsilon, AtpC 
A-22 Gentamycin 0.03125µg/ml ESA_01596 Hypothetical protein, antimicrobial peptide ABC 
transporter substrate-binding protein, SapA 
A-24 Gentamycin 0.03125µg/ml ESA_03779 Hypothetical protein.  
ATP-dependent DNA helicase Rep, UvrD 
A-28 Gentamycin 0.03125µg/ml ESA_04048 Glutamine synthetase, GlnA 
Mutants sensitive to more than one antibiotic 
A-6 Ampicillin and 
Chloramphenicol 
2.5µg/ml 
10µg/ml 
ESA_02859 DNA binding ATP dependent protease La, Lon 
A-9 Ampicillin and 
Chloramphenicol 
5µg/ml 
5µg/ml 
ESA_02808 Multi-drug efflux pump AcrB  
A-18 Ampicillin and 
Chloramphenicol 
5µg/ml 
5µg/ml 
ESA_02808 Multi-drug efflux pump AcrB 
A-20 Ampicillin and 
Chloramphenicol 
5µg/ml 
2.5µg/ml 
ESA_00373 Outer membrane protein TolC 
A-30 Ampicillin and 
Chloramphenicol 
5µg/ml 
5µg/ml 
ESA_02808 Multi-drug efflux pump AcrB 
A-27 Ampicillin and  
Gentamycin 
10µg/ml 
0.0625µg/ml 
ESA_01178 dTDP-glucose 4,6 dehydratase 
 
 
 
Two mutants (A-5 and A-20) were chosen for supplementary bioinformatic analysis. 
Location of transposon insertion sites these mutants are illustrated in Figure 2. 
Conserved domains of the proteins are shown in Figure 3.  
Mutant A-5 
In A-5 the transposon disrupted gene ESA_03191. In C. sakazakii the proposed 
product of this gene is a penicillin-binding protein (PBP) 1b (MrcB). Bioinformatic 
analysis revealed this protein has 85% maximum identity to the penicillin-binding 
protein in Salmonella enterica subsp. enterica serovar Paratyphi C. PBPs catalyze 
the final stages of murein biogenesis and are targets of β-lactam antibiotics (Ghosh et 
al., 2008). This may explain why a mutation in this gene displayed increased 
sensitivity to ampicillin. A search of the conserved domain revealed an MrcB multi-
domain with an e-value of zero.       
Mutant A-20 
In A-20 the transposon inserted into ESA_00373. In silico analysis suggests this gene 
encodes an outer membrane channel protein, TolC. Homology searches reveal 84% 
maximum identity with TolC in E. coli O157:H7 str. EC4024. TolC interacts with 
inner membrane efflux pumps in order to export materials (e.g. antibiotics) outside 
of the cell. TolC mutants in E. coli have previously been shown to be sensitive to 
antibiotics (Augustus et al., 2004). Conserved domain searches reveal a TolC multi-
domain with an e-value of zero. In A-15, the transposon inserted 96 base pairs before 
ESA_00373. This insertion has less of an effect on antibiotic susceptibility compared 
to A-20. A-15 is sensitive to chloramphenicol whereas A-20 is sensitive to ampicillin 
 
 
and chloramphenicol. In addition A-15 has a higher MIC against chloramphenicol 
than A-20. However TolC may form part of an operon (Figure 2) which may explain 
the increased antibiotic sensitivity of A-15 compared to the wild type.    
 
 
 
  
 
Fig 2. Genomic organisation of insertion sites in transposon mutants (A-5 and A-20) 
with increased antibiotic sensitivity. The diagram was drawn approximately to scale 
using C. sakazakii BAA-894 genome sequence data. Open reading frames (shaded in 
grey) are genes with transposon insertion. Black arrowheads represent the 
approximate location of the transposon insertion. White open reading frames are 
flanking genes. 
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Fig 3. Conserved domains present in the putative proteins encoded by the disrupted 
genes in A-5 and A-20. Proteins were analysed for the presence of conserved 
domains using the conserved domain database (http://www.ncbi.nlm.nih.gov/cdd/). 
 
Ampicillin sensitive mutants 
For one of the transposon mutants (A-11) there was no sequence similarity to any 
protein in the NCBI datasite, therefore it were assigned as having unknown function.    
ESA_03633 
In A-1 the transposon disrupted ESA_03633. In C. sakazakii BAA_894 the proposed 
product of this gene is a hypothetical protein and it is suggested to be a predicted 
A-5                                                                                                                                        
ESA_03191
 
 
 
 
 
A-20                                                                                                                                     
ESA_00373
 
 
 
 
 
 
membrane protein. A mutation in a membrane protein may affect membrane 
permeability therefore increasing the susceptibility of the bacteria to antimicrobials.      
ESA_03346 
In A-2, A-4, A-14, A-21, A-23, A-26 and A-29 the transposon inserted in the same 
location in ESA_03646. Bioinformatic analysis indicates this gene encodes a lytic 
murein transglycosylase protein. This is a general peptidoglycan binding molecule. 
Many antibiotics block the biosynthesis of peptidoglycan (Bateman et al., 2000) 
indicating this protein may function in tolerance of C. sakazakii to antibiotics. As the 
transposon inserted in seven of the mutants identified in the screen, this implies it 
may be a hotspot for the transposon. In addition, the results are consistent with all 
the mutants having an MIC of 5µg/ml against ampicillin.      
ESA_03828 
In A-7 the transposon inserted 49 base pairs before ESA_03828. The proposed 
product of this gene is an ATP-dependent protease peptidase subunit, HslV. It may 
form part of an operon with HslU therefore the transposon insertion may have a 
negative effect on the transcription of the operon. HslVU form a novel heat shock 
locus (Rohrwild et al., 1996). Heat shock proteins have been shown to increase 
antimicrobial tolerance (Tran et al., 2011) therefore this may explain why a mutation 
in this heat shock locus resulted in increased antibiotic sensitivity. 
ESA_00124 
In A-8 and A-17 the transposon inserted 44 base pairs before ESA_00124. 
Bioinformatic analysis indicates this gene encodes a hypothetical protein. It may 
form an operon with ESA_00125 therefore the transposon insertion may have 
 
 
affected the functioning of the operon. Both these mutants have an MIC of 10µg/ml 
against ampicillin, therefore the results are consistent. The role of this protein in 
antibiotic tolerance is not known but it is more susceptible than the wild type strain. 
ESA_03188 
In A-10 the transposon disrupted gene ESA_03188. In C. sakazakii the proposed 
product of this gene is an iron hydroxamate transporter substrate binding subunit 
(FhuD). In E. coli it forms part of the ABC transporter operon FhuACDB involved 
in iron
3+
-hydroxamate import (Mademidis et al., 1997). Currently its role in 
antibiotic tolerance is not known.     
ESA_02437 
ESA_02437 was disrupted in A-12.  In silico analysis suggests this gene encodes a 
phosphoserine aminotransferase. It catalyses the conversion of 3-
phosphohydroxypyruvate to L-phosphoserine in serine biosynthesis (Hester et al., 
1999). However, its function in antibiotic tolerance is not currently known.  
ESA_03325 
The transposon disrupted gene ESA_03325 in A-13. Bioinformatic analysis indicates 
this gene encodes a hypothetical protein. It has 72% maximum identity to a 
glutamate dehydrogenase (GDH) in E. coli UTI89. GDH catalyses a reversible 
reaction for the reductive amination of α-ketoglutarate to produce glutamate in the 
presence of the cofactor NAD(P)H (Kumar et al., 2010). Lee et al., (2012a) observed 
that a Bacillus subtilis glutamate dehydrogenase mutant was more sensitive to β-
lactams (e.g. ampicillin). This may explain why a mutation in ESA_03325 resulted in 
increased antibiotic sensitivity. 
 
 
ESA_04118 
In A-16 the transposon inserted into ESA_04118. In silico analysis suggests this gene 
encodes a preprotein translocase subunit, SecB. It is a molecular chaperone that 
functions in the post translational protein translocation pathway of some bacteria 
(Zhou et al., 2005) and forms part of the general secretory Sec system. There is 
interest in exploiting the Sec system as a potential target of novel antibiotics, as it 
functions in assembly and maintenance of the cell envelope and pathogenicity 
through the delivery of toxins (Economou, 2002).  
ESA_03741 
ESA_03741 was disrupted in A-25. The proposed product of this gene is a putative 
chloramphenicol resistance permease RarD. Jack et al., (2001) classifies RarD as a 
member of the drug/metabolite transporter superfamily.  
Gentamycin sensitive mutants 
ESA_03829 
The transposon disrupted ESA_00036 in A-3. In silico analysis suggests this gene 
encodes a potassium transporter peripheral membrane component, TrkA. Parra-
Lopez et al., (1994) describe a Salmonella protein SapG, which is 99% identical to 
TrkA. A mutation in SapG displayed increased sensitivity to the antimicrobial 
peptides protamine and melittin. A mutation in TrkA could also have increased 
susceptibility. This may explain the deceased tolerance of this mutant to antibiotics.    
ESA_04003/ESA_04005 
In A-19 the transposon inserted into ESA_04003/ESA_04005. These genes are 
overlapping and in reverse orientation to each other. In C. sakazakii the proposed 
 
 
product of ESA_04003 is a hypothetical protein. Bioinformatic analysis suggests 
ESA_04005 encodes an F0F1 ATP synthase subunit epsilon (ε). It forms part of 
catalytic core of ATP synthase in addition to α, β, γ and δ subunits and is involved in 
producing ATP from ADP in the presence of the proton motive force across the 
membrane (Stock et al., 2000). McCoy et al., (2001) identified a mutant in the 
transmembrane domain of ATP synthase in Proteus mirabilis which had increased 
sensitivity to antimicrobial peptides. A deficiency in the ability to produce ATP may 
cause the strain to have less energy to repair damage caused by antimicrobial peptide 
or antibiotics 
ESA_01596 
In A-22 the transposon disrupted gene ESA_01596. In silico analysis suggests this 
gene encodes an antimicrobial peptide ABC transporter substrate-binding protein, 
SapA. Parra Lopez et al., (1993) investigated a locus required for resistance to 
antimicrobial peptides in Salmonella Typhimurium, sapABCDF (sap, sensitivity to 
antimicrobial peptides). Therefore it is reasonable that a mutation in this gene also 
has increased sensitivity to antibiotics.   
ESA_03779 
In A-24 the transposon disrupted gene ESA_03779. Bioinformatic analysis indicates 
this gene encodes an ATP-dependent DNA helicase Rep. Liu et al., (2010) 
previously showed a mutation in an ATP-dependent DNA helicase in E. coli K-12 to 
have increased antibiotic sensitivity. 
 
 
 
 
ESA_04048 
ESA_04048 was disrupted in A-28. In silico analysis suggests this gene encodes a 
glutamine synthetase GlnA. It catalyzes the formation of glutamine from glutamate 
and ammonia (Kumar et al., 2010). However its role in antibiotic tolerance is not yet 
known. 
Mutants sensitive to more than one antibiotic 
ESA_02859 
The transposon disrupted gene ESA_02859 in A-6. Bioinformatic analysis indicates 
this gene encodes a DNA binding ATP dependent protease La (Lon). This protein 
plays a significant role in regulating many biological processes in bacteria such as 
cell differentiation, sporulation, pathogenicity and survival under starvation 
conditions (Tsilibaris et al., 2006). Liu et al., (2010) created an antibiotic profile 
with an E. coli gene knockout collection and Lon was one of the antibiotic sensitive 
mutants they identified. This highlights the importance of Lon in antibiotic tolerance.       
ESA_02808 
In A-9, A-18 and A-30 the transposon inserted in different locations in ESA_02808. 
In silico analysis suggests this gene encodes a hypothetical protein with 89% 
maximum identity to an acriflavine resistance protein (AcrB) in E. coli K-12 substr. 
MG1655. This is part of multidrug efflux pump, where AcrB is the transporter that 
works in combination with AcrA, a periplasmic accessory protein (Husain et al., 
2010). The gene product of ESA_02807 has 85% maximum identity to AcrA in E. 
coli K-12 subst. MG1655, therefore it is possible they form part of the AcrAB 
multidrug efflux pump. 
 
 
ESA_01178 
In A-27 the transposon disrupted gene ESA_01178. Bioinformatic analysis indicates 
this gene encodes a dTDP-glucose 4,6 dehydratase. This catalyses the transformation 
of dTDP-glucose into dTDP-4-keto-doeoxyglucose (Okazaki et al., 1962). It is 
further metabolized to produce components of the lipopolysaccharide (LPS) 
(Marolda et al., 1995). LPS mutants have previously been shown to have increased 
sensitivity to antibiotics (Kropinski et al., 1978).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions and suggestions for future work 
In conclusion, this is a novel study that identified thirty antibiotic sensitive mutants 
of C. sakazakii. The majority of the genes that were disrupted could be associated 
with antibiotic tolerance in other bacteria. It could be postulated from this study that 
C. sakazakii utilizes many of the same mechanisms of antibiotic resistance as other 
Enterobacteriaceae. This knowledge is imperative due to the increase in antibiotic 
resistance occurring worldwide. It could also aid in the development of novel and 
more enhanced antibiotics.     
Future work in this study could include further bioinformatic analysis of each of the 
mutants, creation of clean deletion mutants and observing the resulting affects and 
complementation of selected transposon mutants to restore function to wild type 
levels.  
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